Pfizer (PFE) 10-K 23 Feb 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2016	Feb. 21, 2017	Jul. 03, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	PFIZER INC
Entity Central Index Key	78,003
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false
Trading Symbol	PFE
Entity Common Stock, Shares Outstanding		5,951,872,174
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 216

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues	[1]	$ 52,824		$ 48,851	$ 49,605
Costs and expenses:
Cost of sales	[1],[2]	12,329		9,648	9,577
Selling, informational and administrative expenses	[1],[2]	14,837		14,809	14,097
Research and development expenses	[1],[2]	7,872		7,690	8,393
Amortization of intangible assets	[1]	4,056		3,728	4,039
Restructuring charges and certain acquisition-related costs	[1]	1,724		1,152	250
Other (income)/deductions––net	[1]	3,655		2,860	1,009
Income from continuing operations before provision for taxes on income	[1],[3]	8,351		8,965	12,240
Provision for taxes on income	[1]	1,123		1,990	3,120
Income from continuing operations	[1]	7,229		6,975	9,119
Discontinued operations:
Income from discontinued operations––net of tax	[1]	16		17	(6)
Gain/(loss) on disposal of discontinued operations––net of tax	[1]	0		(6)	55
Discontinued operations––net of tax	[1]	17		11	48
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	7,246		6,986	9,168
Less: Net income attributable to noncontrolling interests	[1]	31	[4]	26	32
Net income attributable to Pfizer Inc.	[1]	$ 7,215	[4]	$ 6,960	$ 9,135
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 1.18		$ 1.13	$ 1.43
Discontinued operations––net of tax (in dollars per share)	[1]	0		0	0.01
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	1.18		1.13	1.44
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	1.17		1.11	1.41
Discontinued operations––net of tax (in dollars per share)	[1]	0		0	0.01
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 1.17		$ 1.11	$ 1.42
Weighted-average shares––basic	[1]	6,089		6,176	6,346
Weighted-average shares––diluted	[1],[7],[8]	6,159		6,257	6,424
Cash dividends paid per common share (in dollars per share)	[1]	$ 1.2		$ 1.12	$ 1.04
[1]	Amounts may not add due to rounding.
[2]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.
[3]	Income from continuing operations before provision for taxes on income.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.
[6]	Amounts may not add due to rounding.
[7]	Amount for 2016 reflects the adoption of a new accounting standard, as of January 1, 2016, that requires when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B).
[8]	Amount for 2016 reflects the adoption of a new accounting standard, as of January 1, 2016, that requires when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B).

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 7,246	$ 6,986	$ 9,168
Foreign currency translation adjustments, net	[3]	(815)	(3,110)	(1,992)
Reclassification adjustments	[3],[5]	0	0	(62)
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total	[3]	(815)	(3,110)	(2,054)
Unrealized holding gains/(losses) on derivative financial instruments, net	[3]	(442)	204	24
Reclassification adjustments for realized (gains)/losses	[3],[6]	452	(368)	477
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[3]	10	(165)	501
Unrealized holding gains/(losses) on available-for-sale securities, net	[3]	248	(846)	(640)
Reclassification adjustments for realized (gains)/losses	[3],[6]	(118)	796	222
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total	[3]	130	(50)	(418)
Benefit plans: actuarial losses, net	[3]	(1,888)	(37)	(4,173)
Reclassification adjustments related to amortization	[3],[7]	558	550	195
Reclassification adjustments related to settlements, net	[3],[7]	127	671	101
Other	[3]	195	199	188
Defined benefit Plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[3]	(1,009)	1,383	(3,690)
Benefit plans: prior service credits and other, net	[3]	184	432	746
Reclassification adjustments related to amortization	[3],[7]	(173)	(160)	(73)
Reclassification adjustments related to curtailments, net	[3],[7]	(26)	(32)	8
Other	[3]	6	(3)	(9)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[3]	(8)	237	672
Other comprehensive loss, before tax	[3]	(1,692)	(1,705)	(4,988)
Tax provision/(benefit) on other comprehensive loss	[3],[8]	(174)	528	(946)
Other comprehensive loss before allocation to noncontrolling interests	[1],[3]	(1,518)	(2,232)	(4,042)
Comprehensive income before allocation to noncontrolling interests	[3]	5,728	4,754	5,126
Less: Comprehensive income/(loss) attributable to noncontrolling interests	[3]	28	(1)	36
Comprehensive income attributable to Pfizer Inc.	[3]	$ 5,701	$ 4,755	$ 5,090
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Reclassified into Gain on disposal of discontinued operations—net of tax in the consolidated statements of income.
[6]	Reclassified into Other (income)/deductions—net in the consolidated statements of income.
[7]	Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the consolidated statements of income. For additional information, see Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.
[8]	See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Loss.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	[1],[2]	$ 2,595	$ 3,641
Short-term investments	[1]	15,255	19,649
Trade accounts receivable, less allowance for doubtful accounts: 2016—$609; 2015—$384	[1]	8,225	8,176
Inventories	[1],[3]	6,783	7,513
Current tax assets	[1]	3,041	2,662
Other current assets	[1]	2,249	2,154
Assets held for sale	[1]	801	9
Total current assets	[1]	38,949	43,804
Long-term investments	[1]	7,116	15,999
Property, plant and equipment, less accumulated depreciation	[1],[4],[5]	13,318	13,766
Identifiable intangible assets, less accumulated amortization	[1]	52,648	40,356
Goodwill	[1]	54,449	48,242
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,812	1,794
Other noncurrent assets	[1]	3,323	3,420
Total assets	[1]	171,615	167,381
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2016—$4,225; 2015—$3,719	[1],[6]	10,688	10,159
Trade accounts payable	[1]	4,536	3,620
Dividends payable	[1]	1,944	1,852
Income taxes payable	[1]	437	418
Accrued compensation and related items	[1]	2,487	2,359
Other current liabilities	[1]	11,023	10,990
Total current liabilities	[1]	31,115	29,399
Long-term debt	[1],[7]	31,398	28,740
Pension benefit obligations, net	[1]	6,406	6,310
Postretirement benefit obligations, net	[1]	1,766	1,809
Noncurrent deferred tax liabilities	[1]	30,753	26,877
Other taxes payable	[1]	4,000	3,992
Other noncurrent liabilities	[1]	6,337	5,257
Total liabilities	[1]	111,776	102,384
Commitments and Contingencies	[1]
Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2016—597; 2015—649	[1]	24	26
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2016—9,230; 2015—9,178	[1]	461	459
Additional paid-in capital	[1]	82,685	81,016
Treasury stock, shares at cost: 2016—3,160; 2015—3,003	[1]	(84,364)	(79,252)
Retained earnings	[1]	71,774	71,993
Accumulated other comprehensive loss	[1]	(11,036)	(9,522)
Total Pfizer Inc. shareholders’ equity	[1]	59,544	64,720
Equity attributable to noncontrolling interests	[1]	296	278
Total equity	[1],[8]	59,840	64,998
Total liabilities and equity	[1]	$ 171,615	$ 167,381
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2015 reflects, among other things, the reclassification of $377 million to Assets held for sale (see Note 2B).
[4]	Reflects legacy Medivation and legacy Anacor amounts in 2016, commencing on the Medivation acquisition date, September 28, 2016, and Anacor acquisition date, June 24, 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date, September 3, 2015.
[5]	The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $457 million to Assets held for sale (see Note 2B) and, to a lesser extent, impairments and the impact of foreign exchange, partially offset by capital additions.
[6]	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2016 or December 31, 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments.
[7]	The fair value of our long-term debt (not including the current portion of long-term debt) was $34.9 billion as of December 31, 2016 and $32.7 billion as of December 31, 2015. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach.
[8]	Amounts may not add due to rounding.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	[1]	$ 609	$ 384
Short term borrowings, current portion of long term debt	[1]	$ 4,225	$ 3,719
Preferred stock, shares authorized	[1]	27,000,000	27,000,000
Preferred stock, shares issued	[1]	597	649
Common stock, par value (in dollars per share)	[1]	$ 0.05	$ 0.05
Common stock, shares authorized	[1]	12,000,000,000	12,000,000,000
Common stock, shares issued	[1]	9,230,000,000	9,178,000,000
Treasury stock, shares at cost	[1]	3,160,000,000	3,003,000,000
[1]	Amounts may not add due to rounding.

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions		Total		Shareholders’ Equity		Preferred Stock [Member]	Common Stock [Member]	Add’l Paid-In Capital [Member]	Treasury Stock [Member]		Retained Earnings [Member]	Accum. Other Comp. Loss [Member]	Non-controlling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2013	[1]					829	9,051,000,000		2,652,000,000
Beginning balance at Dec. 31, 2013	[1]	$ 76,620		$ 76,307		$ 33	$ 453	$ 77,283	$ (67,923)		$ 69,732	$ (3,271)	$ 313
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	9,168	[2],[3],[4]	9,135							9,135		32
Other comprehensive income/(loss), net of tax	[1]	(4,042)	[2]	(4,045)								(4,045)	3
Cash dividends declared:
Common stock	[1]	(6,690)		(6,690)							(6,690)
Preferred stock	[1]	(2)		(2)							(2)
Noncontrolling interests	[1]	(6)											(6)
Share-based payment transactions (in shares)	[1]						59,000,000		(2,000,000)
Share-based payment transactions	[1]	$ 1,597		1,597			$ 3	1,693	$ (100)
Purchases of common stock (in shares)		(165,000,000)							(165,000,000)	[1]
Purchases of common stock	[1]	$ (5,000)		(5,000)					$ (5,000)
Preferred stock conversions and redemptions (in shares)	[1]					(112)
Preferred stock conversions and redemptions	[1]	(8)		(8)		$ (4)		(4)	$ 1
Other	[1]	(17)		5			$ (1)	5					(22)
Ending balance (in shares) at Dec. 31, 2014	[1]					717	9,110,000,000		2,819,000,000
Ending balance at Dec. 31, 2014	[1]	71,622		71,301		$ 29	$ 455	78,977	$ (73,021)		72,176	(7,316)	321
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	6,986	[2],[3],[4]	6,960							6,960		26
Other comprehensive income/(loss), net of tax	[1]	(2,232)	[2]	(2,206)								(2,206)	(26)
Cash dividends declared:
Common stock	[1]	(7,141)		(7,141)							(7,141)
Preferred stock	[1]	(2)		(2)							(2)
Noncontrolling interests	[1]	(16)											(16)
Share-based payment transactions (in shares)	[1]						67,000,000		(1,000,000)
Share-based payment transactions	[1]	$ 1,946		1,946			$ 3	2,015	$ (72)
Purchases of common stock (in shares)		(182,000,000)	[5]						(182,000,000)	[1]
Purchases of common stock	[1]	$ (6,160)	[5]	(6,160)					$ (6,160)
Preferred stock conversions and redemptions (in shares)	[1]					(68)
Preferred stock conversions and redemptions	[1]	(5)		(5)		$ (3)		(3)	$ 1
Other	[1]			27				(27)					(27)
Ending balance (in shares) at Dec. 31, 2015	[1]					649	9,178,000,000		3,003,000,000
Ending balance at Dec. 31, 2015	[1]	64,998	[6]	64,720		$ 26	$ 459	81,016	$ (79,252)		71,993	(9,522)	278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		7,246	[1],[2],[3],[4]	7,215							7,215		31
Other comprehensive income/(loss), net of tax	[1]	(1,518)	[2]	(1,514)								(1,514)	(3)
Cash dividends declared:
Common stock		(7,446)	[1]	(7,446)	[1]						(7,446)
Preferred stock	[1]	(2)		(2)							(2)
Noncontrolling interests	[1]	(10)											(10)
Share-based payment transactions (in shares)	[1]						52,000,000		(3,000,000)
Share-based payment transactions	[1]	$ 1,563		1,563			$ 3	1,672	$ (111)
Purchases of common stock (in shares)		(154,000,000)	[7]						(154,000,000)	[1]
Purchases of common stock	[1]	$ (5,000)	[7]	(5,000)					$ (5,000)
Preferred stock conversions and redemptions (in shares)	[1]					(52.32)
Preferred stock conversions and redemptions	[1]	(5)		(5)		$ (2)		(2)
Other	[1],[8]	13		13							13
Ending balance (in shares) at Dec. 31, 2016	[1]					597	9,230,000,000		3,160,000,000
Ending balance at Dec. 31, 2016	[1]	$ 59,840	[6]	$ 59,544		$ 24	$ 461	$ 82,685	$ (84,364)		$ 71,774	$ (11,036)	$ 296
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.
[6]	Amounts may not add due to rounding.
[7]	Represents shares purchased pursuant to and received upon settlement of the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.
[8]	Represents the $13 million cumulative effect of the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, for certain elements of the accounting for share-based payments. For additional information, see Note 1B.

Consolidated Statements of Equ7

Consolidated Statements of Equity (Parenthetical) $ in Millions	Jan. 01, 2016USD ($)
New Accounting Pronouncement, Early Adoption, Effect [Member] | Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]
Cumulative effect of the adoption of new accounting standard	$ 13

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 7,246		$ 6,986		$ 9,168
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[4]	5,757		5,157		5,537
Asset write-offs and impairments	[4]	1,613		1,119		531
Foreign currency loss related to Venezuela	[4]	0	[5]	806	[5]	0	[6],[7]
Gain/(loss) on disposal of discontinued operations	[4]	0		6		(51)
Write-down of HIS net assets to fair value less estimated costs to sell	[4]	1,712	[7]	0	[7]	0
Deferred taxes from continuing operations	[4]	(700)		(20)		320
Deferred taxes from discontinued operations	[4]	0		2		(3)
Share-based compensation expense	[4]	691		669		586
Benefit plan contributions in excess of expense	[4]	(712)		(617)		(199)
Other adjustments, net	[4],[8]	209		(160)		(430)
Other changes in assets and liabilities, net of acquisitions and divestitures:
Trade accounts receivable	[4]	(134)		21		148
Inventories	[4]	365		(199)		175
Other assets	[4]	(60)		236		1,161
Trade accounts payable	[4]	871		254		297
Other liabilities	[4],[8]	(223)		664		(650)
Other tax accounts, net	[4]	(734)		(235)		492
Net cash provided by operating activities	[4]	15,901		14,688		17,084
Investing Activities
Purchases of property, plant and equipment	[4]	(1,823)		(1,397)		(1,199)
Purchases of short-term investments	[4]	(15,957)		(28,581)		(50,954)
Proceeds from redemptions/sales of short-term investments	[4]	29,436		40,064		47,374
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[4]	(4,218)		5,768		3,930
Purchases of long-term investments	[4]	(8,011)		(9,542)		(10,718)
Proceeds from redemptions/sales of long-term investments	[4]	11,254		6,929		6,145
Acquisitions of businesses, net of cash acquired	[4]	(18,368)		(16,466)		(195)
Acquisitions of intangible assets	[4]	(176)		(99)		(384)
Other investing activities, net	[4]	51		344		347
Net cash used in investing activities	[4]	(7,811)		(2,980)		(5,654)
Financing Activities
Proceeds from short-term borrowings	[4]	7,472		5,557		13
Principal payments on short-term borrowings	[4]	(5,102)		(3,965)		(10)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less	[4]	(3,084)		2,717		(1,841)
Proceeds from issuance of long-term debt	[4]	10,976		0		4,491
Principal payments on long-term debt	[4]	(7,689)		(2,990)		(2,110)
Purchases of common stock	[4]	(5,000)		(6,160)		(5,000)
Cash dividends paid	[4]	(7,317)		(6,940)		(6,609)
Proceeds from exercise of stock options	[4]	1,019		1,263		1,002
Other financing activities, net	[4],[8]	(196)		109		(123)
Net cash used in financing activities	[4]	(8,921)		(10,409)		(10,187)
Effect of exchange-rate changes on cash and cash equivalents	[4]	(215)		(1,000)		(83)
Net increase/(decrease) in cash and cash equivalents	[4]	(1,046)		298		1,160
Cash and cash equivalents, beginning	[4]	3,641	[9]	3,343		2,183
Cash and cash equivalents, end	[4]	2,595	[9]	3,641	[9]	3,343
Supplemental Cash Flow Information
Exchange of Hospira subsidiary debt for Pfizer debt	[4],[10]	0		1,669		0
Cash paid (received) during the period for:
Income taxes	[4]	2,521		2,383		2,100
Interest	[4]	1,451		1,302		1,550
Interest rate hedges	[4]	$ (338)		$ (237)		$ (374)
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.30, but rather at the then SIMADI rate of 200, the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy.
[6]	In 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million, partially offset by the reversal of a legal accrual where a loss is no longer deemed probable. For additional information, see Note 17A5. In addition, 2016 includes a settlement related to a patent matter. In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. For additional information, see Note 17A5. In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million to resolve a securities class action against Pfizer in New York federal court, and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable.
[7]	In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[8]	Amounts reflect the adoption of a new accounting standard that requires that cash flows present (i) excess tax benefits as operating activities, rather than financing activities on a prospective basis beginning in the year of adoption, and (ii) cash paid by us when directly withholding shares for tax-withholding purposes as a cash outflow from financing activities, rather than operating activities and is reflected in the year of adoption and retrospectively in 2015 and 2014 (see Note 1B).
[9]	Amounts may not add due to rounding.
[10]	n October 2015, Pfizer exchanged $1.7 billion debt of its then recently acquired subsidiary, Hospira, for virtually the same amount of Pfizer debt. See Note 7D. Financial Instruments: Long-Term Debt.

Consolidated Statements of Cas9

Consolidated Statements of Cash Flows (Parenthetical) - Unsecured Debt [Member] - USD ($)	Nov. 21, 2016	Jun. 03, 2016	Oct. 31, 2015	Oct. 05, 2015	Sep. 03, 2015
Debt instrument, face amount	$ 6,000,000,000	$ 5,000,000,000
Hospira [Member]
Debt instrument, face amount			$ 1,700,000,000	$ 1,700,000,000	$ 1,750,000,000

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this 2016 Financial Report for terms used throughout the consolidated financial statements and related notes of this 2016 Financial Report. The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Taxes paid on intercompany sales transactions are deferred until recognized upon sale of the asset to a third party. In the consolidated statements of cash flows for the years ended December 31, 2015 and 2014, we performed reclassifications to conform to the current period presentation that cash paid by us when directly withholding shares for tax-withholding purposes is presented as cash outflows from financing activities, rather than operating activities in accordance with the adoption of a new accounting standard. For additional information, see Note 1B . In the consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets , Other noncurrent assets , Short-term borrowings, including current portion of long-term debt and Long-term debt , and in the consolidated statements of cash flows for the years ended December 31, 2015 and 2014, we performed certain reclassifications to conform to the current presentation of Other changes in assets and liabilities, net of acquisitions and divestitures , Principal payments on short-term borrowings, and Principal payments on long-term debt, for debt issuance costs in accordance with the adoption of a new accounting standard. For additional information, see Note 1B . We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH), which was previously known as Established Products. Beginning in the second quarter of 2016, we reorganized our operating segments to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH. From the beginning of our fiscal year 2014 until the second quarter of 2016, these operations were managed as two business segments: the GIP segment and the VOC segment. We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 18 . On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical, a global device manufacturer, for up to approximately $900 million , composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. HIS includes IV pumps, solutions and devices. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months. Assets and liabilities associated with HIS are presented as held for sale in the consolidated balance sheet as of December 31, 2016. For additional information, see Note 2B. On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation, and, in accordance with our domestic reporting periods, our consolidated financial statements for the year ended December 31, 2016 reflect approximately three months of legacy Medivation operations. For additional information, see Note 2A . On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion , net of cash acquired), plus $698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor, and, in accordance with our domestic reporting periods, our consolidated financial statements for the year ended December 31, 2016 reflect approximately six months of legacy Anacor operations, which were immaterial . For additional information, see Note 2A. On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which fell into Pfizer’s second fiscal quarter), Pfizer paid Allergan $150 million (pre-tax) for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 4 ). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement. On September 3, 2015, we acquired Hospira for approximately $16.1 billion in cash ( $15.7 billion , net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Hospira. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. For additional information, see Note 2A. Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. B. Adoption of New Accounting Standards In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of shared-based compensation to be recognized as a component of the Provision for taxes on income , whereas excess tax benefits or deficiencies previously were recognized in Additional paid-in capital . The net tax benefit for the Company was $89 million for full-year 2016. The standard requires the modified retrospective transition method of adoption, and as such, does not permit retroactive presentation of this benefit to prior fiscal years in the consolidated statements of income. Further, the net cumulative effect of excess tax benefits not previously recognized because they had not reduced taxes payable, was $13 million and is reflected as an increase to Retained earnings as of January 1, 2016. Another element of the new accounting standard is within our consolidated statements of cash flows, which now present excess tax benefits as operating activities. We have elected to adopt this presentation on a prospective basis as of January 1, 2016, and, therefore, our consolidated statement of cash flows for fiscal years prior to 2016 have not been adjusted for this element. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification is required to be adopted retrospectively. As a result, $137 million for 2016 is presented as financing activities in the consolidated statement of cash flows, and cash outflows of $189 million for 2015 and $195 million for 2014 were reclassified from operating activities to financing activities in the consolidated statements of cash flows, respectively. We also elected to continue to estimate the impact of expected forfeitures of share-based payments when determining the amount of compensation cost to be recognized each period, rather than account for forfeitures as they occur. Finally, in the 2016 diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. We adopted a new accounting standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. The update does not impact the measurement or recognition of debt issuance costs. As of December 31, 2016 , debt issuance costs were $115 million and are presented as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $114 million ). In the December 31, 2015 consolidated balance sheet, we have reclassified debt issuance costs of $79 million ( $1 million from Other current assets and $79 million from Other noncurrent assets ) and have presented them as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $79 million ) to conform to the current period presentation. For additional information, see Note 7A. We adopted a new accounting standard as of January 1, 2016 that requires an acquirer to recognize adjustments made in the measurement period to provisional amounts of assets acquired and liabilities assumed in a business combination in the reporting period in which the adjustment amounts are determined. There was no material impact to our consolidated financial statements in 2016 from adopting this standard. For additional information, see Note 2A. We adopted a new standard as of January 1, 2016 related to the accounting for hybrid financial instruments issued or held as investments and there was no material impact to our consolidated financial statements from adopting this standard. C. Estimates and Assumptions In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income. Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our financial statements on a prospective basis, unless they are required to be treated retrospectively under relevant accounting standards. It is possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. D. Acquisitions Our consolidated financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net . Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. E. Fair Value We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques: • Income approach, which is based on the present value of a future stream of net cash flows. • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. • Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence. For some investments, if certain conditions exist, we may employ a practical expedient wherein we use the NAV per share (or its equivalent), as fair value. When this practical expedient is used, the NAV is not categorized for disclosure purposes within the fair value hierarchy for types of inputs used for valuation. Our fair value methodologies depend on the following types of inputs: • Quoted prices for identical assets or liabilities in active markets (Level 1 inputs). • Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs). • Unobservable inputs that reflect estimates and assumptions (Level 3 inputs). A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. F. Foreign Currency Translation For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss) . The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net . For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net , and we translate non-monetary items at historical rates. G. Revenues and Trade Accounts Receivable Revenue Recognition —We record revenues from product sales when the goods are shipped and title passes to the customer. At the time of sale, we also record estimates for a variety of revenue deductions, such as chargebacks, rebates, sales allowances and sales returns. When we cannot reasonably estimate the amount of future sales returns and/or other revenue deductions, we record revenues when the risk of product return and/or additional revenue deductions has been substantially eliminated. Deductions from Revenues–– Our gross product revenues are subject to a variety of deductions, that generally are estimated and recorded in the same period that the revenues are recognized, and primarily represent chargebacks, rebates and sales allowances to wholesalers, and, to a lesser extent, distributors like managed care organizations, retailers and government agencies with respect to our pharmaceutical products. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. Specifically: • In the U.S., we record provisions for pharmaceutical Medicare, Medicaid, and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates. • Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds, and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals. • Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability. • Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit. • We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $4.3 billion as of December 31, 2016 , of which approximately $2.8 billion is included in Other current liabilities, $357 million is included in Other noncurrent liabilities and approximately $1.2 billion is included against Trade accounts receivable, less allowance for doubtful accounts , in our consolidated balance sheet. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $3.9 billion as of December 31, 2015 , of which approximately $2.6 billion is included in Other current liabilities, $272 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Trade accounts receivable, less allowance for doubtful accounts , in our consolidated balance sheet. Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues . Collaborative Arrangements— Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded when our collaboration partners ship the product and title passes to their customer. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when our collaboration partners sell the product and title passes to their customers. All royalty payments to collaboration partners are included in Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net. Trade Accounts Receivable —Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. H. Cost of Sales and Inventories We carry inventories at the lower of cost or market. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary. I. Selling, Informational and Administrative Expenses Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $3.2 billion in 2016 , $3.1 billion in 2015 and $3.1 billion in 2014 . Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs. J. Research and Development Expenses R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. R&D expenses related to upfront and milestone payments for intellectual property rights totaled $82 million in 2016 , $429 million in 2015 and $1.4 billion in 2014 . For additional information, see Note 2C and Note 2D . K. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets Long-lived assets include: • Property, plant and equipment, less accumulated depreciation —These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws. • Identifiable intangible assets, less accumulated amortization —These acquired assets are recorded at cost. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated. • Goodwill —Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized. Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate. We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Specifically: • For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate. • For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate. • For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value. Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. L. Restructuring Charges and Certain Acquisition-Related Costs We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other costs incurred in connection with a business acquisition are expensed as incurred . Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can r

Acquisitions, Assets and Liabil

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment	12 Months Ended
	Dec. 31, 2016
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment	Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment A. Acquisitions Medivation, Inc. On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Of this consideration, approximately $365 million was not paid as of December 31, 2016, and was recorded in Other current liabilities. Medivation is now a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. Xtandi is being developed and commercialized through a collaboration between Pfizer and Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has two development-stage oncology assets in its pipeline: talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer, and pidilizumab, an immuno-oncology asset being developed for diffuse large B-cell lymphoma and other hematologic malignancies. In connection with this acquisition, we provisionally recorded $13.1 billion in Identifiable intangible assets , primarily consisting of $8.7 billion of Developed technology rights with an average useful life of approximately 12 years and $4.4 billion of IPR&D, and provisionally recorded $5.5 billion of Goodwill, $4.4 billion of net deferred tax liabilities, and $340 million of assumed contingent consideration. We recorded changes in the estimated fair values recognized in the measurement period to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. Bamboo Therapeutics, Inc. On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for $150 million , plus potential milestone payments of up to $495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately $331 million , including cash of $130 million ( $101 million , net of cash acquired), contingent consideration of $157 million , consisting of milestone payments, and the fair value of Pfizer’s previously held equity interest in Bamboo of $44 million . We previously purchased a minority stake in Bamboo in the first quarter of 2016 for a payment of approximately $43 million . Upon acquiring the remaining interest in Bamboo, we recognized a gain of $1 million on our existing investment in Other (income)/deductions––net. This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. Bamboo is now a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we provisionally recorded $325 million of Identifiable intangible assets, consisting entirely of IPR&D. We also provisionally recorded $133 million of Goodwill and $93 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. Anacor Pharmaceuticals, Inc. On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion net of cash acquired), plus $698 million debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA on December 14, 2016 under the trade name, Eucrisa. In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and provisionally recorded $4.9 billion in Identifiable intangible assets , primarily consisting of $4.8 billion of IPR&D , and provisionally recorded $647 million of Goodwill and $352 million of net deferred tax liabilities. We recorded changes in the estimated fair values recognized in the measurement period to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. We do not expect significant adjustments to the allocation of the consideration transferred to the assets acquired and the liabilities assumed, however the assessment has not yet been finalized. Hospira, Inc. On September 3, 2015, we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for $90 per share in cash. The total fair value of consideration transferred for Hospira was approximately $16.1 billion in cash ( $15.7 billion , net of cash acquired). Hospira is now a subsidiary of Pfizer and its commercial operations are included in the EH segment. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps. Hospira’s principal business was the development, manufacture, marketing and distribution of generic acute-care and oncology injectables, biosimilars and integrated infusion therapy and medication management systems (see Note 2B below). Hospira’s broad portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. We believe our acquisition of Hospira has strengthened our EH business, as EH now has a broadened portfolio of generic and branded sterile injectables, marketed biosimilars and biosimilars in development. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in 2016 to the amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. (MILLIONS OF DOLLARS) Amounts Recognized as of Acquisition Date (as previously reported as of December 31, 2015) Measurement Period Adjustments (a) Amounts Recognized as of Acquisition Date (as adjusted) Final Working capital, excluding inventories (b) $ 274 $ 68 $ 342 Inventories 1,924 (23 ) 1,901 PP&E 2,410 (57 ) 2,352 Identifiable intangible assets, excluding IPR&D (c) 8,270 20 8,290 IPR&D 995 35 1,030 Other noncurrent assets 408 (46 ) 362 Long-term debt (1,928 ) — (1,928 ) Benefit obligations (117 ) — (117 ) Net income tax accounts (d) (3,394 ) 14 (3,380 ) Other noncurrent liabilities (39 ) (23 ) (61 ) Total identifiable net assets 8,803 (12 ) 8,791 Goodwill 7,284 12 7,295 Net assets acquired/total consideration transferred $ 16,087 $ — $ 16,087 (a) The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. (b) Includes cash and cash equivalents, short-term investments, accounts receivable, other current assets, assets held for sale, accounts payable and other current liabilities. (c) Comprised of finite-lived developed technology rights with a weighted-average life of approximately 17 years ( $7.7 billion ) and other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ( $570 million ). (d) Final amounts recognized as of the acquisition date (as adjusted), included in Current tax assets ( $57 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $58 million ), Income taxes payable ( $5 million ), Noncurrent deferred tax liabilities ( $3.4 billion ) and Other taxes payable ( $101 million , including accrued interest of $5 million ). Preliminary amounts recognized as of the acquisition date (as previously reported), included in Current tax assets ( $79 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $25 million ), Income taxes payable ( $5 million ), Noncurrent deferred tax liabilities ( $3.4 billion ) and Other taxes payable ( $114 million , including accrued interest of $5 million ). As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $565 million , of which $12 million was not expected to be collected. In the ordinary course of business, Hospira incurs liabilities for environmental, legal and tax matters, as well as guarantees and indemnifications. These matters may include contingencies. Except as specifically excluded by the relevant accounting standard, contingencies are required to be measured at fair value as of the acquisition date if the acquisition-date fair value of the asset or liability arising from a contingency can be determined. If the acquisition-date fair value of the asset or liability cannot be determined, the asset or liability would be recognized at the acquisition date if both of the following criteria are met: (i) it is probable that an asset existed or that a liability had been incurred at the acquisition date, and (ii) the amount of the asset or liability can be reasonably estimated. • Environmental Matters —In the ordinary course of business, Hospira incurs liabilities for environmental matters such as remediation work, asset retirement obligations and environmental guarantees and indemnifications. The contingencies for environmental matters are not significant to Pfizer’s financial statements. • Legal Matters —Hospira is involved in various legal proceedings, including product liability, patent, commercial, antitrust and environmental matters and government investigations, of a nature considered normal to its business. The contingencies arising from legal matters are not significant to Pfizer’s financial statements. • Tax Matters —In the ordinary course of business, Hospira incurs liabilities for income taxes . Income taxes are exceptions to both the recognition and fair value measurement principles associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model as previously used by Hospira. Net liabilities for income taxes approximate $3.4 billion as of the acquisition date, which includes $109 million for uncertain tax positions. The net tax liability includes the recording of additional adjustments of approximately $3.2 billion for the tax impact of fair value adjustments and approximately $719 million for income tax matters that we intend to resolve in a manner different from what Hospira had planned or intended. For example, because we plan to repatriate certain overseas funds, we provided deferred taxes on Hospira’s unremitted earnings for which no taxes have been previously provided by Hospira as it was Hospira’s intention to indefinitely reinvest those earnings. Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of Hospira includes the following: • the expected specific synergies and other benefits that we believe will result from combining the operations of Hospira with the operations of Pfizer; • any intangible assets that do not qualify for separate recognition, as well as future, as yet unidentified projects and products; and • the value of the going-concern element of Hospira’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately). Goodwill is not amortized and is not deductible for tax purposes. All of the goodwill related to the acquisition of Hospira is related to our EH segment (see Note 10 for additional information). Actual and Pro Forma Impact of Acquisition —The following table presents information for Hospira’s operations that are included in Pfizer’s consolidated statements of income beginning from the acquisition date, September 3, 2015 through Pfizer’s domestic and international year-ends in 2015 (see Note 1A ): (MILLIONS OF DOLLARS) December 31, 2015 Revenues $ 1,513 Net loss attributable to Pfizer Inc. common shareholders (a) (575 ) (a) Includes purchase accounting charges related to the provisional estimated fair values recognized as of the acquisition date for (i) the fair value adjustment for acquisition-date inventory that has been sold ( $378 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Hospira ( $161 million pre-tax); (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Hospira ( $34 million pre-tax ); and (iv) amortization expense related to the fair value adjustment of long-term debt acquired from Hospira ( $13 million income pre-tax), as well as restructuring and integration costs ( $556 million pre-tax). The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014: Unaudited Supplemental Pro Forma Consolidated Results Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) 2015 2014 Revenues $ 52,082 $ 54,069 Net income attributable to Pfizer Inc. common shareholders 7,669 8,173 Diluted EPS attributable to Pfizer Inc. common shareholders 1.23 1.27 The unaudited supplemental pro forma consolidated results were prepared using the acquisition method of accounting and do not purport to reflect what the combined company’s results of operations would have been had the acquisition occurred on January 1, 2014, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors. The unaudited supplemental pro forma financial information includes various assumptions, including those related to the purchase price allocation of the assets acquired and the liabilities assumed from Hospira. The unaudited supplemental pro forma consolidated results reflect the historical financial information of Pfizer and Hospira, adjusted to give effect to the acquisition of Hospira as if it had occurred on January 1, 2014, primarily for the following pre-tax adjustments: • Elimination of Hospira’s historical intangible asset amortization expense (approximately $33 million in 2015 and $77 million in 2014). • Additional amortization expense (approximately $342 million in 2015 and $502 million in 2014) related to the fair value of identifiable intangible assets acquired. • Additional depreciation expense (approximately $52 million in 2015 and $102 million in 2014) related to the fair value adjustment to PP&E acquired. • Adjustment related to the non-recurring fair value adjustment to acquisition-date inventory estimated to have been sold (the elimination of $364 million of charges in 2015 and the addition of $591 million of charges in 2014). • Adjustment to decrease interest expense (approximately $18 million in 2015 and $42 million in 2014) related to the fair value adjustment of Hospira debt. • Adjustment for non-recurring acquisition-related costs directly attributable to the acquisition (the elimination of $877 million of charges in 2015, and the addition of $877 million of charges in 2014), reflecting non-recurring charges incurred by both Hospira and Pfizer which would have been recorded in 2014 under the pro forma assumption that the Hospira acquisition was completed on January 1, 2014. The above adjustments were adjusted for the applicable tax impact. The taxes associated with the adjustments related to the fair value adjustment for acquired intangible assets, PP&E, inventory and debt reflect the statutory tax rates in the various jurisdictions where the adjustments are expected to be incurred. The taxes associated with elimination of Hospira’s historical intangible asset amortization expense and the adjustment for the acquisition-related costs directly attributable to the acquisition were based on the tax rate in the jurisdiction in which the related deductible costs were incurred. Marketed Vaccines Business of Baxter International Inc. On December 1, 2014 (which fell in the first fiscal quarter of 2015 for our international operations), we acquired Baxter ’ s portfolio of marketed vaccines for a final purchase price of $648 million . The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. In connection with this acquisition, we recorded $376 million in Identifiable intangible assets, primarily consisting of $371 million in Developed technology rights. We also recorded $194 million of Inventories and $12 million in Goodwill . The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. InnoPharma, Inc. On September 24, 2014, we completed our acquisition of InnoPharma, a privately-held pharmaceutical development company, for an upfront cash payment of $225 million and contingent consideration with an estimated acquisition-date fair value of approximately $67 million . The contingent consideration consists of up to $135 million in additional milestone payments based on application filing with, and acceptance by, the FDA, or approval of marketing applications related to certain pipeline products by the FDA. We believe this acquisition represents a potential innovative growth opportunity for our sterile injectables portfolio in areas such as oncology and central nervous disorders. In connection with this acquisition, we recorded $247 million in Identifiable intangible assets consisting of $212 million in IPR&D and $35 million in Developed technology rights ; $81 million in net deferred tax liabilities; and $125 million in Goodwill . The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. B. Assets and Liabilities Held for Sale On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical agreed to acquire all of our global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical common stock. HIS includes IV pumps, solutions, and devices. As a result of recent performance of HIS relative to ICU Medical’s expectations, on January 5, 2017 we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately $900 million , composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. The revised transaction closed on February 3, 2017. At closing, under the terms of the revised agreement, we received 3.2 million newly issued shares of ICU Medical common stock (as originally agreed), which we valued at approximately $430 million (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability), a promissory note in the amount of $75 million and net cash of approximately $200 million before customary adjustments for net working capital. In addition, we are entitled to receive a contingent amount of up to an additional $225 million in cash based on ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. After receipt of ICU Medical shares, we own approximately 16.4% of ICU Medical as of the closing date. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months. The promissory note from ICU Medical has a term of three years and bears interest at LIBOR plus 2.25% for the first year and LIBOR plus 2.50% for the second and third years. While we have received the full purchase price excluding the contingent amount as of the February 3, 2017 closing, the sale of the HIS net assets was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, which represent a relatively small portion of the HIS net assets, we continue to operate the net assets for the net economic benefit of ICU Medical, and we are indemnified by ICU Medical against any risk associated with such operations during the interim period. We expect the sale of the HIS net assets in these jurisdictions to be completed by the first quarter of 2018. As such, and as we have already received all of the non-contingent proceeds from the sale and ICU Medical is contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes. In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale. At December 31, 2016 , we determined that the carrying value of the HIS net assets held for sale exceeded their fair value less estimated costs to sell, resulting in a pre-tax impairment charge of $1.7 billion , which is included in Other (income)/deductions––net (see Note 4 ). The decline in value resulted from lower expectations as to future cash flows to be generated by HIS, primarily as a result of an increase in competition for customer contracts and pricing factors that were not initially anticipated. Assets and liabilities associated with HIS are presented as held for sale in the consolidated balance sheet as of December 31, 2016 . The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities . The amounts associated with HIS, as well as other assets classified as held for sale as of December 31, 2016 and December 31, 2015 , consisted of the following: As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Assets Held for Sale Inventories $ 377 $ — PP&E 457 — Identifiable intangible assets 1,319 — Goodwill 119 — Other assets 152 — Less: adjustment to HIS assets for net realizable value (a) (1,681 ) — Total HIS assets held for sale 743 — Other assets held for sale (b) 58 9 Assets held for sale $ 801 $ 9 Liabilities Held for Sale Accrued compensation and related items $ 54 $ — Other liabilities 103 — Total HIS liabilities held for sale $ 157 $ — (a) For 2016 , we recorded an adjustment to HIS assets for net realizable value of $1,681 million plus estimated costs to sell of $31 million for a total impairment on HIS net assets of $1,712 million . (b) Other assets held for sale consist primarily of PP&E and other assets. C. Licensing Agreements Cellectis SA (Cellectis) In June 2014, we entered into a global arrangement with Cellectis to develop Chimeric Antigen Receptor T-cell immunotherapies in the field of oncology directed at select cellular surface antigen targets. In August 2014, in connection with this licensing agreement, we made an upfront payment of $80 million to Cellectis, which was recorded in Research and development expenses . We will also fund R&D costs associated with up to 15 Pfizer-selected targets and, for the benefit of Cellectis, a portion of the R&D costs associated with four Cellectis-selected targets within the arrangement. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per product that results from the Pfizer-selected targets, as well as tiered royalties on net sales of any products that are commercialized by Pfizer. In addition, in August 2014, we acquired approximately 10% of the capital of Cellectis through the purchase of newly issued shares, for a total investment of approximately $35 million . As of November 30, 2016 and 2015, Pfizer’s ownership in Cellectis’ outstanding shares was approximately 8% . Nexium Over-the-Counter Rights In August 2012, we entered into an agreement with AstraZeneca for the exclusive, global, OTC rights for Nexium, a prescription drug approved to treat the symptoms of gastroesophageal reflux disease. In connection with this Consumer Healthcare licensing agreement, we made an upfront payment of $250 million to AstraZeneca, which was recorded in Research and development expenses when incurred. On May 27, 2014, we launched Nexium 24HR in the U.S., and on July 11, 2014, we paid AstraZeneca a related $200 million product launch milestone payment. On August 1, 2014, we launched Nexium Control in Europe, and on September 15, 2014, we paid AstraZeneca a related $50 million product launch milestone payment. These post-approval milestone payments were recorded in Identifiable intangible assets, less accumulated amortization and are being amortized over the estimated useful life of the Nexium brand. Included in Other current liabilities at December 31, 2015 are accrued milestone payments to AstraZeneca of $93 million , which were subsequently paid to AstraZeneca in April 2016. AstraZeneca is eligible to receive additional milestone payments of approximately $200 million , based on the level of worldwide sales as well as quarterly royalty payments based on worldwide sales. D. Research and Development and Collaborative Arrangements Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P. On November 1, 2016, we announced the discontinuation of the global clinical development program for bococizumab. During December 2016, $31.3 million was refunded to NovaQuest representing amounts NovaQuest prepaid for development costs (under the May 2016 agreement described below) that were not used for program expenses due to the discontinuation of the development program. No additional payments are expected to be received from or paid to NovaQuest under this agreement, which was effectively terminated on November 18, 2016. In May 2016, our agreement with NovaQuest became effective, under which NovaQuest agreed to fund up to $250 million in development costs related to certain Phase III clinical trials of Pfizer’s bococizumab compound and Pfizer agreed to use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding was expected to cover up to 40% of the development costs and was to be received over five quarters during 2016 and 2017. As there was a substantive and genuine transfer of risk to NovaQuest, the development funding applicable to program expenses during 2016 was recognized as a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for 2016 totaled $180.3 million . Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P. In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest will fund up to $200 million in development costs related to certain Phase III clinical trials of Pfizer’s rivipansel compound and Pfizer will use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding is expected to cover up to 100% of the development costs and will be received over approximately twelve quarters from 2016 to 2019. As there is a substantive and genuine transfer of risk to NovaQuest, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for 2016 totaled $46.6 million . Following potential regulatory approval, NovaQuest will be eligible to receive a combination of fixed milestone payments of up to approximately $267 million in total based on achievement of first commercial sale and certain levels of cumulative net sales, as well as royalties on rivipansel net sales over approximately eight years. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the rivipansel product and royalties on net sales will be recorded as Cost of sales when incurred. Research and Development Arrangement with RPI Finance Trust In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI will fund up to $300 million in development costs related to certain Phase III clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI’s development funding is expected to cover up to 100% of the costs primarily for the applicable clinical trials through 2021. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for 2016 totaled $44.9 million . If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to $250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as Cost of sales when incurred. Collaborative Arrangements In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product. The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Revenues —Revenues (a) $ 659 $ 644 $ 786 Revenue s—Alliance revenues (b) 1,746 1,312 957 Total revenues from collaborative arrangements 2,405 1,956 1,743 Cost o

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	12 Months Ended
	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three -year period post-acquisition, we expect to incur costs of approximately $1 billion (not including costs of $215 million in 2015 associated with the return of acquired IPR&D rights as described in the Current-Period Key Activities section below) associated with the integration of Hospira. In early 2014, we announced that we would incur costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives. We had the following initiatives associated with these programs: • The 2014 global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to the support the businesses, as well as implementing the necessary system changes to support different reporting requirements. Through December 31, 2016, we incurred costs of approximately $219 million and have completed this initiative. • Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. In connection with our plant network strategy and facility optimization of manufacturing operations under the 2014-2016 initiatives, we incurred costs of approximately $367 million associated with prior acquisition activity and costs of approximately $1.1 billion associated with new non-acquisition-related cost-reduction initiatives. • Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and other consolidation and savings opportunities. In connection with these cost-reduction activities, during 2014-2016, we incurred costs of approximately $1.4 billion . The costs incurred during 2014-2016, of approximately $3.1 billion in total for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation––asset restructuring. Of this amount, about a quarter of the charges were non-cash. Current-Period Key Activities In 2016 , we incurred approximately $2.1 billion in cost-reduction and acquisition-related costs (excluding transaction costs) primarily in connection with the integration of Hospira and the aforementioned programs. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Restructuring charges (a) : Employee terminations $ 940 $ 489 $ 68 Asset impairments 142 254 45 Exit costs 74 68 58 Total restructuring charges 1,156 811 170 Transaction costs (b) 127 123 — Integration costs (c) 441 219 80 Restructuring charges and certain acquisition-related costs 1,724 1,152 250 Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows (d) : Cost of sales 201 117 228 Selling, informational and administrative expenses — — 1 Research and development expenses 7 5 31 Total additional depreciation––asset restructuring 207 122 261 Implementation costs recorded in our consolidated statements of income as follows (e) : Cost of sales 230 102 78 Selling, informational and administrative expenses 81 82 140 Research and development expenses 25 14 52 Other (income)/deductions––net 3 5 1 Total implementation costs 340 203 270 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 2,271 $ 1,478 $ 781 (a) In 2016 , Employee terminations represent the expected reduction of the workforce by approximately 4,900 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring charges in 2016 , are associated with the following: • IH ( $272 million ); EH ( $158 million ); WRD, GPD and Medical (M) (WRD/GPD/M) ( $169 million ); manufacturing operations ( $368 million ); and Corporate ( $189 million ). The restructuring charges in 2015 , which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following: • IH ( $85 million ); EH ( $402 million ); WRD/GPD/M ( $80 million ); manufacturing operations ( $80 million ); and Corporate ( $164 million ), The restructuring charges in 2014 are associated with the following: • IH ( $63 million ); EH ( $57 million ); WRD/GPD/M ( $37 million ); manufacturing operations ( $97 million ); and Corporate ( $65 million ). as well as $149 million of income related to the partial reversal of prior-period restructuring charges not directly associated with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans. In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million , which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million , which is included in Asset impairments ; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million , which is included in Asset impairments ; and (iii) a payment to Celltrion of $20 million , which is included in Exit costs . (b) Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which in 2016 are directly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and the terminated transaction with Allergan and primarily include expenditures for banking, legal, accounting and other similar services. (c) I ntegration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, January 1, 2015 $ 1,114 $ — $ 52 $ 1,166 Provision 489 254 68 811 Utilization and other (a) (495 ) (254 ) (71 ) (820 ) Balance, December 31, 2015 (b) 1,109 — 48 1,157 Provision 940 142 74 1,156 Utilization and other (a) (502 ) (142 ) (86 ) (730 ) Balance, December 31, 2016 (c) $ 1,547 $ — $ 36 $ 1,583 (a) Includes adjustments for foreign currency translation. (b) Included in Other current liabilities ( $776 million ) and Other noncurrent liabilities ( $381 million ). (c) Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million ). The asset impairment charges included in restructuring charges for 2016 are primarily associated with abandoned assets.

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	12 Months Ended
	Dec. 31, 2016
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Interest income (a) $ (470 ) $ (471 ) $ (425 ) Interest expense (a) 1,186 1,199 1,360 Net interest expense 716 728 935 Foreign currency loss related to Venezuela (b) — 806 — Royalty-related income (c) (905 ) (922 ) (1,002 ) Certain legal matters, net (d) 510 975 993 Net gains on asset disposals (e) (171 ) (232 ) (288 ) Impairment on remeasurement of HIS net assets (f) 1,712 — — Certain asset impairments (g) 1,447 818 469 Business and legal entity alignment costs (h) 261 282 168 Other, net (i) 85 403 (265 ) Other (income)/deductions––net $ 3,655 $ 2,860 $ 1,009 (a) 2015 v. 2014 ––Interest income increased primarily due to higher investment returns. Interest expense decreased, primarily due to the repayment of a portion of long-term debt in the first quarter of 2015 and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. Capitalized interest expense totaled $ 61 million in 2016 , $ 32 million in 2015 and $ 41 million in 2014 . (b) In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.30 , but rather at the then SIMADI rate of 200 , the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy. (c) Royalty-related income decreased in 2016, reflecting lower royalty income for Enbrel of $54 million , resulting from the expiration on October 31, 2016 of the 36 -month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), and the expiration of other royalty agreements, partially offset by Xtandi royalty-related income of $63 million . (d) In 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss is no longer deemed probable. For additional information, see Note 17A5. In addition, 2016 includes a settlement related to a patent matter. In 2015 , primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. For additional information, see Note 17A5 . In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million to resolve a securities class action against Pfizer in New York federal court, and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable. (e) In 2016 , primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $666 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $548 million ; (iii) loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of approximately $84 million ; and (v) gains on sales of investments in private equity securities of approximately $2 million . Proceeds from the sale of available-for-sale securities were $10.2 billion in 2016 . In 2015 , primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $164 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $960 million ; (iii) net gain of $937 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of approximately $90 million ; and (v) gains on sales of investments in private equity securities of approximately $3 million . Proceeds from the sale of available-for-sale securities were $4.3 billion in 2015. In 2014 , primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $76 million ; (ii) gross realized gains on sales of available-for-sale debt securities of $138 million ; (iii) gross realized losses on sales of available-for-sale debt securities of $436 million ; (iv) net gain of $323 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of approximately $135 million ; and (vi) gains on sales of investments in private equity securities of approximately $39 million . Proceeds from the sale of available-for-sale securities were $10.2 billion in 2014 . (f) In 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information . (g) In 2016 , primarily includes intangible asset impairment charges of $869 million , reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ( $840 million ) and IH ( $29 million ). In addition, 2016 includes an impairment loss of $452 million related to Pfizer’s 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2E. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. In 2015 , primarily includes an impairment loss of $463 million related to Pfizer’s 49% -owned equity-method investment in Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2E ) and intangible asset impairment charges of $323 million , reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: EH ( $294 million ), WRD ( $13 million ); and Consumer Healthcare ( $17 million ). The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. In 2014 includes intangible asset impairment charges of $396 million , reflecting (i) $190 million for an IPR&D compound for the treatment of skin fibrosis (full write-off); (ii) $159 million for developed technology rights, primarily related to Quillivant XR; and (iii) $47 million for indefinite-lived brands. The intangible asset impairment charges for 2014 are associated with the following: IH ( $12 million ); EH ( $166 million ); WRD ( $190 million ); and Consumer Healthcare ( $28 million ). In addition, 2014 includes an impairment charge of approximately $56 million related to our investment in Teuto. The intangible asset impairment charges for 2014 reflect, among other things, updated commercial forecasts and, with regard to IPR&D, the impact of changes to the development program and new scientific findings. (h) Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (i) In 2016, includes among other things, (i) $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A ); (ii) income of $116 million from resolution of a contract disagreement; and (iii) a net loss of approximately $312 million upon the early redemption of debt, which includes the related termination of interest rate swaps. In 2015 , includes, among other things, (i) charges of $194 million related to the write-down of assets to net realizable value; (ii) charges of $159 million , reflecting the change in the fair value of contingent consideration liabilities; and (iii) income of $45 million associated with equity-method investees. In 2014 , includes, among other things, (i) gains of approximately $40 million , reflecting the change in the fair value of contingent consideration liabilities associated with prior acquisitions; (ii) income associated with equity-method investees of $86 million ; (iii) income of $55 million resulting from a decline in the estimated loss on an option to acquire the remaining interest in Teuto; and (iv) a loss of $30 million due to a change in our ownership interest in ViiV. For additional information concerning Teuto and ViiV, see Note 2E. The asset impairment charges included in Other (income)/deductions––net are based on estimates of fair value. The following table provides additional information about the intangible assets that were impaired during 2016 in Other (income)/deductions––net : Year Ended December 31, Fair Value (a) 2016 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets––IPR&D (b) $ 95 $ — $ — $ 95 $ 503 Intangible assets––Developed technology rights (b) 30 — — 30 366 Total $ 125 $ — $ — $ 125 $ 869 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E. (b) Reflects intangible assets written down to fair value in 2016 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters

Tax Matters	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations The following table provides the components of Income from continuing operations before provision for taxes on income : Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 United States $ (8,534 ) $ (6,809 ) $ (4,744 ) International 16,886 15,773 16,984 Income from continuing operations before provision for taxes on income ( a), (b) $ 8,351 $ 8,965 $ 12,240 (a) 2016 v. 2015 –– The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs. (b) 2015 v. 2014 –– The increase in the domestic loss was primarily due to the loss of exclusivity for Celebrex and Zyvox, higher restructuring charges and higher selling, informational and administrative expenses, partially offset by the performance of certain products including Prevnar 13 and Ibrance, and the impact of Hospira operations. The decrease in international income was primarily due to a foreign currency loss related to Venezuela, higher asset impairments, and the loss of exclusivity for Lyrica in certain developed markets, partially offset by lower R&D costs. The following table provides the components of Provision for taxes on income based on the location of the taxing authorities: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 United States Current income taxes: Federal $ 342 $ 67 $ 393 State and local (52 ) (8 ) 85 Deferred income taxes: Federal (419 ) 300 725 State and local (106 ) (36 ) (256 ) Total U.S. tax provision (235 ) 323 948 International Current income taxes 1,532 1,951 2,321 Deferred income taxes (175 ) (284 ) (149 ) Total international tax provision 1,358 1,667 2,172 Provision for taxes on income $ 1,123 $ 1,990 $ 3,120 In 2016 , the Provision for taxes on income was impacted by the following: • U.S. tax expense of approximately $1.1 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year (see Note 5C ); • tax benefits of approximately $460 million , representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations; • benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position; • net tax benefits of $89 million , related to the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, requiring excess tax benefits or deficiencies of share-based compensation to be recognized as a component of the Provision for taxes on income (see Note 1B ); • the non-deductibility of a $312 million fee payable to the federal government as a result of the U.S. Healthcare Legislation; and • the permanent extension of the U.S. R&D tax credit, which was signed into law in December 2015. In 2015 , the Provision for taxes on income was impacted by the following: • U.S. tax expense of approximately $2.1 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year (see Note 5C ); • tax benefits of approximately $360 million , representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations; • the permanent extension of the U.S. R&D tax credit, which was signed into law in December 2015, as well as tax benefits associated with certain tax initiatives; • the non-deductibility of a foreign currency loss related to Venezuela; • the non-deductibility of a charge for the agreement in principle reached in February 2016 to resolve claims relating to Protonix; and • the non-deductibility of a $251 million fee payable to the federal government as a result of the U.S. Healthcare Legislation. In 2014 , the Provision for taxes on income was impacted by the following: • U.S. tax expense of approximately $2.2 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in 2014 (see Note 5C ); • tax benefits of approximately $350 million , representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations; • the favorable impact of the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely; • the extension of the U.S. R&D tax credit, which was signed into law in December 2014; and • the non-deductibility of a $362 million fee payable to the federal government as a result of the U.S. Healthcare Legislation. In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision for taxes on income (see Note 2A ). B. Tax Rate Reconciliation The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows: Year Ended December 31, 2016 2015 2014 U.S. statutory income tax rate 35.0 % 35.0 % 35.0 % Taxation of non-U.S. operations (a), (b), (c) (13.8 ) (9.6 ) (7.4 ) Tax settlements and resolution of certain tax positions (d) (5.5 ) (4.0 ) (2.9 ) U.S. Healthcare Legislation (d) 1.3 0.9 1.0 U.S. R&D tax credit and manufacturing deduction (d) (1.0 ) (1.0 ) (0.9 ) Certain legal settlements and charges (d) (2.9 ) 3.1 — All other, net (e) 0.3 (2.1 ) 0.5 Effective tax rate for income from continuing operations 13.4 % 22.2 % 25.5 % (a) For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision for taxes on income . (b) In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico, Singapore, Costa Rica, and the Dominican Republic. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations. Hospira’s infusion technologies business benefits from income tax exemptions in Costa Rica and the Dominican Republic through 2028 and 2019, respectively. (c) The favorable rate impact in 2016 also includes the non-recurrence of the non-deductibility of a foreign currency loss related to Venezuela. The rate impact in 2015 also includes the non-deductibility of a foreign currency loss related to Venezuela. The favorable rate impact in 2014 also includes the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expected to retain the investment indefinitely. For additional information, see Note 2E. (d) For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and the impact of certain legal settlements and charges, see Note 5A. (e) All other, net in 2015 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. C. Deferred Taxes Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts. The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow: 2016 Deferred Tax 2015 Deferred Tax (MILLIONS OF DOLLARS) Assets (Liabilities) Assets (Liabilities) Prepaid/deferred items $ 2,180 $ (68 ) $ 2,247 $ (38 ) Inventories 366 (47 ) 381 (190 ) Intangible assets 1,139 (15,172 ) 1,063 (10,885 ) Property, plant and equipment 92 (982 ) 65 (1,096 ) Employee benefits 3,356 (74 ) 3,302 (167 ) Restructurings and other charges 458 (2 ) 318 (20 ) Legal and product liability reserves 650 — 730 — Net operating loss/tax credit carryforwards (a) 2,957 — 3,808 — Unremitted earnings (b) — (23,108 ) — (23,626 ) State and local tax adjustments 301 — 328 — All other 306 (503 ) 310 (646 ) 11,806 (39,956 ) 12,552 (36,668 ) Valuation allowances (1,949 ) — (2,029 ) — Total deferred taxes $ 9,857 $ (39,956 ) $ 10,523 $ (36,668 ) Net deferred tax liability (c) $ (30,099 ) $ (26,145 ) (a) The amounts in 2016 and 2015 are reduced for unrecognized tax benefits of $3.0 billion and $2.9 billion , respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. (b) The decrease in 2016 reflects the reversal of certain prior year accruals for earnings outside the U.S. that were not indefinitely reinvested overseas, partially offset by additional accruals for certain funds earned outside the U.S. in the current year that will not be indefinitely reinvested overseas. For additional information, see Note 5A. (c) In 2016 , Noncurrent deferred tax assets and other noncurrent tax assets ( $654 million ), and Noncurrent deferred tax liabilities ( $30.8 billion ). In 2015 , Noncurrent deferred tax assets and other noncurrent tax assets ( $732 million ), and Noncurrent deferred tax liabilities ( $26.8 billion ). We have carryforwards, primarily related to foreign tax credits, net operating and capital losses and charitable contributions, which are available to reduce future U.S. federal and state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2017 to 2036. Certain of our U.S. net operating losses are subject to limitations under IRC Section 382. Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. As of December 31, 2016 , we have not made a U.S. tax provision on approximately $86.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2016 , is not practicable. D. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. For a description of our accounting policies associated with accounting for income tax contingencies, see Note 1O. For a description of the risks associated with estimates and assumptions, see Note 1C. Uncertain Tax Positions As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2016 and 2015 , we had approximately $4.6 billion and $4.8 billion , respectively, in net unrecognized tax benefits, excluding associated interest. • Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2016 and 2015 , we had approximately $1.2 billion and $1.1 billion , respectively, in assets associated with uncertain tax positions. In 2016 , these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ( $1.0 billion ) and Noncurrent deferred tax liabilities ( $201 million ). In 2015 , these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ( $963 million ) and Noncurrent deferred tax liabilities ( $179 million ). • Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows: (MILLIONS OF DOLLARS) 2016 2015 2014 Balance, beginning $ (5,919 ) $ (6,182 ) $ (6,087 ) Acquisitions (a) (83 ) (110 ) — Increases based on tax positions taken during a prior period (b) (11 ) (31 ) (110 ) Decreases based on tax positions taken during a prior period (b), (c) 409 496 473 Decreases based on settlements for a prior period (d) 126 64 70 Increases based on tax positions taken during the current period (b) (489 ) (675 ) (795 ) Impact of foreign exchange (5 ) 319 161 Other, net (b), (e) 146 199 106 Balance, ending (f) $ (5,826 ) $ (5,919 ) $ (6,182 ) (a) For 2016, primarily related to the acquisitions of Medivation and Anacor. For 2015, primarily related to the acquisition of Hospira. See also Note 2A. (b) Primarily included in Provision for taxes on income. (c) Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A. (d) Primarily related to cash payments and reductions of tax attributes. (e) Primarily related to decreases as a result of a lapse of applicable statutes of limitations. (f) In 2016 , included in Income taxes payable ( $14 million ), Current tax assets ( $17 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $184 million ), Noncurrent deferred tax liabilities ( $2.8 billion ) and Other taxes payable ( $2.8 billion ). In 2015 , included in Income taxes payable ( $38 million ), Current tax assets ( $22 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $135 million ), Noncurrent deferred tax liabilities ( $2.7 billion ) and Other taxes payable ( $3.0 billion ). • Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded in Provision for taxes on income in our consolidated statements of income. In 2016 , we recorded net interest expense of $72 million . In 2015 , we recorded net interest expense of $71 million ; and in 2014 , we recorded net interest expense of $40 million . Gross accrued interest totaled $771 million as of December 31, 2016 (reflecting a decrease of approximately $18 million as a result of cash payments) and gross accrued interest totaled $714 million as of December 31, 2015 (reflecting a decrease of approximately $5 million as a result of cash payments). In 2016 , these amounts were included in Income taxes payable ( $4 million ) Current tax asset s ( $13 million ) and Other taxes payable ( $754 million ). In 2015 , these amounts were included in Current tax asset s ( $12 million ) and Other taxes payable ( $702 million ). Accrued penalties are not significant. See also Note 5A. Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS: • With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014-2016 are open, but not under audit. All other tax years are closed. • With respect to Hospira, the federal income tax audit of tax years 2010-2011 was effectively settled in the second quarter of 2016. The IRS is currently auditing tax years 2012-2013 and 2014 through short-year 2015. All other tax years are closed. The tax years under audit for Hospira are not considered material to Pfizer. • With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2016), Japan (2015-2016), Europe (2011-2016, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2016, primarily reflecting Brazil) and Puerto Rico (2010-2016). Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next twelve months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $100 million , as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. E. Tax Provision/(Benefit) on Other Comprehensive Loss The following table provides the components of the Tax provision/(benefit) on other comprehensive loss : Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Foreign currency translation adjustments, net (a) $ (15 ) $ 90 $ 42 Unrealized holding gains/(losses) on derivative financial instruments, net (75 ) (173 ) (199 ) Reclassification adjustments for realized (gains)/losses 158 104 262 83 (69 ) 63 Unrealized holding gains/(losses) on available-for-sale securities, net 49 (104 ) (56 ) Reclassification adjustments for realized (gains)/losses (15 ) 59 10 34 (45 ) (46 ) Benefit plans: actuarial losses, net (535 ) (23 ) (1,416 ) Reclassification adjustments related to amortization 186 183 61 Reclassification adjustments related to settlements, net 45 237 35 Other 36 66 61 (269 ) 462 (1,258 ) Benefit plans: prior service credits and other, net 67 160 281 Reclassification adjustments related to amortization (64 ) (59 ) (28 ) Reclassification adjustments related to curtailments, net (10 ) (12 ) — Other (1 ) — (1 ) (7 ) 89 253 Tax provision/(benefit) on other comprehensive loss $ (174 ) $ 528 $ (946 ) (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gain/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/ Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, January 1, 2014 $ (590 ) $ 79 $ 150 $ (3,223 ) $ 313 $ (3,271 ) Other comprehensive income/(loss) (a) (2,099 ) 438 (372 ) (2,432 ) 419 (4,045 ) Balance, December 31, 2014 (2,689 ) 517 (222 ) (5,654 ) 733 (7,316 ) Other comprehensive income/(loss) (a) (3,174 ) (96 ) (5 ) 921 148 (2,206 ) Balance, December 31, 2015 (5,863 ) 421 (227 ) (4,733 ) 880 (9,522 ) Other comprehensive income/(loss) (a) $ (797 ) $ (73 ) $ 96 $ (740 ) $ (1 ) $ (1,514 ) Balance, December 31, 2016 $ (6,659 ) $ 348 $ (131 ) $ (5,473 ) $ 879 $ (11,036 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $3 million loss in 2016 , $26 million loss in 2015 and $3 million gain in 2014 . As of December 31, 2016 , we estimate that we will reclassify into 2017 income the following pre-tax amounts currently held in Accumulated other comprehensive loss : $328 million of unrealized pre-tax gains on derivative financial instruments (which is expected to be offset primarily by losses resulting from reclassification adjustments related to foreign currency exchange-denominated intercompany sales and available-for-sale securities); $608 million of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and $184 million of prior service credits, primarily related to benefit plan amendments.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2016
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Selected Financial Assets and Liabilities The following table provides additional information about certain of our financial assets and liabilities: As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Selected financial assets measured at fair value on a recurring basis (a) Trading funds and securities (b) $ 325 $ 287 Available-for-sale debt securities (c) 18,632 32,078 Money market funds 1,445 934 Available-for-sale equity securities (c) 540 603 Derivative financial instruments in a receivable position (d) : Interest rate swaps 625 837 Foreign currency swaps 79 135 Foreign currency forward-exchange contracts 551 559 22,198 35,433 Other selected financial assets Held-to-maturity debt securities, carried at amortized cost (c), (e) 1,242 1,388 Private equity securities, carried at equity-method or at cost-method (e), (f) 735 1,336 1,977 2,724 Total selected financial assets $ 24,175 $ 38,157 Selected financial liabilities measured at fair value on a recurring basis (a) Derivative financial instruments in a liability position (g) : Interest rate swaps $ 148 $ 139 Foreign currency swaps 1,374 1,489 Foreign currency forward-exchange contracts 143 81 1,665 1,709 Other selected financial liabilities Short-term borrowings: Principal amount 10,674 10,160 Net fair value adjustments related to hedging and purchase accounting 24 2 Net unamortized discounts, premiums and debt issuance costs (h) (11 ) (3 ) Total short-term borrowings, carried at historical proceeds, as adjusted (e) 10,688 10,159 Long-term debt: Principal amount 30,529 27,573 Net fair value adjustments related to hedging and purchase accounting 998 1,294 Net unamortized discounts, premiums and debt issuance costs (h) (130 ) (127 ) Total long-term debt, carried at historical proceeds, as adjusted (i) 31,398 28,740 42,085 38,899 Total selected financial liabilities $ 43,750 $ 40,608 (a) We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value. (b) As of December 31, 2016 , trading funds and securities are composed of $236 million of trading equity funds and $89 million of trading debt funds. As of December 31, 2015 , trading funds and securities are composed of $185 million of trading equity funds and $102 million of trading debt funds. As of December 31, 2016 and December 31, 2015 , trading equity funds of $71 million and $85 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. (c) Gross unrealized gains and losses related to 2016 are not significant. Unrealized losses related to 2015 available-for-sale debt securities are $593 million and unrealized gains are $44 million . The vast majority of investments related to 2015, in an unrealized loss position, relate to the foreign exchange impact on foreign currency denominated securities, which are hedged with foreign currency forward-exchange contracts and cross-currency swaps. We have the intent and ability to hold such investments to maturity. (d) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $162 million as of December 31, 2016 ; and foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015 . (e) The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2016 or December 31, 2015 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments. (f) Our private equity securities represent investments in the life sciences sector. (g) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $269 million and foreign currency forward-exchange contracts with fair values of $113 million as of December 31, 2016 ; and foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $59 million as of December 31, 2015 . (h) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (i) The fair value of our long-term debt (not including the current portion of long-term debt) was $34.9 billion as of December 31, 2016 and $32.7 billion as of December 31, 2015 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C. The following methods and assumptions were used to estimate the fair value of our financial assets and liabilities: • Trading equity securities—quoted market prices. • Trading debt securities—observable market interest rates. • Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. Receivable-backed, loan-backed, and mortgage-backed securities are valued by third-party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates. • Money market funds—observable net asset value prices. • Available-for-sale equity securities—third-party pricing services that principally use a composite of observable prices. • Derivative financial instruments (assets and liabilities)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant. • Held-to-maturity debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. • Private equity securities, excluding equity-method investments—application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio. • Short-term borrowings and long-term debt—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and our own credit rating. We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments. The following table provides the classification of these selected financial assets and liabilities in our consolidated balance sheets: As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Assets Cash and cash equivalents $ 547 $ 978 Short-term investments 15,255 19,649 Other current assets (a) 567 587 Long-term investments 7,116 15,999 Other noncurrent assets (b) 689 944 $ 24,175 $ 38,157 Liabilities Short-term borrowings, including current portion of long-term debt (c) $ 10,688 $ 10,159 Other current liabilities (d) 443 645 Long-term debt (c) 31,398 28,740 Other noncurrent liabilities (e) 1,222 1,064 $ 43,750 $ 40,608 (a) As of December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $26 million ), foreign currency swaps ( $43 million ) and foreign currency forward-exchange contracts ( $497 million ) and, as of December 31, 2015 , include interest rate swaps ( $2 million ), foreign currency swaps ( $46 million ) and foreign currency forward-exchange contracts ( $538 million ). (b) As of December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $599 million ), foreign currency swaps ( $36 million ) and foreign currency forward-exchange contracts ( $54 million ) and, as of December 31, 2015 , include interest rate swaps ( $835 million ), foreign currency swaps ( $89 million ) and foreign currency forward-exchange contracts ( $20 million ). (c) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (d) At December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $1 million ), foreign currency swaps ( $300 million ) and foreign currency forward-exchange contracts ( $143 million ) and, as of December 31, 2015 , include interest rate swaps ( $5 million ), foreign currency swaps ( $560 million ) and foreign currency forward-exchange contracts ( $80 million ). (e) At December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $147 million ) and foreign currency swaps ( $1.1 billion ) and, as of December 31, 2015 , include interest rate swaps ( $134 million ), foreign currency swaps ( $928 million ) and foreign currency forward-exchange contracts ( $1 million ). In addition, as of December 31, 2016 and 2015 , we had long-term receivables where the determination of fair value employs discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. As of December 31, 2016 and 2015 , the differences between the estimated fair values and carrying values of these receivables were not significant. There were no significant impairments of financial assets recognized in any period presented. B. Investments in Debt Securities The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: Years December 31, (MILLIONS OF DOLLARS) Within 1 Over 1 to 5 Over 5 to 10 Over 10 Total Available-for-sale debt securities Corporate debt (a) $ 2,783 $ 2,727 $ 1,557 $ 23 $ 7,089 Western European, Scandinavian and other government debt (b) 4,661 432 — — 5,093 U.S. government debt 2,134 88 — — 2,222 Western European, Scandinavian, Australian and other government agency debt (b) 1,746 137 — — 1,883 Supranational debt (b) 910 294 — — 1,204 Other asset-backed debt (c) 367 217 18 3 605 Government National Mortgage Association and other U.S. government guaranteed asset-backed securities 535 — — — 535 Held-to-maturity debt securities Time deposits and other 1,000 1 3 — 1,004 Western European government debt (b) 236 2 — — 238 Total debt securities $ 14,371 $ 3,898 $ 1,579 $ 26 $ 19,873 (a) Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade. (b) Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade. (c) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. C. Short-Term Borrowings Short-term borrowings include amounts for commercial paper of $5.8 billion as of December 31, 2016 and $4.9 billion as of December 31, 2015 . The weighted-average effective interest rate on short-term borrowings outstanding was approximately 1.3% as of December 31, 2016 and 1.9% as of December 31, 2015 . On June 24, 2016, we acquired Anacor and assumed its short-term debt with an acquisition date fair value of $698 million which was redeemed in the second and third quarters of 2016. As of December 31, 2016 , we had access to $7.9 billion of lines of credit, of which $790 million expire within one year . Of these lines of credit, $7.8 billion were unused, of which our lenders have committed to loan us $7.1 billion at our request. Also, $7.0 billion of our unused lines of credit, all of which expire in 2021, may be used to support our commercial paper borrowings. D. Long-Term Debt November 2016 Public Debt Offering On November 21, 2016, we completed a public offering of $6.0 billion aggregate principal amount of senior unsecured notes: $1.0 billion of notes due 2019; $1.0 billion of notes due 2021; $1.75 billion of notes due 2026; $1.0 billion of notes due 2036; and $1.25 billion of notes due 2046, with a weighted-average effective interest rate of 3.10% . The notes are redeemable, in whole or in part, at any time at our option, at a redemption price equal to the greater of 100% of the principal amount of the notes or the sum of the present value of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate, plus an incremental spread ranging between 0.10% and 0.20% , depending on the maturity; plus, in each case, accrued and unpaid interest. We used a portion of the proceeds from the November 2016 public debt offering of $6.0 billion to repurchase a total of $3.4 billion carrying value of outstanding debt before the maturity date at a redemption value of $3.7 billion . The debt repurchased included $3.27 billion carrying value of 6.20% senior notes due March 2019. As a result, we recorded a total net loss of approximately $312 million upon the early redemption of debt, which includes the related termination of interest rate swaps, and which was recorded in Other (income)/deductions––net in the consolidated statement of income (see Note 4 ). June 2016 Public Debt Offering On June 3, 2016, we completed a public offering of $5.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.09% . The notes are redeemable, in whole or in part, at any time at our option, at a redemption price equal to the greater of 100% of the principal amount of the notes or the sum of the present value of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate, plus an incremental spread ranging between 0.05% and 0.15% , depending on the maturity; plus, in each case, accrued and unpaid interest. Acquisition of Hospira Debt On September 3, 2015, the Hospira acquisition date, our long-term debt increased due to the addition of an aggregate principal amount of $1,750 million of legacy Hospira debt, recorded at acquisition-date fair value of $1,928 million . In October 2015, Pfizer exchanged $1.7 billion debt of its then recently acquired subsidiary, Hospira, for virtually the same amount of Pfizer debt with the same interest rate and maturity terms as the Hospira debt, leaving a minor amount of outstanding debt in Hospira’s name that was redeemed during the fourth quarter of 2016. In connection with the exchange offers, the indenture governing the Hospira notes and the Hospira notes were amended to, among other things, eliminate substantially all of the restrictive covenants. The net income effect of this exchange was immaterial. Long Term Debt The following table provides the components of our senior unsecured long-term debt (a) : Principal As of December 31, (MILLIONS OF DOLLARS) Maturity Date 2016 2015 4.55% euro (b) May 2017 $ — $ 980 1.10% (b) May 2017 — 1,000 1.20% June 2018 1,250 — 1.50% June 2018 1,000 1,000 6.20% March 2019 — 3,250 2.10% May 2019 1,500 1,500 1.70% December 2019 1,000 — 5.75% euro June 2021 2,108 2,178 1.95% June 2021 1,150 — 2.20% December 2021 1,000 — 3.00% June 2023 1,000 1,000 3.40% May 2024 1,000 1,000 2.75% June 2026 1,250 — 3.00% December 2026 1,750 — 4.00% December 2036 1,000 — 5.95% April 2037 2,000 2,000 6.50% U.K. pound June 2038 1,852 2,223 7.20% March 2039 2,500 2,500 4.40% May 2044 1,000 500 4.125% December 2046 1,250 — Notes and other debt with a weighted-average interest rate of 3.30% (c) 2018–2021 2,464 3,974 Notes and other debt with a weighted-average interest rate of 5.99% (d) 2023–2043 4,455 4,468 Total principal amount of long-term debt 30,529 27,573 Net fair value adjustments related to hedging and purchase accounting 998 1,294 Net unamortized discounts, premiums and debt issuance costs (130 ) (127 ) Total long-term debt, carried at historical proceeds, as adjusted $ 31,398 $ 28,740 Current portion of long-term debt (not included above) $ 4,225 $ 3,719 (a) Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus an incremental spread ranging from 0.05% to 0.50% , plus, in each case, accrued and unpaid interest. (b) At December 31, 2016, the debt issuances have been reclassified to the current portion of long-term debt. (c) Contains debt issuances with a weighted-average maturity of approximately two years for balances that exist as of December 31, 2016 . (d) Contains debt issuances with a weighted-average maturity of approximately 16 years for balances that exist as of December 31, 2016 . The following table provides the maturity schedule of our Long-term debt outstanding as of December 31, 2016: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 After 2021 Total Maturities $ 3,567 $ 3,350 $ 360 $ 4,241 $ 19,879 $ 31,398 E. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income and net investments against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. As of December 31, 2016 , the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was $27.5 billion . The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, and Japanese yen. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.9 billion U.K. pound debt maturing in 2038. All derivative contracts used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings or in Other comprehensive income/(loss) , depending on the nature and purpose of the financial instrument (offset or hedge relationship) and the effectiveness of the hedge relationships, as follows: • We record in Other comprehensive income/(loss) the effective portion of the gains or losses on foreign currency forward-exchange contracts and foreign currency swaps that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. • We recognize the gains and losses on foreign currency forward-exchange contracts and foreign currency swaps that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. • We recognize the gain and loss impact on foreign currency swaps and foreign currency forward-exchange contracts designated as hedges of our net investments in earnings in three ways: over time—for the periodic net swap payments; immediately—to the extent of any change in the difference between the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net investments—to the extent of change in the foreign exchange spot rates. • We record in Other comprehensive income/(loss) the foreign exchange gains and losses related to foreign exchange-denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. We designate foreign currency forward-exchange contracts as cash flow hedges of a portion of our forecasted euro, Japanese yen, U.K. pound, Australian dollar, and Canadian dollar-denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. As of December 31, 2016, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted sales was $3.1 billion , with a pre-tax gain of $222 million deferred in Accumulated other comprehensive loss. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $164 million within the next 12 months into Cost of sales. Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented. Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. We strive to invest and borrow primarily on a floating-rate basis; however, in light of current market conditions, we currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. As of December 31, 2016 , the aggregate notional amount of interest rate derivative financial instruments was $16 billion . The derivative financial instruments primarily hedge U.S. dollar and euro fixed-rate debt. All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows: • We recognize the gains and losses on interest rate swaps that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk also in earnings. Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented. The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion) (a), (d) As of December 31, (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ (280 ) $ (826 ) $ (387 ) $ (613 ) Foreign currency forward-exchange contracts (4 ) — (164 ) 1,028 (65 ) 980 Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts 1 (1 ) (15 ) 256 — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts (92 ) (42 ) — — — — Foreign currency swaps (13 ) (4 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — (26 ) 3 — — All other net — (16 ) 1 — (1 ) — $ (107 ) $ (64 ) $ (483 ) $ 461 $ (452 ) $ 367 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income . OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income . (b) Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships. (c) There was no significant ineffectiveness for any period presented. (d) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive loss––Foreign currency translation adjustments, net. For information about the fair value of our derivative financial instruments, and the impact on our consolidated balance sheets, see Note 7A above . Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. As of December 31, 2016 , the aggregate fair value of these derivative instruments that are in a net liability position was $936 million , for which we have posted collateral of $958 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties. F. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. For additional information, see N ote 18C . As of December 31, 2016 , we had $1.2 billion due from a well-diversified, highly rated group (S&P ratings of mostly A or better) of bank counterparties around the world. For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request collateral payments, depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of December 31, 2016 , we received cash collateral of $613 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Finished goods $ 2,293 $ 2,714 Work in process 3,696 3,932 Raw materials and supplies 793 867 Inventories (a) $ 6,783 $ 7,513 Noncurrent inventories not included above (b) $ 683 $ 594 (a) The change from December 31, 2015 reflects, among other things, the reclassification of $377 million to Assets held for sale (see Note 2B) . (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment The following table provides the components of Property, plant and equipment : Useful Lives As of December 31, (MILLIONS OF DOLLARS) (Years) 2016 2015 Land - $ 530 $ 588 Buildings 33-50 9,810 9,604 Machinery and equipment 8-20 11,248 10,933 Furniture, fixtures and other 3-12 1/2 4,410 4,351 Construction in progress - 2,127 1,791 28,125 27,268 Less: Accumulated depreciation 14,807 13,502 Property, plant and equipment (a) $ 13,318 $ 13,766 (a) The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $457 million to Assets held for sale (see Note 2B) and, to a lesser extent, impairments and the impact of foreign exchange, partially offset by capital additions.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : December 31, 2016 December 31, 2015 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 83,390 $ (49,650 ) $ 33,740 $ 77,613 $ (47,193 ) $ 30,419 Brands 2,092 (1,032 ) 1,060 1,973 (928 ) 1,044 Licensing agreements and other 1,869 (1,005 ) 864 1,619 (918 ) 701 87,351 (51,687 ) 35,664 81,205 (49,040 ) 32,165 Indefinite-lived intangible assets Brands and other 6,883 6,883 7,021 7,021 IPR&D (a) 10,101 10,101 1,171 1,171 16,984 16,984 8,192 8,192 Identifiable intangible assets (a) $ 104,335 $ (51,687 ) $ 52,648 $ 89,396 $ (49,040 ) $ 40,356 (a) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A ), and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A ), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale (see Note 2B ). For information about impairments, see Note 4. The increase in IPR&D, is primarily related to assets acquired as part of the acquisitions of Anacor and Medivation, largely crisaborole and Xtandi. The intellectual property for crisaborole is owned by an international entity. Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: December 31, 2016 IH EH WRD Developed technology rights 64 % 35 % — Brands, finite-lived 73 % 27 % — Brands, indefinite-lived 71 % 29 % — IPR&D 92 % 5 % 4 % Developed Technology Rights Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Xtandi, Prevnar 13/Prevenar 13 Infant, Enbrel and, to a lesser extent, Premarin, Prevnar 13/Prevenar 13 Adult, Pristiq, Tygacil, Refacto AF and Effexor. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products. Brands Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. Most of these assets are associated with our Consumer Healthcare business unit. The more significant components of indefinite-lived brands are the following (in order of significance): Advil, Xanax/Xanax XR, Centrum, Caltrate, Medrol and Preparation H. The more significant components of finite-lived brands are the following (in order of significance): Nexium, Depo-Provera, Zavedos and, to a lesser extent, Advil Cold and Sinus and Idoform Bifiform. IPR&D IPR&D assets represent R&D assets that have not yet received regulatory approval in a major market. The more significant components of IPR&D are the programs for the treatment of mild-to-moderate atopic dermatitis acquired as part of the Anacor acquisition, the treatment of non-mestastatic and mestastatic prostate cancer acquired as part of the Medivation acquisition and the program for the treatment of patients with germline breast cancer susceptibility gene BRCA mutated advanced breast cancer. IPR&D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&D effort. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&D and begin amortization. If the associated R&D effort is abandoned, the related IPR&D assets will likely be written-off, and we will record an impairment charge. For IPR&D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&D assets will become impaired and be written off at some time in the future. Amortization The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately 11 years. Total amortization expense for finite-lived intangible assets was $4.1 billion in 2016 , $3.8 billion in 2015 and $4.1 billion in 2014 . The following table provides the annual amortization expense expected for the years 2017 through 2021: (MILLIONS OF DOLLARS) 2017 2018 2019 2020 2021 Amortization expense $ 4,827 $ 4,706 $ 4,481 $ 3,442 $ 3,348 B. Goodwill The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, January 1, 2015 $ 24,430 $ 17,639 $ 42,069 Additions (a) 39 7,284 7,323 Other (b) (660 ) (489 ) (1,149 ) Balance, December 31, 2015 23,809 24,433 48,242 Additions (c) 6,357 12 6,369 Other (d) (32 ) (130 ) (162 ) Balance, December 31, 2016 $ 30,134 $ 24,315 $ 54,449 (a) EH additions relate to our acquisition of Hospira. For additional information, see Note 2A. (b) Primarily reflects the impact of foreign exchange. (c) IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo and are subject to change until we complete the valuations of assets acquired and liabilities assumed from Medivation, Anacor and Bamboo (see Note 2A ). (d) Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $119 million to Assets held for sale during 2016 (see Note 2B ). We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH), which was previously known as Established Products. Beginning in the second quarter of 2016, we reorganized our operating segments to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH. From the beginning of our fiscal year 2014 until the second quarter of 2016, these operations were managed as two business segments: the GIP segment and the VOC segment. We have retrospectively presented goodwill according to the new operating segment structure. For additional information, see Note 18. As a result of this change, our goodwill associated with our former GIP segment was required to be reallocated to new reporting units based on relative fair value.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans and Defined Contribution Plans	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Pension and Postretirement Benefit Plans and Defined Contribution Plans	Pension and Postretirement Benefit Plans and Defined Contribution Plans The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. During 2015, we recorded net pension and postretirement benefit obligations of approximately $115 million as a result of the acquisition of Hospira and an additional $122 million for the decision to terminate Hospira’s U.S. qualified pension plan. A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Loss The following table provides the annual cost/(income) and changes in Other comprehensive loss for our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c), (f) Postretirement Plans (d), (f) (MILLIONS OF DOLLARS) 2016 2015 2014 2016 2015 2014 2016 2015 2014 2016 2015 2014 Service cost $ 257 $ 287 $ 253 $ 18 $ 22 $ 20 $ 165 $ 186 $ 199 $ 41 $ 55 $ 55 Interest cost 646 676 697 53 54 57 233 307 394 101 117 169 Expected return on plan assets (958 ) (1,089 ) (1,043 ) — — — (381 ) (418 ) (459 ) (34 ) (53 ) (63 ) Amortization of: Actuarial losses 395 346 63 37 44 29 93 122 97 32 38 6 Prior service credits 5 (5 ) (7 ) (1 ) (2 ) (2 ) (3 ) (7 ) (7 ) (174 ) (146 ) (57 ) Curtailments 10 3 2 1 — — (2 ) 5 — (26 ) (31 ) (7 ) Settlements 90 556 52 28 34 28 9 81 22 — — — Special termination benefits — — — — — — 1 1 8 — — — Net periodic benefit costs/(income) reported in Income 444 773 16 137 153 132 115 277 254 (59 ) (21 ) 102 (Income)/cost reported in Other comprehensive loss (e) 253 (396 ) 2,768 121 (143 ) 163 640 (542 ) 260 3 (540 ) (174 ) (Income)/cost recognized in Comprehensive income $ 697 $ 378 $ 2,784 $ 258 $ 10 $ 294 $ 755 $ (265 ) $ 514 $ (56 ) $ (560 ) $ (72 ) (a) 2016 v. 2015 –– The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a year-over-year decrease in settlement activity compared to that of 2015 related to the non-recurring lump-sum settlement option to certain plan participants discussed in the 2015 v. 2014 analysis, below, (ii) lower service costs resulting from a higher discount rate, and (iii) lower interest costs resulting from a lower beginning benefit obligation. The aforementioned decreases were partially offset by (i) a lower expected return on plan assets resulting from both a lower expected rate of return, and a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, and (ii) an increase in the amounts amortized for actuarial losses, primarily resulting from the remeasurement in 2015 of Hospira’s U.S. qualified pension plan due to its plan termination. 2015 v. 2014 –– The increase in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a non-recurring charge of $419 million related to the settlement of pension obligations in accordance with an offer to certain terminated employees who are vested in their pension benefits to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or an annuity of their deferred vested pension benefits, and (ii) the increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation (which increased the amount of deferred actuarial losses), and, to a lesser extent, a 2014 change in mortality assumptions (reflecting a longer life expectancy for plan participants). The aforementioned increases were partially offset by (i) a greater expected return on plan assets resulting from an increased plan asset base due to a voluntary contribution of $1.0 billion made at the beginning of January 2015, which in turn was partially offset by a decrease in the expected rate of return on plan assets from 8.5% to 8.3% and (ii) lower interest costs resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. (b) 2016 v. 2015 –– The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation, (ii) lower settlement activity, and (iii) lower service costs resulting from a higher discount rate. 2015 v. 2014 –– The increase in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (ii) higher settlement activity. (c) 2016 v. 2015 –– The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) lower service and interest costs, resulting from a change in our approach for measuring service and interest costs (see (f) below), (ii) lower settlement activity, and (iii) a decrease in the amounts amortized for actuarial losses resulting from large gains in 2015, which decreased the plan net loss position. The aforementioned decreases to our net periodic benefit costs were partially offset by a decrease in the expected return on plan assets due to a lower asset base and a lower expected rate of return on plan assets. 2015 v. 2014 –– The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets, (ii) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (iii) higher settlement charges due to the settlement of a pension plan in Sweden. The aforementioned increase in net periodic benefit costs was partially offset by the decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. (d) 2016 v. 2015 –– The increase in net periodic benefit income for our postretirement plans was primarily driven by (i) an increase in prior service credits due to the postretirement medical plan cap changes during 2016 and 2015, (ii) lower interest costs resulting from a lower benefit obligation, (iii) lower service costs resulting from a higher discount rate, and (iv) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. The aforementioned changes were partially offset by (i) a decrease in expected return on plan assets, primarily resulting from a decrease in plan assets, reflecting payments by the plan for IRC Section 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees, and (ii) lower curtailment gains. 2015 v. 2014 –– The decrease in net periodic benefit costs for our postretirement plans was primarily driven by (i) the increase in the amounts amortized for prior service credits and (ii) an increase in curtailment gains resulting from the implementation of changes to certain retiree medical benefits to adopt programs eligible for the Medicare Part D plan subsidy, as allowed under the EGWP, and another plan change to establish benefit caps for certain plan participants, as well as (iii) a decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. The aforementioned decreases were partially offset by an increase in actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. (e) For details of the changes in Other comprehensive loss, see the benefit plan activity in the consolidated statements of comprehensive income. (f) Effective January 1, 2016, the Company changed the approach used to measure service and interest costs for certain international pension and other postretirement benefit plans. For fiscal 2015 and 2014, the Company measured service and interest costs utilizing a single weighted-average discount rate derived from the yield curve used to measure the respective plan obligations. For fiscal 2016, we elected to measure service and interest costs by applying the spot rates along the yield curve for certain international plans to the plans' liability cash flows. The Company believes the new approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. This change does not affect the measurement of our plan obligations. We have accounted for this change as a change in accounting estimate and, accordingly, have accounted for it on a prospective basis. The reduction in expense for 2016 associated with this change in estimate was $42 million , primarily related to certain international pension plans, which was recognized evenly over each quarter of the year. The change in approach for the postretirement benefit plans was not material to the 2016 consolidated statement of income. The following table provides the amounts in Accumulated other comprehensive loss expected to be amortized into 2017 net periodic benefit costs: Pension Plans (MILLIONS OF DOLLARS) U.S. U.S. Supplemental International Postretirement Plans Actuarial losses $ (414 ) $ (50 ) $ (113 ) $ (31 ) Prior service credits and other (5 ) 1 4 184 Total $ (419 ) $ (49 ) $ (109 ) $ 153 B. Actuarial Assumptions The following table provides the weighted-average actuarial assumptions of our benefit plans: (PERCENTAGES) 2016 2015 2014 Weighted-average assumptions used to determine benefit obligations Discount rate: U.S. qualified pension plans 4.3% 4.5% 4.2% U.S. non-qualified pension plans 4.2% 4.5% 4.0% International pension plans 2.4% 3.1% 3.0% Postretirement plans 4.2% 4.5% 4.2% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.6% 2.6% 2.7% Weighted-average assumptions used to determine net periodic benefit cost Discount rate: U.S. qualified pension plans 4.5% 4.2% 5.2% U.S. non-qualified pension plans 4.5% 4.0% 4.8% International pension plans interest cost (a) 2.7% 3.0% 3.9% International pension plans service cost (a) 3.0% 3.0% 3.9% Postretirement plans 4.5% 4.2% 5.1% Expected return on plan assets: U.S. qualified pension plans 8.0% 8.3% 8.5% International pension plans 5.2% 5.5% 5.8% Postretirement plans 8.0% 8.3% 8.5% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.6% 2.7% 2.9% (a) As discussed above, effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with this change, the effective rate for interest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans. The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit obligations are established at each fiscal year-end. The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits. The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2016 resulted in lower discount rates as compared to the prior year. The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans: 2016 2015 Healthcare cost trend rate assumed for next year (up to age 65) 6.3 % 6.5 % Healthcare cost trend rate assumed for next year (age 65 and older) 7.4 % 7.9 % Rate to which the cost trend rate is assumed to decline 4.5 % 4.5 % Year that the rate reaches the ultimate trend rate 2037 2037 The following table provides the effects as of December 31, 2016 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits: (MILLIONS OF DOLLARS) Increase Decrease Effect on total service and interest cost components $ 5 $ (5 ) Effect on postretirement benefit obligation 37 (50 ) Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see Note 1C . C. Obligations and Funded Status The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c) Postretirement Plans (d) (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 2016 2015 Change in benefit obligation (e) Benefit obligation, beginning $ 14,926 $ 16,575 $ 1,343 $ 1,481 $ 9,214 $ 10,796 $ 2,463 $ 3,168 Service cost 257 287 18 22 165 186 41 55 Interest cost 646 676 53 54 233 307 101 117 Employee contributions — — — — 7 7 85 79 Plan amendments — 62 — 4 (6 ) (1 ) (177 ) (497 ) Changes in actuarial assumptions and other 725 (774 ) 185 (70 ) 1,273 (273 ) 22 (185 ) Foreign exchange impact — — — — (781 ) (938 ) — (20 ) Acquisitions/divestitures/other, net — 542 — 9 1 19 — 49 Curtailments 9 3 1 — (14 ) (2 ) — (3 ) Settlements (449 ) (2,034 ) (78 ) (93 ) (45 ) (499 ) — — Special termination benefits — — — — 1 1 — — Benefits paid (568 ) (412 ) (72 ) (65 ) (358 ) (389 ) (282 ) (300 ) Benefit obligation, ending (e) 15,547 14,926 1,450 1,343 9,691 9,214 2,254 2,463 Change in plan assets Fair value of plan assets, beginning 11,633 12,706 — — 7,959 8,588 622 762 Actual gain/(loss) on plan assets 939 (124 ) — — 693 290 44 (3 ) Company contributions 1,000 1,000 151 158 209 558 (12 ) 84 Employee contributions — — — — 7 7 85 79 Foreign exchange impact — — — — (782 ) (602 ) — — Acquisitions/divestitures, net — 496 — — (1 ) 6 — — Settlements (449 ) (2,034 ) (78 ) (93 ) (45 ) (499 ) — — Benefits paid (568 ) (412 ) (72 ) (65 ) (358 ) (389 ) (282 ) (300 ) Fair value of plan assets, ending 12,556 11,633 — — 7,683 7,959 458 622 Funded status—Plan assets less than benefit obligation $ (2,990 ) $ (3,292 ) $ (1,450 ) $ (1,343 ) $ (2,008 ) $ (1,255 ) $ (1,796 ) $ (1,841 ) (a) The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016. (b) Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations. The increase in the benefit obligation is primarily due to a decrease in the discount rate. (c) The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets. (d) The favorable change in the funded status of our postretirement plans was primarily due to plan amendments for certain U.S. and Puerto Rico postretirement plans. The U.S. plan change applied a fixed cap on costs for certain groups within the plan. The Puerto Rico plan change includes: (i) a cap on costs for certain groups within the plan, and (ii) the adoption of the EGWP. The changes resulted in reductions to the plan liabilities of $82 million for the U.S. postretirement plan and $95 million for the Puerto Rico postretirement plan. (e) For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $15.4 billion in 2016 and $14.8 billion in 2015 . The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2016 and $1.3 billion in 2015 . The ABO for our international pension plans was $9.3 billion in 2016 and $8.8 billion in 2015 . The following table provides information as to how the funded status is recognized in our consolidated balance sheets: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 2016 2015 Noncurrent assets (a) $ — $ — $ — $ — $ 300 $ 572 $ — $ — Current liabilities (b) (160 ) — (152 ) (126 ) (28 ) (25 ) (30 ) (31 ) Noncurrent liabilities (c) (2,830 ) (3,292 ) (1,297 ) (1,216 ) (2,279 ) (1,801 ) (1,766 ) (1,809 ) Funded status $ (2,990 ) $ (3,292 ) $ (1,450 ) $ (1,343 ) $ (2,008 ) $ (1,255 ) $ (1,796 ) $ (1,841 ) (a) Included primarily in Other noncurrent assets . (b) Included in Accrued compensation and related items . (c) Included in Pension benefit obligations, net and Postretirement benefit obligations , net, as appropriate. The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss : As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 2016 2015 Actuarial losses (a) $ (4,530 ) $ (4,272 ) $ (538 ) $ (419 ) $ (2,629 ) $ (1,979 ) $ (502 ) $ (523 ) Prior service (costs)/credits (27 ) (33 ) 2 4 40 29 1,392 1,415 Total $ (4,558 ) $ (4,305 ) $ (536 ) $ (415 ) $ (2,589 ) $ (1,949 ) $ 889 $ 892 (a) The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants, using the corridor approach. The average amortization periods to be utilized for 2017 are 8.2 years for our U.S. qualified plans, 8.1 years for our U.S. supplemental (non-qualified) plans, 19.3 years for our international plans, and 9.1 years for our postretirement plans. The following table provides information related to the funded status of selected benefit plans: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 Pension plans with an ABO in excess of plan assets: Fair value of plan assets $ 12,556 $ 11,633 $ — $ — $ 4,625 $ 976 ABO 15,422 14,755 1,410 1,324 6,558 2,495 Pension plans with a PBO in excess of plan assets: Fair value of plan assets 12,556 11,633 — — 4,936 1,546 PBO 15,547 14,926 1,450 1,343 7,244 3,373 All of our U.S. plans and many of our international plans were underfunded as of December 31, 2016 . D. Plan Assets The following table provides the components of plan assets: Fair Value (a) Fair Value (a) (MILLIONS OF DOLLARS) As of December 31, 2016 Level 1 Level 2 Level 3 Assets Measured at NAV (b) As of December 31, 2015 Level 1 Level 2 Level 3 Assets Measured at NAV (b) U.S. qualified pension plans Cash and cash equivalents $ 672 $ 92 $ 580 $ — $ — $ 417 $ 81 $ 336 $ — $ — Equity securities: Global equity securities 3,970 3,943 27 — — 3,720 3,717 2 1 — Equity commingled funds 1,062 — 772 — 290 951 — 689 — 262 Fixed income securities: Corporate debt securities 3,232 14 3,217 1 — 2,866 3 2,861 2 — Government and government agency obligations 1,060 — 1,060 — — 989 — 989 — — Fixed income commingled funds 92 — — — 92 222 — 57 — 165 Other investments: Partnership investments (c) 1,093 — — — 1,093 1,120 — — — 1,120 Insurance contracts 235 — 235 — — 259 — 259 — — Other commingled funds (d) 1,140 — — — 1,140 1,089 — — — 1,089 Total 12,556 4,049 5,891 1 2,615 11,633 3,801 5,193 3 2,636 International pension plans Cash and cash equivalents 439 38 401 — — 207 14 193 — — Equity securities: Global equity securities 174 163 11 — — 901 816 85 — — Equity commingled funds 2,490 — 1,265 — 1,224 2,218 16 854 — 1,348 Fixed income securities: Corporate debt securities 489 — 474 — 15 653 171 469 — 12 Government and government agency obligations 853 — 786 — 67 1,224 109 1,048 — 67 Fixed income commingled funds 1,750 — 1,174 — 576 1,216 37 919 — 260 Other investments: Partnership investments (c) 32 — — — 32 40 — 6 — 33 Insurance contracts 272 — 17 254 1 257 — 21 219 17 Other (d) 1,185 — 430 324 431 1,245 59 370 398 418 Total 7,683 201 4,558 578 2,346 7,959 1,222 3,965 618 2,155 U.S. postretirement plans (e) Cash and cash equivalents — — — — — 6 — 6 — — Equity securities: Global equity securities — — — — — 64 64 — — — Equity commingled funds — — — — — 16 — 12 — 4 Fixed income securities: Corporate debt securities — — — — — 49 — 49 — — Government and government agency obligations — — — — — 17 — 17 — — Fixed income commingled funds — — — — — 4 — 1 — 3 Other investments: Partnership investments (c) — — — — — 19 — — — 19 Insurance contracts 458 — 458 — — 429 — 429 — — Other commingled funds (d) — — — — — 19 — — — 19 Total $ 458 $ — $ 458 $ — $ — $ 622 $ 64 $ 514 $ — $ 45 (a) Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E ). (b) In accordance with the provisions of a new accounting standard we adopted on January 1, 2016, described below, certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets. As a result, a reclassification has been made to the prior year’s plan asset classification table to conform to the current year’s presentation. (c) Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital. (d) Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds. (e) Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans. The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs: Year Ended December 31, International Pension Plans Insurance contracts Other (MILLIONS OF DOLLARS) 2016 2015 2016 2015 Fair value, beginning (a) $ 219 $ 254 $ 398 $ 395 Actual return on plan assets: Assets held, ending 11 16 (1 ) 30 Assets sold during the period — — 6 13 Purchases, sales and settlements, net 20 (19 ) (18 ) (21 ) Exchange rate changes 4 (33 ) (61 ) (19 ) Fair value, ending $ 254 $ 219 $ 324 $ 398 (a) We adopted a new accounting standard as of January 1, 2016 whereby certain investments in 2016 and 2015 that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been classified as Level 1, 2 or 3 in the above fair value hierarchy table, but are included in the total. As a result, a reclassification has been made to the prior year's plan asset classification table to conform to the current year's presentation. A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C. Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to 3 months. The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets: • Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds. • Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price. • Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs. • Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures. The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans: As of December 31, Target Allocation Percentage Percentage of Plan Assets (PERCENTAGES) 2016 2016 2015 U.S. qualified pension plans Cash and cash equivalents 0-10% 5.3 % 3.6 % Equity securities 35-55% 40.1 % 40.2 % Fixed income securities 30-55% 34.9 % 35 % Other investments (a) 5-17.5% 19.7 % 21.2 % Total 100 % 100 % 100 % International pension plans Cash and cash equivalents 0-10% 5.7 % 2.6 % Equity securities 25-50% 34.7 % 39.2 % Fixed income securities 30-55% 40.2 % 38.8 % Other investments 10-30% 19.4 % 19.4 % Total 100 % 100 % 100 % U.S. postretirement plans Cash and cash equivalents 0-5% — 1.0 % Equity securities — — 12.8 % Fixed income securities — — 11.2 % Other investments 95-100% 100 % 75 % Total 100 % 100 % 100 % (a) Actual percentage of plan assets in Other investments for 2016 includes $235 million (this amount was $259 million in 2015) related to a group fixed annuity insurance contract that was executed by legacy Wyeth for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $144 million (this amount was $129 million in 2015) related to an investment in a partnership whose primary holdings are public equity securities. Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to minimize net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations. Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans’ long-term benefit obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset classes and our liability profile. Each pension plan is overseen by a local committee or board that is responsible for the overall investment of the pension plan assets. In determining investment policies and associated target allocations, each committee or board considers a wide variety of factors. As such, the target asset allocation for each of our international pension plans is set on a standalone basis by the relevant board or committee. The target asset allocation ranges shown for the international pension plans seek to reflect the combined target allocations across all such plans, while also showing the range within which the target allocations for each plan typically falls. The investment managers of certain commingled funds and private equity funds may be permitted to use derivative securities as described in each respective investment management, subscription, partnership or other governing agreement. E. Cash Flows It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws. The following table provides the expected future cash flow information related to our benefit plans: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Expected employer contributions: 2017 (a) $ 1,160 $ 152 $ 175 $ 179 Expected benefit payments: 2017 $ 1,519 $ 152 $ 331 $ 186 2018 1,058 128 333 196 2019 947 118 335 198 2020 952 119 350 197 2021 930 112 356 196 2022–2026 4,391 503 1,867 919 (a) For the U.S. qualified plans, the $1.0 billion voluntary contribution, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums, was paid in Janu

Equity

Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Equity	Equity A. Common Stock We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. On June 27, 2013, we announced that the Board of Directors had authorized a $10 billion share-purchase plan, which was exhausted in the first quarter of 2015. On October 23, 2014, we announced that the Board of Directors had authorized an additional $11 billion share-purchase plan (the October 2014 Stock Purchase Plan), and share purchases commenced thereunder in January 2015. In December 2015, the Board of Directors authorized a new $11 billion share repurchase program to be utilized over time. On March 8, 2016, we entered into an accelerated share repurchase agreement with GS&Co. to repurchase $5 billion of our common stock. Pursuant to the terms of the agreement, on March 10, 2016, we paid $5 billion to GS&Co. and received an initial delivery of approximately 136 million shares of our common stock from GS&Co. based on a price of $29.36 per share, which represented, based on the closing share price of our common stock on the NYSE on March 8, 2016, approximately 80% of the notional amount of the accelerated share repurchase agreement. On June 20, 2016, the accelerated share repurchase agreement with GS&Co. was completed, which, per the terms of the agreement, resulted in GS&Co. owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 18 million shares of our common stock from GS&Co. on June 20, 2016. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was $32.38 per share. The common stock received is included in Treasury stock . This agreement was entered into pursuant to our previously announced share repurchase authorization. On February 9, 2015, we entered into an accelerated share repurchase agreement with GS&Co. to repurchase shares of our common stock. This agreement was entered into under our previously announced share repurchase authorization. Pursuant to the terms of the agreement, on February 11, 2015, we paid $5 billion to GS&Co. and received approximately 151 million shares of our common stock from GS&Co. On July 2, 2015, the accelerated share repurchase agreement with GS&Co. was completed, which, per the terms of the agreement, resulted in us owing GS&Co. a certain number of shares of Pfizer common stock or its equivalent dollar value. Pursuant to the agreement’s settlement terms, we elected to settle this amount in cash and paid an additional $160 million to GS&Co. on July 13, 2015, resulting in a total of approximately $5.2 billion paid to GS&Co. The final average price paid for the shares delivered under the accelerated share repurchase agreement was $34.13 per share. The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including our accelerated share repurchase agreements: (SHARES IN MILLIONS, DOLLARS IN BILLIONS) 2016 (a) 2015 (b) 2014 Shares of common stock purchased 154 182 165 Cost of purchase $ 5.0 $ 6.2 $ 5.0 (a) Represents shares purchased pursuant to and received upon settlement of the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information. (b) Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015. At December 31, 2016 , our remaining share-purchase authorization was approximately $11.4 billion . On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase $5 billion of our common stock. This agreement was entered into pursuant to our previously announced share repurchase authorization. For additional information, see Note 19. B. Preferred Stock The Series A convertible perpetual preferred stock is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of 6.25% , which are accumulated and paid quarterly. The per-share stated value is $40,300 and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder’s option, into 2,574.87 shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of $40,300 per share. C. Employee Stock Ownership Plans We have two employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP). Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of December 31, 2016 , the Preferred ESOP held preferred shares convertible into approximately 1 million shares of our common stock, and the Common ESOP held approximately 55 million shares of our common stock. As of December 31, 2016 , all shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the common ESOPs was $9 million in 2016 , $8 million in 2015 and $133 million in 2014 . Prior to 2015, Pfizer matching contributions were primarily invested in the Common ESOP. Beginning in January 2015, Pfizer matching contributions are being invested based on the investment direction of the employees’ own contributions. As a result, the compensation cost related to the Common ESOP was significantly lower in 2015 and 2016.

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments Our compensation programs can include share-based payments. The award value is determined by reference to the fair value of share-based awards to similar employees in competitive survey data or industry peer groups used for compensation purposes; and is allocated between different long term incentive vehicles, in the form of RSUs, PPSs, TSRUs, stock options, PSAs and PTUs, as determined by the Compensation Committee. The 2014 Stock Plan (2014 Plan) replaced and superseded the 2004 Plan, as amended and restated. The 2014 Plan provides for 520 million shares to be authorized for grants, plus any shares remaining available for grant under the 2004 Plan as of April 24, 2014 (the carryforward shares). In addition, the 2014 Plan provides that the number of stock options, Stock Appreciation Rights (known as TSRUs), RSUs, or other performance-based awards that may be granted to any one individual during any 36 -month period is limited to 20 million shares, and that RSUs, PPSs and PSAs count as three shares, while TSRUs and stock options count as one share, toward the maximum shares available under the 2014 plan. The 2004 Plan provided that the number of stock options, TSRUs or other performance-based awards granted to any one individual during any 36 -month period was limited to 8 million shares, and that RSUs, PPSs and PSAs counted against the maximum available shares as two shares, while stock options and TSRUs counted as one share. As of December 31, 2016 , 391 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs. We adopted a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . A. Impact on Net Income The following table provides the components of share-based compensation expense and the associated tax benefit: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Restricted Stock Units $ 299 $ 306 $ 270 Portfolio Performance Shares 135 147 96 Total Shareholder Return Units 134 36 37 Stock Options 106 165 150 Performance Share Awards 13 11 30 Directors’ compensation 4 4 3 Share-based payment expense 691 669 586 Tax benefit for share-based compensation expense (205 ) (198 ) (179 ) Share-based payment expense, net of tax $ 486 $ 471 $ 407 Amounts capitalized as part of inventory cost were not significant for any period presented. B. Restricted Stock Units RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after three years of continuous service from the grant date. We measure the value of RSU grants as of the grant date using the closing price of Pfizer common stock. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate. The following table summarizes all RSU activity during 2016: Shares (Thousands) Weighted-Average Grant-Date Fair Value Per Share Nonvested, December 31, 2015 29,135 $ 31.53 Granted 10,581 30.74 Vested (9,630 ) 27.41 Reinvested dividend equivalents 1,093 32.56 Forfeited (1,574 ) 32.18 Nonvested, December 31, 2016 29,605 $ 32.59 The following table provides data related to all RSU activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2016 2015 2014 Total fair value of shares vested $ 293 $ 371 $ 401 Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax $ 262 $ 279 $ 255 Weighted-average period over which RSU cost is expected to be recognized (years) 1.7 1.8 1.8 C. Stock Options Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of Pfizer common stock at a price per share equal to the closing market price of Pfizer common stock on the date of grant. Beginning in 2016, only a limited set of overseas employees received stock option grants. No stock options were awarded to senior and other key management in any period presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted since 2005 vest after three years of continuous service from the grant date and have a contractual term of ten years. In most cases, stock options must be held for at least one year from the grant date before any vesting may occur. In the event of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period from three months to their remaining term, depending on various conditions. We measure the value of stock option grants as of the grant date using the Black-Scholes-Merton option-pricing model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate. The following table provides the weighted-average assumptions used in the valuation of stock options: Year Ended December 31, 2016 2015 2014 Expected dividend yield (a) 3.85 % 3.19 % 3.18 % Risk-free interest rate (b) 1.55 % 1.89 % 1.94 % Expected stock price volatility (c) 21.64 % 18.34 % 19.76 % Expected term (years) (d) 6.75 6.75 6.50 (a) Determined using a constant dividend yield during the expected term of the option. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility. (d) Determined using historical exercise and post-vesting termination patterns. The following table summarizes all stock option activity during 2016: Shares (Thousands) Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (a) (Millions) Outstanding, December 31, 2015 232,554 $ 26.41 Granted 1,371 30.59 Exercised (42,550 ) 24.03 Forfeited (2,949 ) 33.18 Expired (1,750 ) 28.55 Outstanding, December 31, 2016 186,676 26.86 5.7 $ 1,138 Vested and expected to vest, December 31, 2016 (b) 184,537 26.77 5.6 1,138 Exercisable, December 31, 2016 105,862 $ 21.85 4.1 $ 1,126 (a) Market price of underlying Pfizer common stock less exercise price. (b) The number of options expected to vest takes into account an estimate of expected forfeitures. The following table summarizes data related to all stock option activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS) 2016 2015 2014 Weighted-average grant-date fair value per stock option $ 3.89 $ 4.30 $ 4.40 Aggregate intrinsic value on exercise $ 389 $ 666 $ 458 Cash received upon exercise $ 1,019 $ 1,263 $ 1,002 Tax benefits realized related to exercise $ 112 $ 187 $ 131 Total compensation cost related to nonvested stock options not yet recognized, pre-tax $ 58 $ 159 $ 147 Weighted-average period over which stock option compensation cost is expected to be recognized (years) 1.1 1.8 1.8 D. Portfolio Performance Shares PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible range of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards vest after three years of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a five -year performance period from the year of the grant date. The number of shares that may be earned over the performance period ranges from 0% to 200% of the initial award. We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of Pfizer common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved and/or changes in management’s assessment of the probable vesting term. The following table summarizes all PPS activity during 2016, with the shares representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2015 22,503 $ 32.28 Granted 8,059 30.59 Vested (a) (6,900 ) 30.23 Forfeited (1,396 ) 33.29 Nonvested, December 31, 2016 (a) 22,266 $ 32.48 (a) Vested and non-vested shares outstanding, but not paid as of December 31, 2016 were 32,521 . The following table provides data related to all PPS activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2016 2015 2014 Total fair value of shares vested $ 118 $ 60 $ — Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax $ 93 $ 102 $ 139 Weighted-average period over which PPS cost is expected to be recognized (years) 1.8 1.7 1.8 E. Total Shareholder Return Units TSRUs are awarded to senior and other key management, and, beginning in 2016, to certain other employees. TSRUs entitle the holders to receive a number of shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the five -year or seven -year term, if and to the extent the total value is positive. The settlement price is the average closing price of Pfizer common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of Pfizer common stock on the date of the grant. The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture. On October 26, 2016, the Compensation Committee approved the modification of current outstanding grants of TSRU awards, effective November 1, 2016, to permit a holder who is "retiree eligible" (at least age 55 with at least 10 years of service), to elect to exercise and convert his/her TSRUs when vested, into PTUs. The value received upon the election and conversion is calculated by taking the change in stock price ( 20 trading day average ending on the exercise date (Election Price) less the grant price) plus accumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to determine the number of PTUs. The PTUs will be entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in Pfizer common stock on the TSRUs original settlement date (i.e., the fifth or seventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. This modification applies to approximately 2,900 employees, including members of senior management. There was no incremental compensation cost resulting from the modification. We measure the value of TSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate. The following table provides the weighted-average assumptions used in the valuation of TSRUs: Year Ended December 31, 2016 2015 2014 Expected dividend yield (a) 3.85 % 3.19 % 3.18 % Risk-free interest rate (b) 1.31 % 1.76 % 1.78 % Expected stock price volatility (c) 21.64 % 18.41 % 19.76 % Contractual term (years) 5.12 5.91 5.97 (a) Determined using a constant dividend yield during the expected term of the TSRU. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility. The following table summarizes all TSRU activity during 2016: TSRUs (Thousands) Weighted-Average Grant-Date Fair Value Per TSRU Weighted-Average Grant Price Per TSRU Nonvested, December 31, 2015 18,067 $ 6.07 $ 31.27 Granted 53,467 5.83 30.59 Vested (6,440 ) 5.14 27.41 Forfeited (3,087 ) 5.91 30.90 Nonvested, December 31, 2016 62,007 $ 5.97 $ 31.10 The following table summarizes TSRU and PTU information as of December 31, 2016 (a), (b) : TSRUs (Thousands) PTUs (Thousands) Weighted-Average Grant Price Per TSRU Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions) TSRUs Outstanding 81,413 — $ 29.15 3.5 $ 439 TSRUs Vested 19,406 — 22.93 1.5 279 TSRUs Expected to vest 58,362 — 31.13 4.2 150 TSRUs exercised and converted to PTUs — 120 $ — 0.2 $ 4 (a) In 2016 , we settled 4,442,865 TSRUs with a weighted-average grant price of $18.95 per unit. (b) In 2016, 237,246 TSRUs with a weighted-average grant price of $20.86 per unit were converted into 120,273 PTUs. The following table provides data related to all TSRU activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS) 2016 2015 2014 Weighted-average grant-date fair value per TSRU $ 5.83 $ 6.66 $ 6.51 Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax $ 164 $ 29 $ 30 Weighted-average period over which TSRU cost is expected to be recognized (years) 1.9 1.8 1.8 F. Performance Share Awards PSAs are awarded to senior and other key management. PSAs vest after three years of continuous service from the grant date. The number of shares paid, if any, including shares resulting from dividend equivalents, for awards granted in 2016 and 2015, depends upon the achievement of predetermined goals related to two measures: (i) operating income over three one -year periods; and (ii) TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the three -year performance period. The number of shares paid from awards granted in 2014 depends upon the achievement of predetermined goals related to Pfizer's TSR as compared to an industry peer group, for the three -year performance period from the year of the grant date. The number of shares that are earned over the performance period ranges from 0% to 200% of the initial award. We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of Pfizer common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved. The following table summarizes all PSA activity during 2016, with the shares granted representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2015 3,871 $ 32.28 Granted 1,900 30.59 Vested (289 ) 30.23 Forfeited (936 ) 30.61 Nonvested, December 31, 2016 4,546 $ 32.48 The following table provides data related to all PSA activity: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Total fair value of shares vested $ 9 $ 14 $ 39 Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax $ 30 $ 24 $ 21 Weighted-average period over which PSA cost is expected to be recognized (years) 1.8 1.9 1.7

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders The following table provides the detailed calculation of Earnings per common share (EPS): Year Ended December 31, (IN MILLIONS) 2016 2015 2014 EPS Numerator––Basic Income from continuing operations $ 7,229 $ 6,975 $ 9,119 Less: Net income attributable to noncontrolling interests 31 26 32 Income from continuing operations attributable to Pfizer Inc. 7,198 6,949 9,087 Less: Preferred stock dividends––net of tax 1 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 7,197 6,948 9,086 Discontinued operations––net of tax 17 11 48 Less: Discontinued operations––net of tax, attributable to noncontrolling interests — — — Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders 17 11 48 Net income attributable to Pfizer Inc. common shareholders $ 7,214 $ 6,959 $ 9,134 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,197 $ 6,948 $ 9,087 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 17 11 48 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,214 $ 6,960 $ 9,135 EPS Denominator Weighted-average number of common shares outstanding––Basic 6,089 6,176 6,346 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (a) 70 81 78 Weighted-average number of common shares outstanding––Diluted (a) 6,159 6,257 6,424 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (b) 63 50 44 (a) Amount for 2016 reflects the adoption of a new accounting standard, as of January 1, 2016, that requires when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B ). (b) These common stock equivalents were outstanding for the years ended December 31, 2016 , 2015 and 2014 , but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Lease Commitments	Lease Commitments We lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay directly for taxes, insurance, maintenance and other operating expenses or to pay higher rent when operating expenses increase. Rental expense, net of sublease income, was $292 million in 2016 , $243 million in 2015 and $216 million in 2014 . The future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2017 2018 2019 2020 2021 After 2021 Lease commitments $ 220 $ 188 $ 163 $ 138 $ 125 $ 967

Insurance

Insurance	12 Months Ended
	Dec. 31, 2016
Insurance Coverage [Abstract]
Insurance	Insurance Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued (see Note 17 ).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 5D. A. Legal Proceedings Our non-tax contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff Bosulif (bosutinib) In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Both Alembic and Sun are challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic myelogenous leukemia. EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz, Inc., a division of Novartis AG (Sandoz), in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Flector Patch (diclofenac) In October 2015, the owners (Teikoku Seiyaku Co., Ltd. and Altergon SA) of a patent covering Pfizer's Flector Patch product, along with the New Drug Application holder (IBSA Institut Biochemique SA), brought a patent-infringement action against Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed by Actavis Laboratories UT, Inc. with the FDA requesting approval to launch a generic version of Flector Patch prior to the 2019 expiration of the patent. In August 2016, Pfizer subsidiary Alpharma Pharmaceuticals LLC was added as a plaintiff to the lawsuit. Precedex Premix In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent that is the subject of the lawsuit. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer. In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit. In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals). Toviaz (fesoterodine) We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH (UCB), which owns the patents relating to Toviaz. Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book”. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with four of the generic defendants. The trial relating to the four remaining defendants occurred in July 2015. In April 2016, the District Court held that the patents that were the subject of the lawsuit were valid and infringed. The defendants’ deadline to appeal this decision expired in June 2016. In December 2014, Mylan Pharmaceuticals, Inc. (Mylan Pharmaceuticals) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In January 2015, we filed an action against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In January 2017, the District Court issued a verdict finding that the five patents that are the subject of the lawsuit are valid and infringed. Tygacil (tigecycline) In November 2014, Mylan Laboratories Limited (formerly Agila Specialties Private Limited) (Mylan Laboratories) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Tygacil. Mylan Laboratories asserts the invalidity and non-infringement of the polymorph patent for Tygacil that expires in 2030 and the formulation patent for Tygacil that expires in 2029. Mylan Laboratories has not challenged the composition-of-matter patent. In January 2015, we filed suit against Mylan Laboratories in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the polymorph patent and the formulation patent for Tygacil. In December 2016, we settled our claims against Mylan Laboratories on terms not material to Pfizer and the case was dismissed. In addition, in September 2015 and December 2015, we received notices of Section 505(b)(2) new drug applications filed by each of Mylan Laboratories and Accord Healthcare Inc. (Accord) for tigecycline injectable products. Mylan Laboratories and Accord assert the invalidity and non-infringement of the polymorph patent for Tygacil and two formulation patents for Tygacil that expire in 2028 and 2029, respectively. In October 2015, we filed suit against Mylan Laboratories in the U.S. District Court for the District of Delaware and in the U.S. District Court for the District of West Virginia asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, we settled our claims against Mylan Laboratories on terms not material to Pfizer and the case against Mylan Laboratories was dismissed. In February 2016, we filed suit against Accord in the U.S. District Court for the District of Delaware and in the U.S. District Court for the Middle District of North Carolina asserting the validity and infringement of the patents that are the subject of the lawsuit. In February 2017, we settled our claims against Accord on terms not material to Pfizer and the case against Accord was dismissed. Xeljanz (tofacitinib) In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Of the three patents that are the subject of the lawsuit, one covers the active ingredient and expires in December 2020, the second covers an enantiomer of tofacitinib and expires in 2022, and the third covers a polymorphic form of tofacitinib and expires in 2023. Three other patents for Xeljanz expiring in December 2020 have not been challenged by MicroLabs. Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. Xtandi (enzalutamide) In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); and Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd (collectively, Zydus); and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’ respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. Matters Involving Our Collaboration/Licensing Partners Nexium 24HR (esomeprazole) We have an exclusive license from AstraZeneca PLC (AstraZeneca) to market in the U.S. the OTC version of Nexium (Nexium 24HR). Beginning in October 2014, Actavis Laboratories FL, Inc., and subsequently Andrx Labs, LLC (Andrx), Perrigo Company plc (Perrigo), Lupin Limited and, in October 2015, Dr. Reddy’s Laboratories, Inc. & Ltd. (Dr. Reddy’s) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca’s patents listed in the Orange Book for Nexium 24HR. From November 2014 through November 2015, AstraZeneca filed actions against each of Actavis Laboratories FL, Inc., Andrx, Perrigo, Lupin Limited and Dr. Reddy’s in the U.S. District Court for the District of New Jersey asserting the infringement of the challenged patents. We are not a party to AstraZeneca’s patent-infringement actions. Toviaz (fesoterodine)––Inter Partes Reviews In January 2016, Mylan Pharmaceuticals and Mylan Laboratories filed petitions with the U.S. Patent & Trademark Office requesting Inter Partes Reviews of five of the patents covering fesoterodine, the active ingredient in Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute Inter Partes Reviews of all five patents. Amerigen Pharmaceuticals Limited, Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have joined the Inter-Partes Reviews. Action In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Four of the patents have since been dismissed by the plaintiffs, leaving two patents at issue in the ongoing action: the infliximab antibody patent and a patent relating to cell culture media. In August 2016, the U.S. District Court for the District of Massachusetts ruled that the antibody patent was invalid, and Janssen has appealed that ruling to the Court of Appeals for the Federal Circuit. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of December 31, 2016 , approximately 56,200 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor • Personal Injury Actions A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Effexor ( Venlafaxine Hydrochloride) Products Liability Litigation MDL-2458 ) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions. The Multi-District Litigation, as well as the coordinated state court proceedings in California, have been administratively stayed. • Antitrust Actions Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs have appealed to the U.S. Court of Appeals for the Third Circuit. Motions to dismiss remain pending as to the end-payer plaintiffs’ remaining claims. Zoloft A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Zoloft Products Liability Litigation MDL-2342 ) in the U.S. District Court for the Eastern District of Pennsylvania. A number of plaintiffs have voluntarily dismissed their actions. In April 2016, the District Court granted our motion for summary judgment, dismissing the claims of almost all of the remaining plaintiffs. In May 2016, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Third Circuit. Lipitor • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. • Personal Injury Actions A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. In 2016, certain cases in the Multi-District Litigation were remanded to federal courts in California and certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court's decision to the U.S. Court of Appeals for the Fourth Circuit. Viagra A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the exacerbation of melanoma as a result of the purported ingestion of Viagra. Plaintiffs seek compensatory and punitive damages. In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691 ) in the U.S. District Court for the Northern District of California. Chantix/Champix Beginning in December 2008, purported class actions were filed against us in the Ontario Superior Court of Justice (Toronto Region), the Superior Court of Quebec (District of Montreal), the Court of Queen’s Bench of Alberta, Judicial District of Calgary, and the Superior Court of British Columbia (Vancouver Registry) on behalf of all individuals and third-party payers in Canada who have purchased and ingested Champix or reimbursed patients for the purchase of Champix. Each of these actions asserts claims under Canadian product liability law, including with respect to the safety and efficacy of Champix, and, on behalf of the putative class, seeks monetary relief, including punitive damages. In June 2012, the Ontario Superior Court of Justice certified the Ontario proceeding as a class action, defining the class as consisting of the following: (i) all persons in Canada who ingested Champix during the period from April 2, 2007 to May 31, 2010 and who experienced at least one of a number of specified neuropsychiatric adverse events; (ii) all persons who are entitled to assert claims in respect of Champix pursuant to Canadian legislation as the result of their relationship with a class member; and (iii) all health insurers who are entitled to assert claims in respect of Champix pursuant to Canadian legislation. The Ontario Superior Court of Justice certified the class against Pfizer Canada Inc. only and ruled that the action against Pfizer should be stayed until after the trial of the issues that are common to the class members. The actions in Quebec, Alberta and British Columbia have been stayed in favor of the Ontario action, which is proceeding on a national basis. Celebrex Beginning in July 2014, purported class actions were filed in the U.S. District

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH), which was previously known as Established Products. Beginning in the second quarter of 2016, we reorganized our operating segments to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH. From the beginning of our fiscal year 2014 until the second quarter of 2016, these operations were managed as two business segments: the GIP segment and the VOC segment. We have revised prior-period information (Revenues and Earnings, as defined by management) to reflect the reorganization. The IH and EH operating segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. We regularly review our segments and the approach used by management to evaluate performance and allocate resources. Operating Segments Some additional information about our business segments follows: IH Segment EH Segment IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients’ lives, as well as products for consumer healthcare. Key therapeutic areas include internal medicine, vaccines, oncology, inflammation & immunology, rare diseases and consumer healthcare. EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars and, through February 2, 2017, infusion systems. EH also includes an R&D organization, as well as our contract manufacturing business. Leading brands include: - Prevnar 13 - Xeljanz - Eliquis - Lyrica (U.S., Japan and certain other markets) - Enbrel (outside the U.S. and Canada) - Viagra (U.S. and Canada) - Ibrance - Xtandi - Several OTC consumer products (e.g., Advil and Centrum ) Leading brands include: - Lipitor - Premarin family - Norvasc - Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries) - Celebrex - Pristiq - Several sterile injectable products The following change in 2016 impacted IH: • In connection with the formation in early 2016 of the GPD organization, a new unified center for late-stage development for our innovative products, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios, effective in the second quarter of 2016, certain development-related functions transferred from IH to GPD. The following changes in 2016 impacted EH: • Beginning in 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including the revenues and expenses related to our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. • In connection with the formation of a new EH R&D organization effective in the first quarter of 2016, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. The new R&D organization within EH expects to develop potential new sterile injectable drugs and therapeutic solutions, as well as biosimilars. Our chief operating decision maker uses the revenues and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. Other Costs and Business Activities Certain costs are not allocated to our operating segment results, such as costs associated with the following: • WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the newly formed GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects, including EH R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities. • GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&D projects. In connection with the formation of the GPD organization, effective in the second quarter of 2016, certain development-related functions transferred from WRD and IH to GPD. We have reclassified approximately $78 million of costs in the first quarter of 2016, $341 million of costs in 2015, and $343 million of costs in 2014 from WRD to GPD as well as $76 million of costs in the first quarter of 2016, $318 million of costs in 2015 and $271 million of costs in 2014 from IH to GPD to conform to the presentation as part of GPD in 2016. • Pfizer Medical, which is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. In 2015 and 2014, Medical was also responsible for regulatory inspection readiness reviews, internal audits of Pfizer-sponsored clinical trials and internal regulatory compliance processes, which are now part of the compliance function within Corporate. • Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. • Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production). The increase in Cost of sales in 2016 reflects, among other items, the change in manufacturing variances driven by demand decreases versus plan for certain legacy Hospira and legacy Pfizer products. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and which include non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $172 billion as of December 31, 2016 and approximately $167 billion as of December 31, 2015 . Selected Income Statement Information The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 2016 2015 2014 2016 2015 2014 Reportable Segments: IH (c) $ 29,197 $ 26,758 $ 24,005 $ 15,854 $ 14,581 $ 12,743 $ 583 $ 552 $ 522 EH (d) 23,627 22,094 25,401 12,898 12,714 16,020 600 446 490 Total reportable segments 52,824 48,851 49,406 28,752 27,295 28,763 1,183 998 1,012 Other business activities (e) — — — (3,184 ) (3,091 ) (3,151 ) 86 77 74 Reconciling Items: Corporate (f) — — — (5,326 ) (5,430 ) (5,200 ) 356 354 384 Purchase accounting adjustments (f) — — — (4,185 ) (3,953 ) (3,641 ) 3,890 3,573 3,782 Acquisition-related costs (f) — — — (785 ) (894 ) (183 ) 7 75 53 Certain significant items (g) — — 198 (5,888 ) (4,321 ) (3,749 ) 200 48 207 Other unallocated (f) — — — (1,032 ) (642 ) (601 ) 35 33 24 $ 52,824 $ 48,851 $ 49,605 $ 8,351 $ 8,965 $ 12,240 $ 5,757 $ 5,157 $ 5,537 (a) Income from continuing operations before provision for taxes on income. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations and IH’s operating results for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. Additionally, in connection with the formation in early 2016 of the GPD organization, effective in the second quarter of 2016, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, $318 million of costs in 2015 and $271 million of costs in 2014 from IH to GPD to conform to the presentation as part of GPD in 2016. (d) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations and EH’s operating results include legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira International operations. See Note 2A for additional information. Beginning in 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including the revenues and expenses related to our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. We have reclassified prior period PCS operating results ( $506 million of PCS revenues and $96 million of PCS earnings in 2015, which in 2015 includes revenues and expenses related to our manufacturing and supply agreements with Zoetis, and $253 million of PCS revenues and $69 million of PCS earnings in 2014) to conform to the current period presentation as part of EH. As noted above, in connection with the formation in 2016 of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $274 million of costs in 2015 and $281 million of costs in 2014 from WRD to EH to conform to the current period presentation as part of EH. (e) Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations. (f) For a description, see the “Other Costs and Business Activities” section above. (g) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in 2014, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million and (vi) other charges of $509 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4. For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million , (ii) certain asset impairments of $440 million , (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million , (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million , (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion , (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million . For additional information, see Note 2D, Note 3 and Note 4 . Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information Revenues exceeded $500 million in each of 11 countries outside the U.S. in 2016 and in each of 12 countries outside the U.S. in 2015 and 2014 , respectively. The U.S. is the only country to contribute more than 10% of total revenue in 2016 , 2015 and 2014. The following table provides revenues by geographic area: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 United States (a) $ 26,369 $ 21,704 $ 19,073 Developed Europe (a), (b) 9,306 9,714 11,719 Developed Rest of World (a), (c) 6,729 6,298 7,314 Emerging Markets (a), (d) 10,420 11,136 11,499 Revenues $ 52,824 $ 48,851 $ 49,605 (a) On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations include the operating results of Anacor and Medivation. In accordance with our domestic reporting period, our results of operations for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations include the operating results of Hospira. In accordance with our domestic and international reporting periods, our results of operations for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information. (b) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.2 billion in 2016 , $7.4 billion in 2015 and $9.0 billion in 2014 . (c) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (d) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey. Long-lived assets by geographic region follow (a) : As of December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Property, plant and equipment, net United States $ 6,649 $ 7,072 $ 5,575 Developed Europe (b) 4,228 4,376 4,606 Developed Rest of World (c) 643 660 617 Emerging Markets (d) 1,797 1,658 963 Property, plant and equipment, net $ 13,318 $ 13,766 $ 11,762 (a) Reflects legacy Medivation and legacy Anacor amounts in 2016, commencing on the Medivation acquisition date, September 28, 2016, and Anacor acquisition date, June 24, 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date, September 3, 2015. (b) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. (c) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey. C. Other Revenue Information Significant Customers We sell our biopharmaceutical products primarily to customers in the wholesale sector. In 2016 , sales to our three largest U.S. wholesaler customers represented approximately 16% , 12% and 10% of total revenues, respectively, and, collectively, represented approximately 29% of total trade accounts receivable as of December 31, 2016 . In 2015, sales to our three largest U.S. wholesaler customers represented approximately 14% , 11% and 10% of total revenues, respectively, and, collectively, represented approximately 23% of total trade accounts receivable as of December 31, 2015 . In 2014, sales to our three largest U.S. wholesaler customers represented approximately 13% , 10% and 9% of total revenues, respectively, and, collectively, represented approximately 25% of total trade accounts receivable as of December 31, 2014 . For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses. Significant Product Revenues The following table provides detailed revenue information: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 PFIZER INNOVATIVE HEALTH (IH) (a) $ 29,197 $ 26,758 $ 24,005 Internal Medicine $ 8,858 $ 7,611 $ 6,727 Lyrica IH (b) 4,165 3,655 3,350 Viagra IH (c) 1,181 1,297 1,181 Chantix/Champix 842 671 647 Toviaz 258 267 288 BMP2 251 232 228 Alliance revenues (d) 1,588 1,256 759 All other Internal Medicine (e) 573 233 276 Vaccines $ 6,071 $ 6,454 $ 4,480 Prevnar 13/Prevenar 13 5,718 6,245 4,464 FSME/IMMUN-TicoVac 114 104 — All other Vaccines 239 104 16 Oncology $ 4,563 $ 2,955 $ 2,218 Ibrance 2,135 723 — Sutent 1,095 1,120 1,174 Xalkori 561 488 438 Inlyta 401 430 410 Xtandi alliance revenues 140 — — All other Oncology 231 194 195 Inflammation & Immunology (I&I) $ 3,928 $ 3,918 $ 4,241 Enbrel (Outside the U.S. and Canada) 2,909 3,333 3,850 Xeljanz 927 523 308 All other I&I 93 61 82 Rare Disease $ 2,369 $ 2,425 2,893 BeneFIX 712 752 856 Genotropin 579 617 723 Refacto AF/Xyntha 554 533 631 Somavert 232 218 229 Rapamune 170 197 339 All other Rare Disease 122 108 114 Consumer Healthcare $ 3,407 $ 3,395 $ 3,446 PFIZER ESSENTIAL HEALTH (EH) (f) $ 23,627 $ 22,094 $ 25,600 Legacy Established Products (LEP) (g) $ 11,194 $ 11,745 $ 13,016 Lipitor 1,758 1,860 2,061 Premarin family 1,017 1,018 1,076 Norvasc 962 991 1,112 EpiPen 386 339 294 Xalatan/Xalacom 363 399 495 Relpax 323 352 382 Zoloft 304 374 423 Effexor 278 288 344 Zithromax/Zmax 272 275 311 Xanax/Xanax XR 222 224 253 Cardura 192 210 263 Neurontin 182 196 210 Tikosyn 153 179 141 Depo-Provera 126 170 201 Diflucan 119 181 208 All other LEP 4,538 4,689 5,242 Sterile Injectable Pharmaceuticals (SIP) (h) $ 6,018 $ 3,944 $ 3,277 Medrol 450 402 381 Sulperazon 396 339 354 Fragmin 318 335 364 Tygacil 274 304 323 All other SIP 4,579 2,563 1,855 Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Peri-LOE Products (i) $ 4,220 $ 5,326 $ 8,855 Lyrica EH (b) 801 1,183 1,818 Celebrex 733 830 2,699 Pristiq 732 715 737 Vfend 590 682 756 Zyvox 421 883 1,352 Viagra EH (c) 383 411 504 Revatio 285 260 276 All Other Peri-LOE Products 276 362 714 Infusion Systems (j) $ 1,158 $ 403 $ — Biosimilars (k) $ 319 $ 63 $ — Inflectra/Remsima 192 30 — All Other Biosimilars 127 33 — Pfizer CentreOne (l) $ 718 $ 612 $ 451 Revenues $ 52,824 $ 48,851 $ 49,605 Total Lyrica (b) $ 4,966 $ 4,839 $ 5,168 Total Viagra (c) $ 1,564 $ 1,708 $ 1,685 Total Alliance revenues $ 1,746 $ 1,312 $ 957 (a) The IH business, previously known as the Innovative Products business, encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Anacor and Medivation commercial operations. Anacor's and Medivation's commercial operations are included in IH's operating results in our consolidated statements of income, commencing from the acquisition date of June 24, 2016 for Anacor and from the acquisition date of September 28, 2016 for Medivation. As a result, IH's revenues for 2016 reflect approximately six months of legacy Anacor operations, which were immaterial, and three months of legacy Medivation operations. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) Includes Eliquis for all years presented and Rebif for 2015 and 2014. (e) Includes Eliquis direct sales markets. (f) The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems (through February 2, 2017), Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. Also, effective as of the beginning of 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. We have reclassified prior period PCS revenues ( $506 million in 2015 and $253 million in 2014) to conform to the current period presentation as part of EH. (g) Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). (h) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (i) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Lyrica in certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and Revatio in most developed markets, Vfend and Viagra in certain developed Europe markets and Japan, and Inspra in the EU. (j) Infusion Systems (through February 2, 2017) include Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. (k) Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle East markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle East markets. (l) Pfizer CentreOne includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation. We performed certain reclassifications, primarily between Legacy Established and Sterile Injectable Pharmaceuticals, to conform to current period presentation.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event A. Accelerated Share Repurchase Agreement On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase $5 billion of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid $5 billion to Citibank and received an initial delivery of approximately 126 million shares of our common stock from Citibank at a price of $31.73 per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately 80% of the notional amount of the accelerated share repurchase agreement. As of February 6, 2017, the common stock received is included in Treasury Stock . At settlement of the agreement, which is expected to occur during or prior to the third quarter of 2017, Citibank may be required to deliver additional shares of common stock to us, or, under certain circumstances, we may be required to deliver shares of our common stock or may elect to make a cash payment to Citibank, with the number of shares to be delivered or the amount of such payment, as well as the final average price per share, based on the difference between the volume-weighted average price, less a discount, of Pfizer’s common stock during the term of the transaction. This agreement was entered into pursuant to our previously announced share repurchase authorization. After giving effect to the accelerated share repurchase agreement, our remaining share-purchase authorization was approximately $6.4 billion at February 6, 2017.

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).
Consolidation	The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Taxes paid on intercompany sales transactions are deferred until recognized upon sale of the asset to a third party.
Adoption of New Accounting Standards	In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of shared-based compensation to be recognized as a component of the Provision for taxes on income , whereas excess tax benefits or deficiencies previously were recognized in Additional paid-in capital . The net tax benefit for the Company was $89 million for full-year 2016. The standard requires the modified retrospective transition method of adoption, and as such, does not permit retroactive presentation of this benefit to prior fiscal years in the consolidated statements of income. Further, the net cumulative effect of excess tax benefits not previously recognized because they had not reduced taxes payable, was $13 million and is reflected as an increase to Retained earnings as of January 1, 2016. Another element of the new accounting standard is within our consolidated statements of cash flows, which now present excess tax benefits as operating activities. We have elected to adopt this presentation on a prospective basis as of January 1, 2016, and, therefore, our consolidated statement of cash flows for fiscal years prior to 2016 have not been adjusted for this element. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification is required to be adopted retrospectively. As a result, $137 million for 2016 is presented as financing activities in the consolidated statement of cash flows, and cash outflows of $189 million for 2015 and $195 million for 2014 were reclassified from operating activities to financing activities in the consolidated statements of cash flows, respectively. We also elected to continue to estimate the impact of expected forfeitures of share-based payments when determining the amount of compensation cost to be recognized each period, rather than account for forfeitures as they occur. Finally, in the 2016 diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. We adopted a new accounting standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. The update does not impact the measurement or recognition of debt issuance costs. As of December 31, 2016 , debt issuance costs were $115 million and are presented as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $114 million ). In the December 31, 2015 consolidated balance sheet, we have reclassified debt issuance costs of $79 million ( $1 million from Other current assets and $79 million from Other noncurrent assets ) and have presented them as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $79 million ) to conform to the current period presentation. For additional information, see Note 7A. We adopted a new accounting standard as of January 1, 2016 that requires an acquirer to recognize adjustments made in the measurement period to provisional amounts of assets acquired and liabilities assumed in a business combination in the reporting period in which the adjustment amounts are determined. There was no material impact to our consolidated financial statements in 2016 from adopting this standard. For additional information, see Note 2A. We adopted a new standard as of January 1, 2016 related to the accounting for hybrid financial instruments issued or held as investments and there was no material impact to our consolidated financial statements from adopting this standard.
Estimates and Assumptions	In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income. Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our financial statements on a prospective basis, unless they are required to be treated retrospectively under relevant accounting standards. It is possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.
Acquisitions	Our consolidated financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net . Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Fair Value	We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques: • Income approach, which is based on the present value of a future stream of net cash flows. • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. • Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence. For some investments, if certain conditions exist, we may employ a practical expedient wherein we use the NAV per share (or its equivalent), as fair value. When this practical expedient is used, the NAV is not categorized for disclosure purposes within the fair value hierarchy for types of inputs used for valuation. Our fair value methodologies depend on the following types of inputs: • Quoted prices for identical assets or liabilities in active markets (Level 1 inputs). • Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs). • Unobservable inputs that reflect estimates and assumptions (Level 3 inputs). A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Foreign Currency Translation	For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss) . The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net . For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net , and we translate non-monetary items at historical rates.
Revenues	Revenue Recognition —We record revenues from product sales when the goods are shipped and title passes to the customer. At the time of sale, we also record estimates for a variety of revenue deductions, such as chargebacks, rebates, sales allowances and sales returns. When we cannot reasonably estimate the amount of future sales returns and/or other revenue deductions, we record revenues when the risk of product return and/or additional revenue deductions has been substantially eliminated. Deductions from Revenues–– Our gross product revenues are subject to a variety of deductions, that generally are estimated and recorded in the same period that the revenues are recognized, and primarily represent chargebacks, rebates and sales allowances to wholesalers, and, to a lesser extent, distributors like managed care organizations, retailers and government agencies with respect to our pharmaceutical products. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. Specifically: • In the U.S., we record provisions for pharmaceutical Medicare, Medicaid, and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates. • Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds, and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals. • Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability. • Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit. • We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $4.3 billion as of December 31, 2016 , of which approximately $2.8 billion is included in Other current liabilities, $357 million is included in Other noncurrent liabilities and approximately $1.2 billion is included against Trade accounts receivable, less allowance for doubtful accounts , in our consolidated balance sheet. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $3.9 billion as of December 31, 2015 , of which approximately $2.6 billion is included in Other current liabilities, $272 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Trade accounts receivable, less allowance for doubtful accounts , in our consolidated balance sheet. Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues . Collaborative Arrangements— Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded when our collaboration partners ship the product and title passes to their customer. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when our collaboration partners sell the product and title passes to their customers. All royalty payments to collaboration partners are included in Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net.
Trade Accounts Receivable	Trade Accounts Receivable —Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
Cost of Sales and Inventories	We carry inventories at the lower of cost or market. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.
Selling, Informational and Administrative Expenses	Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.
Research and Development Expenses	R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
Property, Plant and Equipment	Property, plant and equipment, less accumulated depreciation —These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
Goodwill and Intangible Assets	• Identifiable intangible assets, less accumulated amortization —These acquired assets are recorded at cost. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated. • Goodwill —Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized. Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate. Specifically: • For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate. • For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate. • For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.
Property, Plant and Equipment, Impairment	We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
Restructuring Charges and Certain Acquisition-Related Costs	We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other costs incurred in connection with a business acquisition are expensed as incurred .
Cash Equivalents	Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments .
Statement of Cash Flows	Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.
Investments	Our investments are comprised of the following: trading funds and securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and ability to hold the investment to maturity) and private equity securities. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. • Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net. • Available-for-sale debt and equity securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized. • Held-to-maturity debt securities are carried at amortized cost. • Private equity securities are carried at equity-method or at cost-method. For equity investments where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in Other (income)/deductions—net . The excess of the cost of the investment over our share of the equity of the investee as of the acquisition date is allocated to the identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not include amounts of contingent consideration. Realized gains or losses on sales of investments are determined by using the specific identification cost method. We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Derivative Financial Instruments	Derivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A ), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E ).
Tax Assets and Liabilities and Income Tax Contingencies	Current tax assets primarily includes (i) tax effects associated with intercompany transfers of assets within our consolidated group, which are recognized in the consolidated statement of income when the asset transferred is sold to a third-party or recovered through amortization of the asset's remaining economic life; and (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations. Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet. We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information. Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision for taxes on income and are classified on our consolidated balance sheet with the related tax liability.
Pension and Postretirement Benefit Plans	The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both qualified and supplemental (non-qualified) defined benefit and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic benefit costs are recognized, as required, into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Legal and Environmental Contingencies	We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured. Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Share-Based Payments	Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Acquisitions, Assets and Liab30

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Schedule of Amounts Recognized for Assets Acquired and Liabilities Assumed	The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in 2016 to the amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. (MILLIONS OF DOLLARS) Amounts Recognized as of Acquisition Date (as previously reported as of December 31, 2015) Measurement Period Adjustments (a) Amounts Recognized as of Acquisition Date (as adjusted) Final Working capital, excluding inventories (b) $ 274 $ 68 $ 342 Inventories 1,924 (23 ) 1,901 PP&E 2,410 (57 ) 2,352 Identifiable intangible assets, excluding IPR&D (c) 8,270 20 8,290 IPR&D 995 35 1,030 Other noncurrent assets 408 (46 ) 362 Long-term debt (1,928 ) — (1,928 ) Benefit obligations (117 ) — (117 ) Net income tax accounts (d) (3,394 ) 14 (3,380 ) Other noncurrent liabilities (39 ) (23 ) (61 ) Total identifiable net assets 8,803 (12 ) 8,791 Goodwill 7,284 12 7,295 Net assets acquired/total consideration transferred $ 16,087 $ — $ 16,087 (a) The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. (b) Includes cash and cash equivalents, short-term investments, accounts receivable, other current assets, assets held for sale, accounts payable and other current liabilities. (c) Comprised of finite-lived developed technology rights with a weighted-average life of approximately 17 years ( $7.7 billion ) and other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ( $570 million ). (d) Final amounts recognized as of the acquisition date (as adjusted), included in Current tax assets ( $57 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $58 million ), Income taxes payable ( $5 million ), Noncurrent deferred tax liabilities ( $3.4 billion ) and Other taxes payable ( $101 million , including accrued interest of $5 million ). Preliminary amounts recognized as of the acquisition date (as previously reported), included in Current tax assets ( $79 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $25 million ), Income taxes payable ( $5 million ), Noncurrent deferred tax liabilities ( $3.4 billion ) and Other taxes payable ( $114 million , including accrued interest of $5 million ).
Summary of Pro Forma Information	The following table presents information for Hospira’s operations that are included in Pfizer’s consolidated statements of income beginning from the acquisition date, September 3, 2015 through Pfizer’s domestic and international year-ends in 2015 (see Note 1A ): (MILLIONS OF DOLLARS) December 31, 2015 Revenues $ 1,513 Net loss attributable to Pfizer Inc. common shareholders (a) (575 ) (a) Includes purchase accounting charges related to the provisional estimated fair values recognized as of the acquisition date for (i) the fair value adjustment for acquisition-date inventory that has been sold ( $378 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Hospira ( $161 million pre-tax); (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Hospira ( $34 million pre-tax ); and (iv) amortization expense related to the fair value adjustment of long-term debt acquired from Hospira ( $13 million income pre-tax), as well as restructuring and integration costs ( $556 million pre-tax). The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014: Unaudited Supplemental Pro Forma Consolidated Results Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) 2015 2014 Revenues $ 52,082 $ 54,069 Net income attributable to Pfizer Inc. common shareholders 7,669 8,173 Diluted EPS attributable to Pfizer Inc. common shareholders 1.23 1.27
Summary of Assets and Liabilities Held For Sale	The amounts associated with HIS, as well as other assets classified as held for sale as of December 31, 2016 and December 31, 2015 , consisted of the following: As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Assets Held for Sale Inventories $ 377 $ — PP&E 457 — Identifiable intangible assets 1,319 — Goodwill 119 — Other assets 152 — Less: adjustment to HIS assets for net realizable value (a) (1,681 ) — Total HIS assets held for sale 743 — Other assets held for sale (b) 58 9 Assets held for sale $ 801 $ 9 Liabilities Held for Sale Accrued compensation and related items $ 54 $ — Other liabilities 103 — Total HIS liabilities held for sale $ 157 $ — (a) For 2016 , we recorded an adjustment to HIS assets for net realizable value of $1,681 million plus estimated costs to sell of $31 million for a total impairment on HIS net assets of $1,712 million . (b) Other assets held for sale consist primarily of PP&E and other assets.
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions	The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Revenues —Revenues (a) $ 659 $ 644 $ 786 Revenue s—Alliance revenues (b) 1,746 1,312 957 Total revenues from collaborative arrangements 2,405 1,956 1,743 Cost of sales (c) (315 ) (282 ) (280 ) Selling, informational and administrative expenses (d) (5 ) (287 ) (268 ) Research and development expenses (e) 64 (330 ) (1,210 ) Other income/(deductions)—net (f) 542 482 518 (a) Represents sales to our partners of products manufactured by us. (b) Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2016 reflects an increase in alliance revenues from Eliquis and the inclusion of Xtandi revenues resulting from the acquisition of Medivation in September 2016, partially offset by the expiration of the Rebif co-promotion collaboration at the end of 2015. The increase in 2015 reflects an increase in alliance revenues from Eliquis, partially offset by Spiriva (as a result of the expiration of the co-promotion collaboration in the U.S. and certain European countries during 2014). (c) Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners. (d) Represents net reimbursements to our partners for selling, informational and administrative expenses incurred. (e) Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $15 million in 2016 , $310 million in 2015 (primarily related to our collaboration with OPKO, see below) and $1.2 billion in 2014 (related to our collaboration with Merck KGaA, see below). 2016 also includes a $120 million reimbursement related to our collaboration with Lilly (see below). (f) In 2016 , 2015 and 2014 , includes royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and we became entitled to royalties for a 36 -month period thereafter until October 31, 2016.

Restructuring Charges and Oth31

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	12 Months Ended
	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Restructuring charges (a) : Employee terminations $ 940 $ 489 $ 68 Asset impairments 142 254 45 Exit costs 74 68 58 Total restructuring charges 1,156 811 170 Transaction costs (b) 127 123 — Integration costs (c) 441 219 80 Restructuring charges and certain acquisition-related costs 1,724 1,152 250 Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows (d) : Cost of sales 201 117 228 Selling, informational and administrative expenses — — 1 Research and development expenses 7 5 31 Total additional depreciation––asset restructuring 207 122 261 Implementation costs recorded in our consolidated statements of income as follows (e) : Cost of sales 230 102 78 Selling, informational and administrative expenses 81 82 140 Research and development expenses 25 14 52 Other (income)/deductions––net 3 5 1 Total implementation costs 340 203 270 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 2,271 $ 1,478 $ 781 (a) In 2016 , Employee terminations represent the expected reduction of the workforce by approximately 4,900 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring charges in 2016 , are associated with the following: • IH ( $272 million ); EH ( $158 million ); WRD, GPD and Medical (M) (WRD/GPD/M) ( $169 million ); manufacturing operations ( $368 million ); and Corporate ( $189 million ). The restructuring charges in 2015 , which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following: • IH ( $85 million ); EH ( $402 million ); WRD/GPD/M ( $80 million ); manufacturing operations ( $80 million ); and Corporate ( $164 million ), The restructuring charges in 2014 are associated with the following: • IH ( $63 million ); EH ( $57 million ); WRD/GPD/M ( $37 million ); manufacturing operations ( $97 million ); and Corporate ( $65 million ). as well as $149 million of income related to the partial reversal of prior-period restructuring charges not directly associated with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans. In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million , which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million , which is included in Asset impairments ; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million , which is included in Asset impairments ; and (iii) a payment to Celltrion of $20 million , which is included in Exit costs . (b) Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which in 2016 are directly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and the terminated transaction with Allergan and primarily include expenditures for banking, legal, accounting and other similar services. (c) I ntegration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives
Schedule of Restructuring Reserve by Type of Cost	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, January 1, 2015 $ 1,114 $ — $ 52 $ 1,166 Provision 489 254 68 811 Utilization and other (a) (495 ) (254 ) (71 ) (820 ) Balance, December 31, 2015 (b) 1,109 — 48 1,157 Provision 940 142 74 1,156 Utilization and other (a) (502 ) (142 ) (86 ) (730 ) Balance, December 31, 2016 (c) $ 1,547 $ — $ 36 $ 1,583 (a) Includes adjustments for foreign currency translation. (b) Included in Other current liabilities ( $776 million ) and Other noncurrent liabilities ( $381 million ). (c) Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million ). The asset impairment charges included in restructuring charges for 2016 are primarily associated with abandoned assets.

Other (Income)_Deductions - N32

Other (Income)/Deductions - Net (Tables)	12 Months Ended
	Dec. 31, 2016
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	The following table provides components of Other (income)/deductions––net : Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Interest income (a) $ (470 ) $ (471 ) $ (425 ) Interest expense (a) 1,186 1,199 1,360 Net interest expense 716 728 935 Foreign currency loss related to Venezuela (b) — 806 — Royalty-related income (c) (905 ) (922 ) (1,002 ) Certain legal matters, net (d) 510 975 993 Net gains on asset disposals (e) (171 ) (232 ) (288 ) Impairment on remeasurement of HIS net assets (f) 1,712 — — Certain asset impairments (g) 1,447 818 469 Business and legal entity alignment costs (h) 261 282 168 Other, net (i) 85 403 (265 ) Other (income)/deductions––net $ 3,655 $ 2,860 $ 1,009 (a) 2015 v. 2014 ––Interest income increased primarily due to higher investment returns. Interest expense decreased, primarily due to the repayment of a portion of long-term debt in the first quarter of 2015 and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. Capitalized interest expense totaled $ 61 million in 2016 , $ 32 million in 2015 and $ 41 million in 2014 . (b) In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.30 , but rather at the then SIMADI rate of 200 , the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy. (c) Royalty-related income decreased in 2016, reflecting lower royalty income for Enbrel of $54 million , resulting from the expiration on October 31, 2016 of the 36 -month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), and the expiration of other royalty agreements, partially offset by Xtandi royalty-related income of $63 million . (d) In 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss is no longer deemed probable. For additional information, see Note 17A5. In addition, 2016 includes a settlement related to a patent matter. In 2015 , primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. For additional information, see Note 17A5 . In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million to resolve a securities class action against Pfizer in New York federal court, and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable. (e) In 2016 , primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $666 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $548 million ; (iii) loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of approximately $84 million ; and (v) gains on sales of investments in private equity securities of approximately $2 million . Proceeds from the sale of available-for-sale securities were $10.2 billion in 2016 . In 2015 , primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $164 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $960 million ; (iii) net gain of $937 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of approximately $90 million ; and (v) gains on sales of investments in private equity securities of approximately $3 million . Proceeds from the sale of available-for-sale securities were $4.3 billion in 2015. In 2014 , primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $76 million ; (ii) gross realized gains on sales of available-for-sale debt securities of $138 million ; (iii) gross realized losses on sales of available-for-sale debt securities of $436 million ; (iv) net gain of $323 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of approximately $135 million ; and (vi) gains on sales of investments in private equity securities of approximately $39 million . Proceeds from the sale of available-for-sale securities were $10.2 billion in 2014 . (f) In 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information . (g) In 2016 , primarily includes intangible asset impairment charges of $869 million , reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ( $840 million ) and IH ( $29 million ). In addition, 2016 includes an impairment loss of $452 million related to Pfizer’s 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2E. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. In 2015 , primarily includes an impairment loss of $463 million related to Pfizer’s 49% -owned equity-method investment in Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2E ) and intangible asset impairment charges of $323 million , reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: EH ( $294 million ), WRD ( $13 million ); and Consumer Healthcare ( $17 million ). The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. In 2014 includes intangible asset impairment charges of $396 million , reflecting (i) $190 million for an IPR&D compound for the treatment of skin fibrosis (full write-off); (ii) $159 million for developed technology rights, primarily related to Quillivant XR; and (iii) $47 million for indefinite-lived brands. The intangible asset impairment charges for 2014 are associated with the following: IH ( $12 million ); EH ( $166 million ); WRD ( $190 million ); and Consumer Healthcare ( $28 million ). In addition, 2014 includes an impairment charge of approximately $56 million related to our investment in Teuto. The intangible asset impairment charges for 2014 reflect, among other things, updated commercial forecasts and, with regard to IPR&D, the impact of changes to the development program and new scientific findings. (h) Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (i) In 2016, includes among other things, (i) $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A ); (ii) income of $116 million from resolution of a contract disagreement; and (iii) a net loss of approximately $312 million upon the early redemption of debt, which includes the related termination of interest rate swaps. In 2015 , includes, among other things, (i) charges of $194 million related to the write-down of assets to net realizable value; (ii) charges of $159 million , reflecting the change in the fair value of contingent consideration liabilities; and (iii) income of $45 million associated with equity-method investees. In 2014 , includes, among other things, (i) gains of approximately $40 million , reflecting the change in the fair value of contingent consideration liabilities associated with prior acquisitions; (ii) income associated with equity-method investees of $86 million ; (iii) income of $55 million resulting from a decline in the estimated loss on an option to acquire the remaining interest in Teuto; and (iv) a loss of $30 million due to a change in our ownership interest in ViiV. For additional information concerning Teuto and ViiV, see Note 2E.
Schedule of Additional Information About Intangible Assets Impaired	The following table provides additional information about the intangible assets that were impaired during 2016 in Other (income)/deductions––net : Year Ended December 31, Fair Value (a) 2016 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets––IPR&D (b) $ 95 $ — $ — $ 95 $ 503 Intangible assets––Developed technology rights (b) 30 — — 30 366 Total $ 125 $ — $ — $ 125 $ 869 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E. (b) Reflects intangible assets written down to fair value in 2016 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters (Tables)

Tax Matters (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The following table provides the components of Income from continuing operations before provision for taxes on income : Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 United States $ (8,534 ) $ (6,809 ) $ (4,744 ) International 16,886 15,773 16,984 Income from continuing operations before provision for taxes on income ( a), (b) $ 8,351 $ 8,965 $ 12,240 (a) 2016 v. 2015 –– The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs. (b) 2015 v. 2014 –– The increase in the domestic loss was primarily due to the loss of exclusivity for Celebrex and Zyvox, higher restructuring charges and higher selling, informational and administrative expenses, partially offset by the performance of certain products including Prevnar 13 and Ibrance, and the impact of Hospira operations. The decrease in international income was primarily due to a foreign currency loss related to Venezuela, higher asset impairments, and the loss of exclusivity for Lyrica in certain developed markets, partially offset by lower R&D costs.
Schedule of Provision for Taxes on Income	The following table provides the components of Provision for taxes on income based on the location of the taxing authorities: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 United States Current income taxes: Federal $ 342 $ 67 $ 393 State and local (52 ) (8 ) 85 Deferred income taxes: Federal (419 ) 300 725 State and local (106 ) (36 ) (256 ) Total U.S. tax provision (235 ) 323 948 International Current income taxes 1,532 1,951 2,321 Deferred income taxes (175 ) (284 ) (149 ) Total international tax provision 1,358 1,667 2,172 Provision for taxes on income $ 1,123 $ 1,990 $ 3,120
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows: Year Ended December 31, 2016 2015 2014 U.S. statutory income tax rate 35.0 % 35.0 % 35.0 % Taxation of non-U.S. operations (a), (b), (c) (13.8 ) (9.6 ) (7.4 ) Tax settlements and resolution of certain tax positions (d) (5.5 ) (4.0 ) (2.9 ) U.S. Healthcare Legislation (d) 1.3 0.9 1.0 U.S. R&D tax credit and manufacturing deduction (d) (1.0 ) (1.0 ) (0.9 ) Certain legal settlements and charges (d) (2.9 ) 3.1 — All other, net (e) 0.3 (2.1 ) 0.5 Effective tax rate for income from continuing operations 13.4 % 22.2 % 25.5 % (a) For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision for taxes on income . (b) In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico, Singapore, Costa Rica, and the Dominican Republic. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations. Hospira’s infusion technologies business benefits from income tax exemptions in Costa Rica and the Dominican Republic through 2028 and 2019, respectively. (c) The favorable rate impact in 2016 also includes the non-recurrence of the non-deductibility of a foreign currency loss related to Venezuela. The rate impact in 2015 also includes the non-deductibility of a foreign currency loss related to Venezuela. The favorable rate impact in 2014 also includes the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expected to retain the investment indefinitely. For additional information, see Note 2E. (d) For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and the impact of certain legal settlements and charges, see Note 5A. (e) All other, net in 2015 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business.
Schedule of Deferred Tax Assets and Liabilities	The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow: 2016 Deferred Tax 2015 Deferred Tax (MILLIONS OF DOLLARS) Assets (Liabilities) Assets (Liabilities) Prepaid/deferred items $ 2,180 $ (68 ) $ 2,247 $ (38 ) Inventories 366 (47 ) 381 (190 ) Intangible assets 1,139 (15,172 ) 1,063 (10,885 ) Property, plant and equipment 92 (982 ) 65 (1,096 ) Employee benefits 3,356 (74 ) 3,302 (167 ) Restructurings and other charges 458 (2 ) 318 (20 ) Legal and product liability reserves 650 — 730 — Net operating loss/tax credit carryforwards (a) 2,957 — 3,808 — Unremitted earnings (b) — (23,108 ) — (23,626 ) State and local tax adjustments 301 — 328 — All other 306 (503 ) 310 (646 ) 11,806 (39,956 ) 12,552 (36,668 ) Valuation allowances (1,949 ) — (2,029 ) — Total deferred taxes $ 9,857 $ (39,956 ) $ 10,523 $ (36,668 ) Net deferred tax liability (c) $ (30,099 ) $ (26,145 ) (a) The amounts in 2016 and 2015 are reduced for unrecognized tax benefits of $3.0 billion and $2.9 billion , respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. (b) The decrease in 2016 reflects the reversal of certain prior year accruals for earnings outside the U.S. that were not indefinitely reinvested overseas, partially offset by additional accruals for certain funds earned outside the U.S. in the current year that will not be indefinitely reinvested overseas. For additional information, see Note 5A. (c) In 2016 , Noncurrent deferred tax assets and other noncurrent tax assets ( $654 million ), and Noncurrent deferred tax liabilities ( $30.8 billion ). In 2015 , Noncurrent deferred tax assets and other noncurrent tax assets ( $732 million ), and Noncurrent deferred tax liabilities ( $26.8 billion ).
Schedule of Unrecognized Tax Benefits Roll Forward	The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows: (MILLIONS OF DOLLARS) 2016 2015 2014 Balance, beginning $ (5,919 ) $ (6,182 ) $ (6,087 ) Acquisitions (a) (83 ) (110 ) — Increases based on tax positions taken during a prior period (b) (11 ) (31 ) (110 ) Decreases based on tax positions taken during a prior period (b), (c) 409 496 473 Decreases based on settlements for a prior period (d) 126 64 70 Increases based on tax positions taken during the current period (b) (489 ) (675 ) (795 ) Impact of foreign exchange (5 ) 319 161 Other, net (b), (e) 146 199 106 Balance, ending (f) $ (5,826 ) $ (5,919 ) $ (6,182 ) (a) For 2016, primarily related to the acquisitions of Medivation and Anacor. For 2015, primarily related to the acquisition of Hospira. See also Note 2A. (b) Primarily included in Provision for taxes on income. (c) Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A. (d) Primarily related to cash payments and reductions of tax attributes. (e) Primarily related to decreases as a result of a lapse of applicable statutes of limitations. (f) In 2016 , included in Income taxes payable ( $14 million ), Current tax assets ( $17 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $184 million ), Noncurrent deferred tax liabilities ( $2.8 billion ) and Other taxes payable ( $2.8 billion ). In 2015 , included in Income taxes payable ( $38 million ), Current tax assets ( $22 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $135 million ), Noncurrent deferred tax liabilities ( $2.7 billion ) and Other taxes payable ( $3.0 billion ).
Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)	The following table provides the components of the Tax provision/(benefit) on other comprehensive loss : Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Foreign currency translation adjustments, net (a) $ (15 ) $ 90 $ 42 Unrealized holding gains/(losses) on derivative financial instruments, net (75 ) (173 ) (199 ) Reclassification adjustments for realized (gains)/losses 158 104 262 83 (69 ) 63 Unrealized holding gains/(losses) on available-for-sale securities, net 49 (104 ) (56 ) Reclassification adjustments for realized (gains)/losses (15 ) 59 10 34 (45 ) (46 ) Benefit plans: actuarial losses, net (535 ) (23 ) (1,416 ) Reclassification adjustments related to amortization 186 183 61 Reclassification adjustments related to settlements, net 45 237 35 Other 36 66 61 (269 ) 462 (1,258 ) Benefit plans: prior service credits and other, net 67 160 281 Reclassification adjustments related to amortization (64 ) (59 ) (28 ) Reclassification adjustments related to curtailments, net (10 ) (12 ) — Other (1 ) — (1 ) (7 ) 89 253 Tax provision/(benefit) on other comprehensive loss $ (174 ) $ 528 $ (946 ) (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensi34

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gain/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/ Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, January 1, 2014 $ (590 ) $ 79 $ 150 $ (3,223 ) $ 313 $ (3,271 ) Other comprehensive income/(loss) (a) (2,099 ) 438 (372 ) (2,432 ) 419 (4,045 ) Balance, December 31, 2014 (2,689 ) 517 (222 ) (5,654 ) 733 (7,316 ) Other comprehensive income/(loss) (a) (3,174 ) (96 ) (5 ) 921 148 (2,206 ) Balance, December 31, 2015 (5,863 ) 421 (227 ) (4,733 ) 880 (9,522 ) Other comprehensive income/(loss) (a) $ (797 ) $ (73 ) $ 96 $ (740 ) $ (1 ) $ (1,514 ) Balance, December 31, 2016 $ (6,659 ) $ 348 $ (131 ) $ (5,473 ) $ 879 $ (11,036 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $3 million loss in 2016 , $26 million loss in 2015 and $3 million gain in 2014 .

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Financial Instruments [Abstract]
Information about Certain Financial Assets and Liabilities	The following table provides additional information about certain of our financial assets and liabilities: As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Selected financial assets measured at fair value on a recurring basis (a) Trading funds and securities (b) $ 325 $ 287 Available-for-sale debt securities (c) 18,632 32,078 Money market funds 1,445 934 Available-for-sale equity securities (c) 540 603 Derivative financial instruments in a receivable position (d) : Interest rate swaps 625 837 Foreign currency swaps 79 135 Foreign currency forward-exchange contracts 551 559 22,198 35,433 Other selected financial assets Held-to-maturity debt securities, carried at amortized cost (c), (e) 1,242 1,388 Private equity securities, carried at equity-method or at cost-method (e), (f) 735 1,336 1,977 2,724 Total selected financial assets $ 24,175 $ 38,157 Selected financial liabilities measured at fair value on a recurring basis (a) Derivative financial instruments in a liability position (g) : Interest rate swaps $ 148 $ 139 Foreign currency swaps 1,374 1,489 Foreign currency forward-exchange contracts 143 81 1,665 1,709 Other selected financial liabilities Short-term borrowings: Principal amount 10,674 10,160 Net fair value adjustments related to hedging and purchase accounting 24 2 Net unamortized discounts, premiums and debt issuance costs (h) (11 ) (3 ) Total short-term borrowings, carried at historical proceeds, as adjusted (e) 10,688 10,159 Long-term debt: Principal amount 30,529 27,573 Net fair value adjustments related to hedging and purchase accounting 998 1,294 Net unamortized discounts, premiums and debt issuance costs (h) (130 ) (127 ) Total long-term debt, carried at historical proceeds, as adjusted (i) 31,398 28,740 42,085 38,899 Total selected financial liabilities $ 43,750 $ 40,608 (a) We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value. (b) As of December 31, 2016 , trading funds and securities are composed of $236 million of trading equity funds and $89 million of trading debt funds. As of December 31, 2015 , trading funds and securities are composed of $185 million of trading equity funds and $102 million of trading debt funds. As of December 31, 2016 and December 31, 2015 , trading equity funds of $71 million and $85 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. (c) Gross unrealized gains and losses related to 2016 are not significant. Unrealized losses related to 2015 available-for-sale debt securities are $593 million and unrealized gains are $44 million . The vast majority of investments related to 2015, in an unrealized loss position, relate to the foreign exchange impact on foreign currency denominated securities, which are hedged with foreign currency forward-exchange contracts and cross-currency swaps. We have the intent and ability to hold such investments to maturity. (d) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $162 million as of December 31, 2016 ; and foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015 . (e) The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2016 or December 31, 2015 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments. (f) Our private equity securities represent investments in the life sciences sector. (g) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $269 million and foreign currency forward-exchange contracts with fair values of $113 million as of December 31, 2016 ; and foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $59 million as of December 31, 2015 . (h) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (i) The fair value of our long-term debt (not including the current portion of long-term debt) was $34.9 billion as of December 31, 2016 and $32.7 billion as of December 31, 2015 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach.
Selected Financial Assets and Liabilities Presented in the Condensed Consolidated Balance Sheets	The following table provides the classification of these selected financial assets and liabilities in our consolidated balance sheets: As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Assets Cash and cash equivalents $ 547 $ 978 Short-term investments 15,255 19,649 Other current assets (a) 567 587 Long-term investments 7,116 15,999 Other noncurrent assets (b) 689 944 $ 24,175 $ 38,157 Liabilities Short-term borrowings, including current portion of long-term debt (c) $ 10,688 $ 10,159 Other current liabilities (d) 443 645 Long-term debt (c) 31,398 28,740 Other noncurrent liabilities (e) 1,222 1,064 $ 43,750 $ 40,608 (a) As of December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $26 million ), foreign currency swaps ( $43 million ) and foreign currency forward-exchange contracts ( $497 million ) and, as of December 31, 2015 , include interest rate swaps ( $2 million ), foreign currency swaps ( $46 million ) and foreign currency forward-exchange contracts ( $538 million ). (b) As of December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $599 million ), foreign currency swaps ( $36 million ) and foreign currency forward-exchange contracts ( $54 million ) and, as of December 31, 2015 , include interest rate swaps ( $835 million ), foreign currency swaps ( $89 million ) and foreign currency forward-exchange contracts ( $20 million ). (c) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (d) At December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $1 million ), foreign currency swaps ( $300 million ) and foreign currency forward-exchange contracts ( $143 million ) and, as of December 31, 2015 , include interest rate swaps ( $5 million ), foreign currency swaps ( $560 million ) and foreign currency forward-exchange contracts ( $80 million ). (e) At December 31, 2016 , derivative instruments at fair value include interest rate swaps ( $147 million ) and foreign currency swaps ( $1.1 billion ) and, as of December 31, 2015 , include interest rate swaps ( $134 million ), foreign currency swaps ( $928 million ) and foreign currency forward-exchange contracts ( $1 million ).
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: Years December 31, (MILLIONS OF DOLLARS) Within 1 Over 1 to 5 Over 5 to 10 Over 10 Total Available-for-sale debt securities Corporate debt (a) $ 2,783 $ 2,727 $ 1,557 $ 23 $ 7,089 Western European, Scandinavian and other government debt (b) 4,661 432 — — 5,093 U.S. government debt 2,134 88 — — 2,222 Western European, Scandinavian, Australian and other government agency debt (b) 1,746 137 — — 1,883 Supranational debt (b) 910 294 — — 1,204 Other asset-backed debt (c) 367 217 18 3 605 Government National Mortgage Association and other U.S. government guaranteed asset-backed securities 535 — — — 535 Held-to-maturity debt securities Time deposits and other 1,000 1 3 — 1,004 Western European government debt (b) 236 2 — — 238 Total debt securities $ 14,371 $ 3,898 $ 1,579 $ 26 $ 19,873 (a) Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade. (b) Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade. (c) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
Schedule of Long-term Debt Instruments	Long Term Debt The following table provides the components of our senior unsecured long-term debt (a) : Principal As of December 31, (MILLIONS OF DOLLARS) Maturity Date 2016 2015 4.55% euro (b) May 2017 $ — $ 980 1.10% (b) May 2017 — 1,000 1.20% June 2018 1,250 — 1.50% June 2018 1,000 1,000 6.20% March 2019 — 3,250 2.10% May 2019 1,500 1,500 1.70% December 2019 1,000 — 5.75% euro June 2021 2,108 2,178 1.95% June 2021 1,150 — 2.20% December 2021 1,000 — 3.00% June 2023 1,000 1,000 3.40% May 2024 1,000 1,000 2.75% June 2026 1,250 — 3.00% December 2026 1,750 — 4.00% December 2036 1,000 — 5.95% April 2037 2,000 2,000 6.50% U.K. pound June 2038 1,852 2,223 7.20% March 2039 2,500 2,500 4.40% May 2044 1,000 500 4.125% December 2046 1,250 — Notes and other debt with a weighted-average interest rate of 3.30% (c) 2018–2021 2,464 3,974 Notes and other debt with a weighted-average interest rate of 5.99% (d) 2023–2043 4,455 4,468 Total principal amount of long-term debt 30,529 27,573 Net fair value adjustments related to hedging and purchase accounting 998 1,294 Net unamortized discounts, premiums and debt issuance costs (130 ) (127 ) Total long-term debt, carried at historical proceeds, as adjusted $ 31,398 $ 28,740 Current portion of long-term debt (not included above) $ 4,225 $ 3,719 (a) Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus an incremental spread ranging from 0.05% to 0.50% , plus, in each case, accrued and unpaid interest. (b) At December 31, 2016, the debt issuances have been reclassified to the current portion of long-term debt. (c) Contains debt issuances with a weighted-average maturity of approximately two years for balances that exist as of December 31, 2016 . (d) Contains debt issuances with a weighted-average maturity of approximately 16 years for balances that exist as of December 31, 2016 . The following table provides the maturity schedule of our Long-term debt outstanding as of December 31, 2016: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 After 2021 Total Maturities $ 3,567 $ 3,350 $ 360 $ 4,241 $ 19,879 $ 31,398
Schedule of Maturities of Long-term Debt	The following table provides the maturity schedule of our Long-term debt outstanding as of December 31, 2016: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 After 2021 Total Maturities $ 3,567 $ 3,350 $ 360 $ 4,241 $ 19,879 $ 31,398
Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion) (a), (d) As of December 31, (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ (280 ) $ (826 ) $ (387 ) $ (613 ) Foreign currency forward-exchange contracts (4 ) — (164 ) 1,028 (65 ) 980 Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts 1 (1 ) (15 ) 256 — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts (92 ) (42 ) — — — — Foreign currency swaps (13 ) (4 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — (26 ) 3 — — All other net — (16 ) 1 — (1 ) — $ (107 ) $ (64 ) $ (483 ) $ 461 $ (452 ) $ 367 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income . OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income . (b) Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships. (c) There was no significant ineffectiveness for any period presented. (d) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive loss––Foreign currency translation adjustments, net.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Finished goods $ 2,293 $ 2,714 Work in process 3,696 3,932 Raw materials and supplies 793 867 Inventories (a) $ 6,783 $ 7,513 Noncurrent inventories not included above (b) $ 683 $ 594 (a) The change from December 31, 2015 reflects, among other things, the reclassification of $377 million to Assets held for sale (see Note 2B) . (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Component of Inventories, Noncurrent	The following table provides the components of Inventories : As of December 31, (MILLIONS OF DOLLARS) 2016 2015 Finished goods $ 2,293 $ 2,714 Work in process 3,696 3,932 Raw materials and supplies 793 867 Inventories (a) $ 6,783 $ 7,513 Noncurrent inventories not included above (b) $ 683 $ 594 (a) The change from December 31, 2015 reflects, among other things, the reclassification of $377 million to Assets held for sale (see Note 2B) . (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Components of Property, Plant and Equipment	The following table provides the components of Property, plant and equipment : Useful Lives As of December 31, (MILLIONS OF DOLLARS) (Years) 2016 2015 Land - $ 530 $ 588 Buildings 33-50 9,810 9,604 Machinery and equipment 8-20 11,248 10,933 Furniture, fixtures and other 3-12 1/2 4,410 4,351 Construction in progress - 2,127 1,791 28,125 27,268 Less: Accumulated depreciation 14,807 13,502 Property, plant and equipment (a) $ 13,318 $ 13,766 (a) The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $457 million to Assets held for sale (see Note 2B) and, to a lesser extent, impairments and the impact of foreign exchange, partially offset by capital additions.

Identifiable Intangible Asset38

Identifiable Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : December 31, 2016 December 31, 2015 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 83,390 $ (49,650 ) $ 33,740 $ 77,613 $ (47,193 ) $ 30,419 Brands 2,092 (1,032 ) 1,060 1,973 (928 ) 1,044 Licensing agreements and other 1,869 (1,005 ) 864 1,619 (918 ) 701 87,351 (51,687 ) 35,664 81,205 (49,040 ) 32,165 Indefinite-lived intangible assets Brands and other 6,883 6,883 7,021 7,021 IPR&D (a) 10,101 10,101 1,171 1,171 16,984 16,984 8,192 8,192 Identifiable intangible assets (a) $ 104,335 $ (51,687 ) $ 52,648 $ 89,396 $ (49,040 ) $ 40,356 (a) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A ), and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A ), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale (see Note 2B ). For information about impairments, see Note 4. The increase in IPR&D, is primarily related to assets acquired as part of the acquisitions of Anacor and Medivation, largely crisaborole and Xtandi. The intellectual property for crisaborole is owned by an international entity. Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: December 31, 2016 IH EH WRD Developed technology rights 64 % 35 % — Brands, finite-lived 73 % 27 % — Brands, indefinite-lived 71 % 29 % — IPR&D 92 % 5 % 4 %
Schedule of Indefinite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : December 31, 2016 December 31, 2015 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 83,390 $ (49,650 ) $ 33,740 $ 77,613 $ (47,193 ) $ 30,419 Brands 2,092 (1,032 ) 1,060 1,973 (928 ) 1,044 Licensing agreements and other 1,869 (1,005 ) 864 1,619 (918 ) 701 87,351 (51,687 ) 35,664 81,205 (49,040 ) 32,165 Indefinite-lived intangible assets Brands and other 6,883 6,883 7,021 7,021 IPR&D (a) 10,101 10,101 1,171 1,171 16,984 16,984 8,192 8,192 Identifiable intangible assets (a) $ 104,335 $ (51,687 ) $ 52,648 $ 89,396 $ (49,040 ) $ 40,356 (a) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A ), and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A ), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale (see Note 2B ). For information about impairments, see Note 4. The increase in IPR&D, is primarily related to assets acquired as part of the acquisitions of Anacor and Medivation, largely crisaborole and Xtandi. The intellectual property for crisaborole is owned by an international entity. Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: December 31, 2016 IH EH WRD Developed technology rights 64 % 35 % — Brands, finite-lived 73 % 27 % — Brands, indefinite-lived 71 % 29 % — IPR&D 92 % 5 % 4 %
Schedule of Expected Amortization Expense	The following table provides the annual amortization expense expected for the years 2017 through 2021: (MILLIONS OF DOLLARS) 2017 2018 2019 2020 2021 Amortization expense $ 4,827 $ 4,706 $ 4,481 $ 3,442 $ 3,348
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, January 1, 2015 $ 24,430 $ 17,639 $ 42,069 Additions (a) 39 7,284 7,323 Other (b) (660 ) (489 ) (1,149 ) Balance, December 31, 2015 23,809 24,433 48,242 Additions (c) 6,357 12 6,369 Other (d) (32 ) (130 ) (162 ) Balance, December 31, 2016 $ 30,134 $ 24,315 $ 54,449 (a) EH additions relate to our acquisition of Hospira. For additional information, see Note 2A. (b) Primarily reflects the impact of foreign exchange. (c) IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo and are subject to change until we complete the valuations of assets acquired and liabilities assumed from Medivation, Anacor and Bamboo (see Note 2A ). (d) Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $119 million to Assets held for sale during 2016 (see Note 2B ). We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH), which was previously known as Established Products. Beginning in the second quarter of 2016, we reorganized our operating segments to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH. From the beginning of our fiscal year 2014 until the second quarter of 2016, these operations were managed as two business segments: the GIP segment and the VOC segment. We have retrospectively presented goodwill according to the new operating segment structure. For additional information, see Note 18. As a result of this change, our goodwill associated with our former GIP segment was required to be reallocated to new reporting units based on relative fair value.

Pension and Postretirement Be39

Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the annual cost/(income) and changes in Other comprehensive loss for our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c), (f) Postretirement Plans (d), (f) (MILLIONS OF DOLLARS) 2016 2015 2014 2016 2015 2014 2016 2015 2014 2016 2015 2014 Service cost $ 257 $ 287 $ 253 $ 18 $ 22 $ 20 $ 165 $ 186 $ 199 $ 41 $ 55 $ 55 Interest cost 646 676 697 53 54 57 233 307 394 101 117 169 Expected return on plan assets (958 ) (1,089 ) (1,043 ) — — — (381 ) (418 ) (459 ) (34 ) (53 ) (63 ) Amortization of: Actuarial losses 395 346 63 37 44 29 93 122 97 32 38 6 Prior service credits 5 (5 ) (7 ) (1 ) (2 ) (2 ) (3 ) (7 ) (7 ) (174 ) (146 ) (57 ) Curtailments 10 3 2 1 — — (2 ) 5 — (26 ) (31 ) (7 ) Settlements 90 556 52 28 34 28 9 81 22 — — — Special termination benefits — — — — — — 1 1 8 — — — Net periodic benefit costs/(income) reported in Income 444 773 16 137 153 132 115 277 254 (59 ) (21 ) 102 (Income)/cost reported in Other comprehensive loss (e) 253 (396 ) 2,768 121 (143 ) 163 640 (542 ) 260 3 (540 ) (174 ) (Income)/cost recognized in Comprehensive income $ 697 $ 378 $ 2,784 $ 258 $ 10 $ 294 $ 755 $ (265 ) $ 514 $ (56 ) $ (560 ) $ (72 ) (a) 2016 v. 2015 –– The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a year-over-year decrease in settlement activity compared to that of 2015 related to the non-recurring lump-sum settlement option to certain plan participants discussed in the 2015 v. 2014 analysis, below, (ii) lower service costs resulting from a higher discount rate, and (iii) lower interest costs resulting from a lower beginning benefit obligation. The aforementioned decreases were partially offset by (i) a lower expected return on plan assets resulting from both a lower expected rate of return, and a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, and (ii) an increase in the amounts amortized for actuarial losses, primarily resulting from the remeasurement in 2015 of Hospira’s U.S. qualified pension plan due to its plan termination. 2015 v. 2014 –– The increase in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a non-recurring charge of $419 million related to the settlement of pension obligations in accordance with an offer to certain terminated employees who are vested in their pension benefits to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or an annuity of their deferred vested pension benefits, and (ii) the increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation (which increased the amount of deferred actuarial losses), and, to a lesser extent, a 2014 change in mortality assumptions (reflecting a longer life expectancy for plan participants). The aforementioned increases were partially offset by (i) a greater expected return on plan assets resulting from an increased plan asset base due to a voluntary contribution of $1.0 billion made at the beginning of January 2015, which in turn was partially offset by a decrease in the expected rate of return on plan assets from 8.5% to 8.3% and (ii) lower interest costs resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. (b) 2016 v. 2015 –– The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation, (ii) lower settlement activity, and (iii) lower service costs resulting from a higher discount rate. 2015 v. 2014 –– The increase in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (ii) higher settlement activity. (c) 2016 v. 2015 –– The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) lower service and interest costs, resulting from a change in our approach for measuring service and interest costs (see (f) below), (ii) lower settlement activity, and (iii) a decrease in the amounts amortized for actuarial losses resulting from large gains in 2015, which decreased the plan net loss position. The aforementioned decreases to our net periodic benefit costs were partially offset by a decrease in the expected return on plan assets due to a lower asset base and a lower expected rate of return on plan assets. 2015 v. 2014 –– The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets, (ii) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (iii) higher settlement charges due to the settlement of a pension plan in Sweden. The aforementioned increase in net periodic benefit costs was partially offset by the decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. (d) 2016 v. 2015 –– The increase in net periodic benefit income for our postretirement plans was primarily driven by (i) an increase in prior service credits due to the postretirement medical plan cap changes during 2016 and 2015, (ii) lower interest costs resulting from a lower benefit obligation, (iii) lower service costs resulting from a higher discount rate, and (iv) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. The aforementioned changes were partially offset by (i) a decrease in expected return on plan assets, primarily resulting from a decrease in plan assets, reflecting payments by the plan for IRC Section 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees, and (ii) lower curtailment gains. 2015 v. 2014 –– The decrease in net periodic benefit costs for our postretirement plans was primarily driven by (i) the increase in the amounts amortized for prior service credits and (ii) an increase in curtailment gains resulting from the implementation of changes to certain retiree medical benefits to adopt programs eligible for the Medicare Part D plan subsidy, as allowed under the EGWP, and another plan change to establish benefit caps for certain plan participants, as well as (iii) a decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. The aforementioned decreases were partially offset by an increase in actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. (e) For details of the changes in Other comprehensive loss, see the benefit plan activity in the consolidated statements of comprehensive income. (f) Effective January 1, 2016, the Company changed the approach used to measure service and interest costs for certain international pension and other postretirement benefit plans. For fiscal 2015 and 2014, the Company measured service and interest costs utilizing a single weighted-average discount rate derived from the yield curve used to measure the respective plan obligations. For fiscal 2016, we elected to measure service and interest costs by applying the spot rates along the yield curve for certain international plans to the plans' liability cash flows. The Company believes the new approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. This change does not affect the measurement of our plan obligations. We have accounted for this change as a change in accounting estimate and, accordingly, have accounted for it on a prospective basis. The reduction in expense for 2016 associated with this change in estimate was $42 million , primarily related to certain international pension plans, which was recognized evenly over each quarter of the year. The change in approach for the postretirement benefit plans was not material to the 2016 consolidated statement of income.
Schedule of Amounts in Accumulated Other Comprehensive Income/(Loss) Expected to be Amortized into 2014 Net Periodic Benefit Costs	The following table provides the amounts in Accumulated other comprehensive loss expected to be amortized into 2017 net periodic benefit costs: Pension Plans (MILLIONS OF DOLLARS) U.S. U.S. Supplemental International Postretirement Plans Actuarial losses $ (414 ) $ (50 ) $ (113 ) $ (31 ) Prior service credits and other (5 ) 1 4 184 Total $ (419 ) $ (49 ) $ (109 ) $ 153
Schedule of Assumptions Used	The following table provides the weighted-average actuarial assumptions of our benefit plans: (PERCENTAGES) 2016 2015 2014 Weighted-average assumptions used to determine benefit obligations Discount rate: U.S. qualified pension plans 4.3% 4.5% 4.2% U.S. non-qualified pension plans 4.2% 4.5% 4.0% International pension plans 2.4% 3.1% 3.0% Postretirement plans 4.2% 4.5% 4.2% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.6% 2.6% 2.7% Weighted-average assumptions used to determine net periodic benefit cost Discount rate: U.S. qualified pension plans 4.5% 4.2% 5.2% U.S. non-qualified pension plans 4.5% 4.0% 4.8% International pension plans interest cost (a) 2.7% 3.0% 3.9% International pension plans service cost (a) 3.0% 3.0% 3.9% Postretirement plans 4.5% 4.2% 5.1% Expected return on plan assets: U.S. qualified pension plans 8.0% 8.3% 8.5% International pension plans 5.2% 5.5% 5.8% Postretirement plans 8.0% 8.3% 8.5% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.6% 2.7% 2.9% (a) As discussed above, effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with this change, the effective rate for interest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans.
Schedule of Health Care Cost Trend Rates	The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans: 2016 2015 Healthcare cost trend rate assumed for next year (up to age 65) 6.3 % 6.5 % Healthcare cost trend rate assumed for next year (age 65 and older) 7.4 % 7.9 % Rate to which the cost trend rate is assumed to decline 4.5 % 4.5 % Year that the rate reaches the ultimate trend rate 2037 2037 The following table provides the effects as of December 31, 2016 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits: (MILLIONS OF DOLLARS) Increase Decrease Effect on total service and interest cost components $ 5 $ (5 ) Effect on postretirement benefit obligation 37 (50 )
Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates	The following table provides the effects as of December 31, 2016 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits: (MILLIONS OF DOLLARS) Increase Decrease Effect on total service and interest cost components $ 5 $ (5 ) Effect on postretirement benefit obligation 37 (50 )
Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans	The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c) Postretirement Plans (d) (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 2016 2015 Change in benefit obligation (e) Benefit obligation, beginning $ 14,926 $ 16,575 $ 1,343 $ 1,481 $ 9,214 $ 10,796 $ 2,463 $ 3,168 Service cost 257 287 18 22 165 186 41 55 Interest cost 646 676 53 54 233 307 101 117 Employee contributions — — — — 7 7 85 79 Plan amendments — 62 — 4 (6 ) (1 ) (177 ) (497 ) Changes in actuarial assumptions and other 725 (774 ) 185 (70 ) 1,273 (273 ) 22 (185 ) Foreign exchange impact — — — — (781 ) (938 ) — (20 ) Acquisitions/divestitures/other, net — 542 — 9 1 19 — 49 Curtailments 9 3 1 — (14 ) (2 ) — (3 ) Settlements (449 ) (2,034 ) (78 ) (93 ) (45 ) (499 ) — — Special termination benefits — — — — 1 1 — — Benefits paid (568 ) (412 ) (72 ) (65 ) (358 ) (389 ) (282 ) (300 ) Benefit obligation, ending (e) 15,547 14,926 1,450 1,343 9,691 9,214 2,254 2,463 Change in plan assets Fair value of plan assets, beginning 11,633 12,706 — — 7,959 8,588 622 762 Actual gain/(loss) on plan assets 939 (124 ) — — 693 290 44 (3 ) Company contributions 1,000 1,000 151 158 209 558 (12 ) 84 Employee contributions — — — — 7 7 85 79 Foreign exchange impact — — — — (782 ) (602 ) — — Acquisitions/divestitures, net — 496 — — (1 ) 6 — — Settlements (449 ) (2,034 ) (78 ) (93 ) (45 ) (499 ) — — Benefits paid (568 ) (412 ) (72 ) (65 ) (358 ) (389 ) (282 ) (300 ) Fair value of plan assets, ending 12,556 11,633 — — 7,683 7,959 458 622 Funded status—Plan assets less than benefit obligation $ (2,990 ) $ (3,292 ) $ (1,450 ) $ (1,343 ) $ (2,008 ) $ (1,255 ) $ (1,796 ) $ (1,841 ) (a) The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016. (b) Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations. The increase in the benefit obligation is primarily due to a decrease in the discount rate. (c) The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets. (d) The favorable change in the funded status of our postretirement plans was primarily due to plan amendments for certain U.S. and Puerto Rico postretirement plans. The U.S. plan change applied a fixed cap on costs for certain groups within the plan. The Puerto Rico plan change includes: (i) a cap on costs for certain groups within the plan, and (ii) the adoption of the EGWP. The changes resulted in reductions to the plan liabilities of $82 million for the U.S. postretirement plan and $95 million for the Puerto Rico postretirement plan. (e) For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $15.4 billion in 2016 and $14.8 billion in 2015 . The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2016 and $1.3 billion in 2015 . The ABO for our international pension plans was $9.3 billion in 2016 and $8.8 billion in 2015 .
Schedule of Amounts Recognized in Balance Sheet	The following table provides information as to how the funded status is recognized in our consolidated balance sheets: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 2016 2015 Noncurrent assets (a) $ — $ — $ — $ — $ 300 $ 572 $ — $ — Current liabilities (b) (160 ) — (152 ) (126 ) (28 ) (25 ) (30 ) (31 ) Noncurrent liabilities (c) (2,830 ) (3,292 ) (1,297 ) (1,216 ) (2,279 ) (1,801 ) (1,766 ) (1,809 ) Funded status $ (2,990 ) $ (3,292 ) $ (1,450 ) $ (1,343 ) $ (2,008 ) $ (1,255 ) $ (1,796 ) $ (1,841 ) (a) Included primarily in Other noncurrent assets . (b) Included in Accrued compensation and related items . (c) Included in Pension benefit obligations, net and Postretirement benefit obligations , net, as appropriate.
Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)	The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss : As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 2016 2015 Actuarial losses (a) $ (4,530 ) $ (4,272 ) $ (538 ) $ (419 ) $ (2,629 ) $ (1,979 ) $ (502 ) $ (523 ) Prior service (costs)/credits (27 ) (33 ) 2 4 40 29 1,392 1,415 Total $ (4,558 ) $ (4,305 ) $ (536 ) $ (415 ) $ (2,589 ) $ (1,949 ) $ 889 $ 892 (a) The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants, using the corridor approach. The average amortization periods to be utilized for 2017 are 8.2 years for our U.S. qualified plans, 8.1 years for our U.S. supplemental (non-qualified) plans, 19.3 years for our international plans, and 9.1 years for our postretirement plans.
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets	The following table provides information related to the funded status of selected benefit plans: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 Pension plans with an ABO in excess of plan assets: Fair value of plan assets $ 12,556 $ 11,633 $ — $ — $ 4,625 $ 976 ABO 15,422 14,755 1,410 1,324 6,558 2,495 Pension plans with a PBO in excess of plan assets: Fair value of plan assets 12,556 11,633 — — 4,936 1,546 PBO 15,547 14,926 1,450 1,343 7,244 3,373
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets	The following table provides information related to the funded status of selected benefit plans: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International (MILLIONS OF DOLLARS) 2016 2015 2016 2015 2016 2015 Pension plans with an ABO in excess of plan assets: Fair value of plan assets $ 12,556 $ 11,633 $ — $ — $ 4,625 $ 976 ABO 15,422 14,755 1,410 1,324 6,558 2,495 Pension plans with a PBO in excess of plan assets: Fair value of plan assets 12,556 11,633 — — 4,936 1,546 PBO 15,547 14,926 1,450 1,343 7,244 3,373
Schedule of Allocation of Plan Assets	The following table provides the components of plan assets: Fair Value (a) Fair Value (a) (MILLIONS OF DOLLARS) As of December 31, 2016 Level 1 Level 2 Level 3 Assets Measured at NAV (b) As of December 31, 2015 Level 1 Level 2 Level 3 Assets Measured at NAV (b) U.S. qualified pension plans Cash and cash equivalents $ 672 $ 92 $ 580 $ — $ — $ 417 $ 81 $ 336 $ — $ — Equity securities: Global equity securities 3,970 3,943 27 — — 3,720 3,717 2 1 — Equity commingled funds 1,062 — 772 — 290 951 — 689 — 262 Fixed income securities: Corporate debt securities 3,232 14 3,217 1 — 2,866 3 2,861 2 — Government and government agency obligations 1,060 — 1,060 — — 989 — 989 — — Fixed income commingled funds 92 — — — 92 222 — 57 — 165 Other investments: Partnership investments (c) 1,093 — — — 1,093 1,120 — — — 1,120 Insurance contracts 235 — 235 — — 259 — 259 — — Other commingled funds (d) 1,140 — — — 1,140 1,089 — — — 1,089 Total 12,556 4,049 5,891 1 2,615 11,633 3,801 5,193 3 2,636 International pension plans Cash and cash equivalents 439 38 401 — — 207 14 193 — — Equity securities: Global equity securities 174 163 11 — — 901 816 85 — — Equity commingled funds 2,490 — 1,265 — 1,224 2,218 16 854 — 1,348 Fixed income securities: Corporate debt securities 489 — 474 — 15 653 171 469 — 12 Government and government agency obligations 853 — 786 — 67 1,224 109 1,048 — 67 Fixed income commingled funds 1,750 — 1,174 — 576 1,216 37 919 — 260 Other investments: Partnership investments (c) 32 — — — 32 40 — 6 — 33 Insurance contracts 272 — 17 254 1 257 — 21 219 17 Other (d) 1,185 — 430 324 431 1,245 59 370 398 418 Total 7,683 201 4,558 578 2,346 7,959 1,222 3,965 618 2,155 U.S. postretirement plans (e) Cash and cash equivalents — — — — — 6 — 6 — — Equity securities: Global equity securities — — — — — 64 64 — — — Equity commingled funds — — — — — 16 — 12 — 4 Fixed income securities: Corporate debt securities — — — — — 49 — 49 — — Government and government agency obligations — — — — — 17 — 17 — — Fixed income commingled funds — — — — — 4 — 1 — 3 Other investments: Partnership investments (c) — — — — — 19 — — — 19 Insurance contracts 458 — 458 — — 429 — 429 — — Other commingled funds (d) — — — — — 19 — — — 19 Total $ 458 $ — $ 458 $ — $ — $ 622 $ 64 $ 514 $ — $ 45 (a) Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E ). (b) In accordance with the provisions of a new accounting standard we adopted on January 1, 2016, described below, certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets. As a result, a reclassification has been made to the prior year’s plan asset classification table to conform to the current year’s presentation. (c) Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital. (d) Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds. (e) Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans. The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans: As of December 31, Target Allocation Percentage Percentage of Plan Assets (PERCENTAGES) 2016 2016 2015 U.S. qualified pension plans Cash and cash equivalents 0-10% 5.3 % 3.6 % Equity securities 35-55% 40.1 % 40.2 % Fixed income securities 30-55% 34.9 % 35 % Other investments (a) 5-17.5% 19.7 % 21.2 % Total 100 % 100 % 100 % International pension plans Cash and cash equivalents 0-10% 5.7 % 2.6 % Equity securities 25-50% 34.7 % 39.2 % Fixed income securities 30-55% 40.2 % 38.8 % Other investments 10-30% 19.4 % 19.4 % Total 100 % 100 % 100 % U.S. postretirement plans Cash and cash equivalents 0-5% — 1.0 % Equity securities — — 12.8 % Fixed income securities — — 11.2 % Other investments 95-100% 100 % 75 % Total 100 % 100 % 100 % (a) Actual percentage of plan assets in Other investments for 2016 includes $235 million (this amount was $259 million in 2015) related to a group fixed annuity insurance contract that was executed by legacy Wyeth for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $144 million (this amount was $129 million in 2015) related to an investment in a partnership whose primary holdings are public equity securities.
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs: Year Ended December 31, International Pension Plans Insurance contracts Other (MILLIONS OF DOLLARS) 2016 2015 2016 2015 Fair value, beginning (a) $ 219 $ 254 $ 398 $ 395 Actual return on plan assets: Assets held, ending 11 16 (1 ) 30 Assets sold during the period — — 6 13 Purchases, sales and settlements, net 20 (19 ) (18 ) (21 ) Exchange rate changes 4 (33 ) (61 ) (19 ) Fair value, ending $ 254 $ 219 $ 324 $ 398 (a) We adopted a new accounting standard as of January 1, 2016 whereby certain investments in 2016 and 2015 that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been classified as Level 1, 2 or 3 in the above fair value hierarchy table, but are included in the total. As a result, a reclassification has been made to the prior year's plan asset classification table to conform to the current year's presentation.
Schedule of Expected Future Cash Flow Information	The following table provides the expected future cash flow information related to our benefit plans: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Expected employer contributions: 2017 (a) $ 1,160 $ 152 $ 175 $ 179 Expected benefit payments: 2017 $ 1,519 $ 152 $ 331 $ 186 2018 1,058 128 333 196 2019 947 118 335 198 2020 952 119 350 197 2021 930 112 356 196 2022–2026 4,391 503 1,867 919 (a) For the U.S. qualified plans, the $1.0 billion voluntary contribution, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums, was paid in January 2017.

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Summary of Common Stock Purchases	The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including our accelerated share repurchase agreements: (SHARES IN MILLIONS, DOLLARS IN BILLIONS) 2016 (a) 2015 (b) 2014 Shares of common stock purchased 154 182 165 Cost of purchase $ 5.0 $ 6.2 $ 5.0 (a) Represents shares purchased pursuant to and received upon settlement of the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information. (b) Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table provides the components of share-based compensation expense and the associated tax benefit: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Restricted Stock Units $ 299 $ 306 $ 270 Portfolio Performance Shares 135 147 96 Total Shareholder Return Units 134 36 37 Stock Options 106 165 150 Performance Share Awards 13 11 30 Directors’ compensation 4 4 3 Share-based payment expense 691 669 586 Tax benefit for share-based compensation expense (205 ) (198 ) (179 ) Share-based payment expense, net of tax $ 486 $ 471 $ 407
Schedule of Nonvested Restricted Stock Units Activity	The following table provides data related to all RSU activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2016 2015 2014 Total fair value of shares vested $ 293 $ 371 $ 401 Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax $ 262 $ 279 $ 255 Weighted-average period over which RSU cost is expected to be recognized (years) 1.7 1.8 1.8 The following table summarizes all RSU activity during 2016: Shares (Thousands) Weighted-Average Grant-Date Fair Value Per Share Nonvested, December 31, 2015 29,135 $ 31.53 Granted 10,581 30.74 Vested (9,630 ) 27.41 Reinvested dividend equivalents 1,093 32.56 Forfeited (1,574 ) 32.18 Nonvested, December 31, 2016 29,605 $ 32.59
Schedule of Valuation Assumptions	The following table provides the weighted-average assumptions used in the valuation of stock options: Year Ended December 31, 2016 2015 2014 Expected dividend yield (a) 3.85 % 3.19 % 3.18 % Risk-free interest rate (b) 1.55 % 1.89 % 1.94 % Expected stock price volatility (c) 21.64 % 18.34 % 19.76 % Expected term (years) (d) 6.75 6.75 6.50 (a) Determined using a constant dividend yield during the expected term of the option. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility. (d) Determined using historical exercise and post-vesting termination patterns.
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes data related to all stock option activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS) 2016 2015 2014 Weighted-average grant-date fair value per stock option $ 3.89 $ 4.30 $ 4.40 Aggregate intrinsic value on exercise $ 389 $ 666 $ 458 Cash received upon exercise $ 1,019 $ 1,263 $ 1,002 Tax benefits realized related to exercise $ 112 $ 187 $ 131 Total compensation cost related to nonvested stock options not yet recognized, pre-tax $ 58 $ 159 $ 147 Weighted-average period over which stock option compensation cost is expected to be recognized (years) 1.1 1.8 1.8 The following table summarizes all stock option activity during 2016: Shares (Thousands) Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (a) (Millions) Outstanding, December 31, 2015 232,554 $ 26.41 Granted 1,371 30.59 Exercised (42,550 ) 24.03 Forfeited (2,949 ) 33.18 Expired (1,750 ) 28.55 Outstanding, December 31, 2016 186,676 26.86 5.7 $ 1,138 Vested and expected to vest, December 31, 2016 (b) 184,537 26.77 5.6 1,138 Exercisable, December 31, 2016 105,862 $ 21.85 4.1 $ 1,126 (a) Market price of underlying Pfizer common stock less exercise price. (b) The number of options expected to vest takes into account an estimate of expected forfeitures.
Schedule of Nonvested Performance-based Units Activity	The following table provides data related to all PSA activity: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Total fair value of shares vested $ 9 $ 14 $ 39 Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax $ 30 $ 24 $ 21 Weighted-average period over which PSA cost is expected to be recognized (years) 1.8 1.9 1.7 The following table summarizes all PSA activity during 2016, with the shares granted representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2015 3,871 $ 32.28 Granted 1,900 30.59 Vested (289 ) 30.23 Forfeited (936 ) 30.61 Nonvested, December 31, 2016 4,546 $ 32.48 The following table summarizes all PPS activity during 2016, with the shares representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2015 22,503 $ 32.28 Granted 8,059 30.59 Vested (a) (6,900 ) 30.23 Forfeited (1,396 ) 33.29 Nonvested, December 31, 2016 (a) 22,266 $ 32.48 (a) Vested and non-vested shares outstanding, but not paid as of December 31, 2016 were 32,521 . The following table provides data related to all PPS activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2016 2015 2014 Total fair value of shares vested $ 118 $ 60 $ — Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax $ 93 $ 102 $ 139 Weighted-average period over which PPS cost is expected to be recognized (years) 1.8 1.7 1.8
Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions	The following table provides the weighted-average assumptions used in the valuation of TSRUs: Year Ended December 31, 2016 2015 2014 Expected dividend yield (a) 3.85 % 3.19 % 3.18 % Risk-free interest rate (b) 1.31 % 1.76 % 1.78 % Expected stock price volatility (c) 21.64 % 18.41 % 19.76 % Contractual term (years) 5.12 5.91 5.97 (a) Determined using a constant dividend yield during the expected term of the TSRU. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility.
Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity	The following table summarizes TSRU and PTU information as of December 31, 2016 (a), (b) : TSRUs (Thousands) PTUs (Thousands) Weighted-Average Grant Price Per TSRU Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions) TSRUs Outstanding 81,413 — $ 29.15 3.5 $ 439 TSRUs Vested 19,406 — 22.93 1.5 279 TSRUs Expected to vest 58,362 — 31.13 4.2 150 TSRUs exercised and converted to PTUs — 120 $ — 0.2 $ 4 (a) In 2016 , we settled 4,442,865 TSRUs with a weighted-average grant price of $18.95 per unit. (b) In 2016, 237,246 TSRUs with a weighted-average grant price of $20.86 per unit were converted into 120,273 PTUs. The following table provides data related to all TSRU activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS) 2016 2015 2014 Weighted-average grant-date fair value per TSRU $ 5.83 $ 6.66 $ 6.51 Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax $ 164 $ 29 $ 30 Weighted-average period over which TSRU cost is expected to be recognized (years) 1.9 1.8 1.8 The following table summarizes all TSRU activity during 2016: TSRUs (Thousands) Weighted-Average Grant-Date Fair Value Per TSRU Weighted-Average Grant Price Per TSRU Nonvested, December 31, 2015 18,067 $ 6.07 $ 31.27 Granted 53,467 5.83 30.59 Vested (6,440 ) 5.14 27.41 Forfeited (3,087 ) 5.91 30.90 Nonvested, December 31, 2016 62,007 $ 5.97 $ 31.10 The following table summarizes TSRU and PTU information as of December 31, 2016 (a), (b) : TSRUs (Thousands) PTUs (Thousands) Weighted-Average Grant Price Per TSRU Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions) TSRUs Outstanding 81,413 — $ 29.15 3.5 $ 439 TSRUs Vested 19,406 — 22.93 1.5 279 TSRUs Expected to vest 58,362 — 31.13 4.2 150 TSRUs exercised and converted to PTUs — 120 $ — 0.2 $ 4

Earnings Per Common Share Att42

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of Earnings per common share (EPS): Year Ended December 31, (IN MILLIONS) 2016 2015 2014 EPS Numerator––Basic Income from continuing operations $ 7,229 $ 6,975 $ 9,119 Less: Net income attributable to noncontrolling interests 31 26 32 Income from continuing operations attributable to Pfizer Inc. 7,198 6,949 9,087 Less: Preferred stock dividends––net of tax 1 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 7,197 6,948 9,086 Discontinued operations––net of tax 17 11 48 Less: Discontinued operations––net of tax, attributable to noncontrolling interests — — — Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders 17 11 48 Net income attributable to Pfizer Inc. common shareholders $ 7,214 $ 6,959 $ 9,134 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,197 $ 6,948 $ 9,087 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 17 11 48 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,214 $ 6,960 $ 9,135 EPS Denominator Weighted-average number of common shares outstanding––Basic 6,089 6,176 6,346 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (a) 70 81 78 Weighted-average number of common shares outstanding––Diluted (a) 6,159 6,257 6,424 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (b) 63 50 44 (a) Amount for 2016 reflects the adoption of a new accounting standard, as of January 1, 2016, that requires when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B ). (b) These common stock equivalents were outstanding for the years ended December 31, 2016 , 2015 and 2014 , but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Schedule of Future Minimum Rental Commitments Under Non-Cancelable Operating Leases	The future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2017 2018 2019 2020 2021 After 2021 Lease commitments $ 220 $ 188 $ 163 $ 138 $ 125 $ 967

Segment, Geographic and Other44

Segment, Geographic and Other Revenue Information (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 2016 2015 2014 2016 2015 2014 Reportable Segments: IH (c) $ 29,197 $ 26,758 $ 24,005 $ 15,854 $ 14,581 $ 12,743 $ 583 $ 552 $ 522 EH (d) 23,627 22,094 25,401 12,898 12,714 16,020 600 446 490 Total reportable segments 52,824 48,851 49,406 28,752 27,295 28,763 1,183 998 1,012 Other business activities (e) — — — (3,184 ) (3,091 ) (3,151 ) 86 77 74 Reconciling Items: Corporate (f) — — — (5,326 ) (5,430 ) (5,200 ) 356 354 384 Purchase accounting adjustments (f) — — — (4,185 ) (3,953 ) (3,641 ) 3,890 3,573 3,782 Acquisition-related costs (f) — — — (785 ) (894 ) (183 ) 7 75 53 Certain significant items (g) — — 198 (5,888 ) (4,321 ) (3,749 ) 200 48 207 Other unallocated (f) — — — (1,032 ) (642 ) (601 ) 35 33 24 $ 52,824 $ 48,851 $ 49,605 $ 8,351 $ 8,965 $ 12,240 $ 5,757 $ 5,157 $ 5,537 (a) Income from continuing operations before provision for taxes on income. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations and IH’s operating results for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. Additionally, in connection with the formation in early 2016 of the GPD organization, effective in the second quarter of 2016, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, $318 million of costs in 2015 and $271 million of costs in 2014 from IH to GPD to conform to the presentation as part of GPD in 2016. (d) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations and EH’s operating results include legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira International operations. See Note 2A for additional information. Beginning in 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including the revenues and expenses related to our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. We have reclassified prior period PCS operating results ( $506 million of PCS revenues and $96 million of PCS earnings in 2015, which in 2015 includes revenues and expenses related to our manufacturing and supply agreements with Zoetis, and $253 million of PCS revenues and $69 million of PCS earnings in 2014) to conform to the current period presentation as part of EH. As noted above, in connection with the formation in 2016 of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $274 million of costs in 2015 and $281 million of costs in 2014 from WRD to EH to conform to the current period presentation as part of EH. (e) Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations. (f) For a description, see the “Other Costs and Business Activities” section above. (g) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in 2014, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million and (vi) other charges of $509 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4. For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million , (ii) certain asset impairments of $440 million , (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million , (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million , (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion , (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million . For additional information, see Note 2D, Note 3 and Note 4 .
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 2016 2015 2014 2016 2015 2014 Reportable Segments: IH (c) $ 29,197 $ 26,758 $ 24,005 $ 15,854 $ 14,581 $ 12,743 $ 583 $ 552 $ 522 EH (d) 23,627 22,094 25,401 12,898 12,714 16,020 600 446 490 Total reportable segments 52,824 48,851 49,406 28,752 27,295 28,763 1,183 998 1,012 Other business activities (e) — — — (3,184 ) (3,091 ) (3,151 ) 86 77 74 Reconciling Items: Corporate (f) — — — (5,326 ) (5,430 ) (5,200 ) 356 354 384 Purchase accounting adjustments (f) — — — (4,185 ) (3,953 ) (3,641 ) 3,890 3,573 3,782 Acquisition-related costs (f) — — — (785 ) (894 ) (183 ) 7 75 53 Certain significant items (g) — — 198 (5,888 ) (4,321 ) (3,749 ) 200 48 207 Other unallocated (f) — — — (1,032 ) (642 ) (601 ) 35 33 24 $ 52,824 $ 48,851 $ 49,605 $ 8,351 $ 8,965 $ 12,240 $ 5,757 $ 5,157 $ 5,537 (a) Income from continuing operations before provision for taxes on income. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations and IH’s operating results for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. Additionally, in connection with the formation in early 2016 of the GPD organization, effective in the second quarter of 2016, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, $318 million of costs in 2015 and $271 million of costs in 2014 from IH to GPD to conform to the presentation as part of GPD in 2016. (d) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations and EH’s operating results include legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira International operations. See Note 2A for additional information. Beginning in 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including the revenues and expenses related to our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. We have reclassified prior period PCS operating results ( $506 million of PCS revenues and $96 million of PCS earnings in 2015, which in 2015 includes revenues and expenses related to our manufacturing and supply agreements with Zoetis, and $253 million of PCS revenues and $69 million of PCS earnings in 2014) to conform to the current period presentation as part of EH. As noted above, in connection with the formation in 2016 of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $274 million of costs in 2015 and $281 million of costs in 2014 from WRD to EH to conform to the current period presentation as part of EH. (e) Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations. (f) For a description, see the “Other Costs and Business Activities” section above. (g) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in 2014, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million and (vi) other charges of $509 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4. For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million , (ii) certain asset impairments of $440 million , (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million , (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million , (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion , (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million . For additional information, see Note 2D, Note 3 and Note 4 .
Reconciliation Of Depreciation And Amortization From Segments To Consolidated	The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 2016 2015 2014 2016 2015 2014 Reportable Segments: IH (c) $ 29,197 $ 26,758 $ 24,005 $ 15,854 $ 14,581 $ 12,743 $ 583 $ 552 $ 522 EH (d) 23,627 22,094 25,401 12,898 12,714 16,020 600 446 490 Total reportable segments 52,824 48,851 49,406 28,752 27,295 28,763 1,183 998 1,012 Other business activities (e) — — — (3,184 ) (3,091 ) (3,151 ) 86 77 74 Reconciling Items: Corporate (f) — — — (5,326 ) (5,430 ) (5,200 ) 356 354 384 Purchase accounting adjustments (f) — — — (4,185 ) (3,953 ) (3,641 ) 3,890 3,573 3,782 Acquisition-related costs (f) — — — (785 ) (894 ) (183 ) 7 75 53 Certain significant items (g) — — 198 (5,888 ) (4,321 ) (3,749 ) 200 48 207 Other unallocated (f) — — — (1,032 ) (642 ) (601 ) 35 33 24 $ 52,824 $ 48,851 $ 49,605 $ 8,351 $ 8,965 $ 12,240 $ 5,757 $ 5,157 $ 5,537 (a) Income from continuing operations before provision for taxes on income. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations and IH’s operating results for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. Additionally, in connection with the formation in early 2016 of the GPD organization, effective in the second quarter of 2016, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, $318 million of costs in 2015 and $271 million of costs in 2014 from IH to GPD to conform to the presentation as part of GPD in 2016. (d) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations and EH’s operating results include legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira International operations. See Note 2A for additional information. Beginning in 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including the revenues and expenses related to our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. We have reclassified prior period PCS operating results ( $506 million of PCS revenues and $96 million of PCS earnings in 2015, which in 2015 includes revenues and expenses related to our manufacturing and supply agreements with Zoetis, and $253 million of PCS revenues and $69 million of PCS earnings in 2014) to conform to the current period presentation as part of EH. As noted above, in connection with the formation in 2016 of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $274 million of costs in 2015 and $281 million of costs in 2014 from WRD to EH to conform to the current period presentation as part of EH. (e) Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations. (f) For a description, see the “Other Costs and Business Activities” section above. (g) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in 2014, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million and (vi) other charges of $509 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4. For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million , (ii) certain asset impairments of $440 million , (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million , (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million , (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion , (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million . For additional information, see Note 2D, Note 3 and Note 4 .
Revenue from External Customers by Geographic Areas	(a) On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations include the operating results of Anacor and Medivation. In accordance with our domestic reporting period, our results of operations for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations include the operating results of Hospira. In accordance with our domestic and international reporting periods, our results of operations for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information. (b) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.2 billion in 2016 , $7.4 billion in 2015 and $9.0 billion in 2014 . (c) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (d) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.
Long-lived Assets by Geographic Areas	Long-lived assets by geographic region follow (a) : As of December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Property, plant and equipment, net United States $ 6,649 $ 7,072 $ 5,575 Developed Europe (b) 4,228 4,376 4,606 Developed Rest of World (c) 643 660 617 Emerging Markets (d) 1,797 1,658 963 Property, plant and equipment, net $ 13,318 $ 13,766 $ 11,762 (a) Reflects legacy Medivation and legacy Anacor amounts in 2016, commencing on the Medivation acquisition date, September 28, 2016, and Anacor acquisition date, June 24, 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date, September 3, 2015. (b) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. (c) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 PFIZER INNOVATIVE HEALTH (IH) (a) $ 29,197 $ 26,758 $ 24,005 Internal Medicine $ 8,858 $ 7,611 $ 6,727 Lyrica IH (b) 4,165 3,655 3,350 Viagra IH (c) 1,181 1,297 1,181 Chantix/Champix 842 671 647 Toviaz 258 267 288 BMP2 251 232 228 Alliance revenues (d) 1,588 1,256 759 All other Internal Medicine (e) 573 233 276 Vaccines $ 6,071 $ 6,454 $ 4,480 Prevnar 13/Prevenar 13 5,718 6,245 4,464 FSME/IMMUN-TicoVac 114 104 — All other Vaccines 239 104 16 Oncology $ 4,563 $ 2,955 $ 2,218 Ibrance 2,135 723 — Sutent 1,095 1,120 1,174 Xalkori 561 488 438 Inlyta 401 430 410 Xtandi alliance revenues 140 — — All other Oncology 231 194 195 Inflammation & Immunology (I&I) $ 3,928 $ 3,918 $ 4,241 Enbrel (Outside the U.S. and Canada) 2,909 3,333 3,850 Xeljanz 927 523 308 All other I&I 93 61 82 Rare Disease $ 2,369 $ 2,425 2,893 BeneFIX 712 752 856 Genotropin 579 617 723 Refacto AF/Xyntha 554 533 631 Somavert 232 218 229 Rapamune 170 197 339 All other Rare Disease 122 108 114 Consumer Healthcare $ 3,407 $ 3,395 $ 3,446 PFIZER ESSENTIAL HEALTH (EH) (f) $ 23,627 $ 22,094 $ 25,600 Legacy Established Products (LEP) (g) $ 11,194 $ 11,745 $ 13,016 Lipitor 1,758 1,860 2,061 Premarin family 1,017 1,018 1,076 Norvasc 962 991 1,112 EpiPen 386 339 294 Xalatan/Xalacom 363 399 495 Relpax 323 352 382 Zoloft 304 374 423 Effexor 278 288 344 Zithromax/Zmax 272 275 311 Xanax/Xanax XR 222 224 253 Cardura 192 210 263 Neurontin 182 196 210 Tikosyn 153 179 141 Depo-Provera 126 170 201 Diflucan 119 181 208 All other LEP 4,538 4,689 5,242 Sterile Injectable Pharmaceuticals (SIP) (h) $ 6,018 $ 3,944 $ 3,277 Medrol 450 402 381 Sulperazon 396 339 354 Fragmin 318 335 364 Tygacil 274 304 323 All other SIP 4,579 2,563 1,855 Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014 Peri-LOE Products (i) $ 4,220 $ 5,326 $ 8,855 Lyrica EH (b) 801 1,183 1,818 Celebrex 733 830 2,699 Pristiq 732 715 737 Vfend 590 682 756 Zyvox 421 883 1,352 Viagra EH (c) 383 411 504 Revatio 285 260 276 All Other Peri-LOE Products 276 362 714 Infusion Systems (j) $ 1,158 $ 403 $ — Biosimilars (k) $ 319 $ 63 $ — Inflectra/Remsima 192 30 — All Other Biosimilars 127 33 — Pfizer CentreOne (l) $ 718 $ 612 $ 451 Revenues $ 52,824 $ 48,851 $ 49,605 Total Lyrica (b) $ 4,966 $ 4,839 $ 5,168 Total Viagra (c) $ 1,564 $ 1,708 $ 1,685 Total Alliance revenues $ 1,746 $ 1,312 $ 957 (a) The IH business, previously known as the Innovative Products business, encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Anacor and Medivation commercial operations. Anacor's and Medivation's commercial operations are included in IH's operating results in our consolidated statements of income, commencing from the acquisition date of June 24, 2016 for Anacor and from the acquisition date of September 28, 2016 for Medivation. As a result, IH's revenues for 2016 reflect approximately six months of legacy Anacor operations, which were immaterial, and three months of legacy Medivation operations. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) Includes Eliquis for all years presented and Rebif for 2015 and 2014. (e) Includes Eliquis direct sales markets. (f) The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems (through February 2, 2017), Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. Also, effective as of the beginning of 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. We have reclassified prior period PCS revenues ( $506 million in 2015 and $253 million in 2014) to conform to the current period presentation as part of EH. (g) Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). (h) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (i) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Lyrica in certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and Revatio in most developed markets, Vfend and Viagra in certain developed Europe markets and Japan, and Inspra in the EU. (j) Infusion Systems (through February 2, 2017) include Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. (k) Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle East markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle East markets. (l) Pfizer CentreOne includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation. We performed certain reclassifications, primarily between Legacy Established and Sterile Injectable Pharmaceuticals, to conform to current period presentation.

Basis of Presentation and Sig45

Basis of Presentation and Significant Accounting Policies (Details) $ / shares in Units, $ in Millions		Feb. 03, 2017USD ($)	Sep. 28, 2016USD ($)$ / shares	Jun. 24, 2016USD ($)$ / shares	Apr. 08, 2016USD ($)	Sep. 03, 2015USD ($)$ / shares	Dec. 31, 2016USD ($)Operating_Segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Jan. 01, 2016USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of operating segments | Operating_Segment							2
Cash payments for acquisition, net of cash acquired	[1]						$ 18,368	$ 16,466	$ 195
Payments for merger termination costs					$ 150		150
Tax benefit due to adoption of accounting standard							89
Net cash provided by (used in) financing activities	[1]						(8,921)	(10,409)	(10,187)
Net cash provided by (used in) operating activities	[1]						15,901	14,688	17,084
Debt issuance costs							115
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns							4,300	3,900
Advertising expense							3,200	3,100	3,100
Research and development expenses	[2],[3]						7,872	7,690	8,393
Nonsoftware License Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Research and development expenses							82	429	1,400
Short-term Debt [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt issuance costs							1
Long-term Debt [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt issuance costs							114
Other Current Liabilities [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns							2,800	2,600
Other Noncurrent Liabilities [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns							357	272
Accounts Receivable, less Allowance for Doubtful Accounts [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns							1,200	1,100
Medivation [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares			$ 81.50
Payments to acquire businesses, cash portion			$ 14,300
Cash payments for acquisition, net of cash acquired			$ 13,900
Anacor [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares				$ 99.25
Payments to acquire businesses, cash portion				$ 4,900
Cash payments for acquisition, net of cash acquired				4,500
Debt assumed				$ 698
Hospira [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares						$ 90
Payments to acquire businesses, cash portion						$ 16,100
Cash payments for acquisition, net of cash acquired						$ 15,700
Accounting Standards Update 2015-03 [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt issuance costs								(79)
Accounting Standards Update 2015-03 [Member] | Short-term Debt [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt issuance costs								1
Accounting Standards Update 2015-03 [Member] | Long-term Debt [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt issuance costs								79
Accounting Standards Update 2015-03 [Member] | Other Current Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt issuance costs								(1)
Accounting Standards Update 2015-03 [Member] | Other Noncurrent Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt issuance costs								(79)
ICU Medical [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member] | Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received for disposition		$ 900
Share transfer restriction term for disposition		18 months
New Accounting Pronouncement, Early Adoption, Effect [Member] | Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net cash provided by (used in) financing activities							$ 137	189	195
Net cash provided by (used in) operating activities	[1]							$ (189)	$ (195)
New Accounting Pronouncement, Early Adoption, Effect [Member] | Retained Earnings [Member] | Accounting Standards Update 2016-09 [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Increase in retained earnings due to adoption of new accounting standard										$ 13
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

Acquisitions, Assets and Liab46

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Medivation, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 28, 2016	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 18,368		$ 16,466		$ 195
Goodwill			54,449	[2]	$ 48,242	[2]	$ 42,069
Medivation [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 81.50
Payments to acquire businesses, cash portion		$ 14,300
Cash payments for acquisition, net of cash acquired		13,900
Intangible assets		13,100
Goodwill		5,500
Net deferred tax liabilities		4,400
Assumed contingent consideration		340
Other Current Liabilities [Member] | Medivation [Member]
Business Acquisition [Line Items]
Acquisition consideration, amount payable			$ 365
Developed Technology Rights [Member] | Medivation [Member]
Business Acquisition [Line Items]
Intangible assets		$ 8,700
Acquired intangible assets, useful life		12 years
In Process Research and Development [Member] | Medivation [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets		$ 4,400
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab47

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Bamboo Therapeutics, Inc. (Details) - USD ($) $ in Millions		Aug. 01, 2016	Apr. 03, 2016	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]			$ 18,368		$ 16,466		$ 195
Goodwill				$ 54,449	[2]	$ 48,242	[2]	$ 42,069
Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Total consideration transferred		$ 150
Potential milestone payments		495
Consideration transferred, including equity interest held prior to business combination		331
Payments to acquire businesses, cash portion		130	$ 43
Cash payments for acquisition, net of cash acquired		101
Assumed contingent consideration		157
Fair value of previously held equity interest in acquiree		44
Goodwill		133
Net deferred tax liabilities		93
Bamboo Therapeutics [Member] | Other Nonoperating Income (Expense) [Member]
Business Acquisition [Line Items]
Gain recognized		1
In Process Research and Development [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets		$ 325
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab48

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Anacor Pharmaceuticals, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		Jun. 24, 2016	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 18,368		$ 16,466		$ 195
Goodwill			$ 54,449	[2]	$ 48,242	[2]	$ 42,069
Anacor [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 99.25
Payments to acquire businesses, cash portion		$ 4,900
Cash payments for acquisition, net of cash acquired		4,500
Debt assumed		698
Indefinite-lived intangible assets		4,900
Goodwill		647
Net deferred tax liabilities		352
In Process Research and Development [Member] | Anacor [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets		$ 4,800
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab49

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Hospira Acquisition (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 03, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 18,368		$ 16,466		$ 195
Amounts Recognized as of Acquisition Date
Goodwill			54,449	[2]	48,242	[2]	42,069
Measurement Period Adjustments
Uncertain tax positions			5,826	[3]	5,919	[3]	6,182	[3]	$ 6,087
Tax impact from tax matters to be resolved in a different manner following acquisition			503		646
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)	[4]		7,215	[5]	6,960		9,135
Hospira [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 90
Payments to acquire businesses, cash portion		$ 16,100
Cash payments for acquisition, net of cash acquired		15,700
Amounts Recognized as of Acquisition Date
Working capital, excluding inventories	[6]	342
Inventories		1,901
PP&E		2,352
Other noncurrent assets		362
Long-term debt		(1,928)
Benefit obligations		(117)
Net income tax accounts	[7]	(3,380)
Other noncurrent liabilities		(61)
Total identifiable net assets		8,791
Goodwill		7,295
Net assets acquired/total consideration transferred		16,087
Measurement Period Adjustments
Working capital, excluding inventories	[6],[8]		68
Inventories	[8]		(23)
PP&E	[8]		(57)
Other noncurrent assets	[8]		(46)
Long-term debt	[8]		0
Benefit obligations	[8]		0
Net income tax accounts	[7],[8]		14
Other noncurrent liabilities	[8]		(23)
Total identifiable net assets	[8]		(12)
Goodwill	[8]		12
Net assets acquired/total consideration transferred	[8]		0
Current tax assets		57
Noncurrent tax assets		58
Income taxes payable		5
Other taxes payable		101
Accrued interest		5
Acquired receivables, gross contractual amount		565
Acquired receivables, not expected to be collected		12
Uncertain tax positions		109
Additional tax liability adjustments		3,200
Tax impact from tax matters to be resolved in a different manner following acquisition		719
Business Acquisition, Pro Forma Information [Abstract]
Revenues					1,513
Net loss attributable to Pfizer Inc. common shareholders	[9]				(575)
Revenues					52,082		54,069
Net income attributable to Pfizer Inc. common shareholders					$ 7,669		$ 8,173
Diluted EPS attributable to Pfizer Inc. common shareholders (in dollars per share)					$ 1.23		$ 1.27
Additional amortization expense					$ 342		$ 502
Additional depreciation expense					52		102
Adjustment to interest expense					(18)		(42)
Hospira [Member] | Developed Technology Rights and Other Intangible Assets [Member]
Amounts Recognized as of Acquisition Date
Identifiable intangible assets	[10]	$ 8,290
Measurement Period Adjustments
Identifiable intangible assets, excluding IPR&D	[8],[10]		20
Hospira [Member] | Developed Technology Rights [Member]
Measurement Period Adjustments
Acquired intangible assets, useful life		17 years
Acquire intangible assets		$ 7,700
Hospira [Member] | Other Intangible Assets [Member]
Measurement Period Adjustments
Acquired intangible assets, useful life		12 years
Acquire intangible assets		$ 570
Fair Value Adjustment to Inventory [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)					378		(591)
Amortization Expense Adjustment to Intangible Assets [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)					161
Depreciation Expense Adjustment to Fixed Assets [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)					34
Amortization Expense Adjustment to Long-term Debt [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)					(13)
Restructuring and Integration Costs [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)					(556)
Acquisition-related Costs [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							877
Eliminations [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Elimination of intangible asset amortization expense					33		$ 77
Eliminations [Member] | Fair Value Adjustment to Inventory [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)					(364)
Eliminations [Member] | Acquisition-related Costs [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)					$ 877
Scenario, Previously Reported [Member] | Hospira [Member]
Amounts Recognized as of Acquisition Date
Working capital, excluding inventories	[6]	274
Inventories		1,924
PP&E		2,410
Other noncurrent assets		408
Long-term debt		(1,928)
Benefit obligations		(117)
Net income tax accounts	[7]	(3,394)
Other noncurrent liabilities		(39)
Total identifiable net assets		8,803
Goodwill		7,284
Net assets acquired/total consideration transferred		16,087
Measurement Period Adjustments
Current tax assets		79
Noncurrent tax assets		25
Income taxes payable		5
Noncurrent deferred tax liabilities		3,400
Other taxes payable		114
Accrued interest		5
Scenario, Previously Reported [Member] | Hospira [Member] | Developed Technology Rights and Other Intangible Assets [Member]
Amounts Recognized as of Acquisition Date
Identifiable intangible assets	[10]	8,270
In Process Research and Development [Member] | Hospira [Member]
Amounts Recognized as of Acquisition Date
Indefinite-lived intangible assets		1,030
Measurement Period Adjustments
Identifiable intangible assets, excluding IPR&D	[8]		$ 35
In Process Research and Development [Member] | Scenario, Previously Reported [Member] | Hospira [Member]
Amounts Recognized as of Acquisition Date
Indefinite-lived intangible assets		$ 995
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	In 2016, included in Income taxes payable ($14 million), Current tax assets ($17 million), Noncurrent deferred tax assets and other noncurrent tax assets ($184 million), Noncurrent deferred tax liabilities ($2.8 billion) and Other taxes payable ($2.8 billion). In 2015, included in Income taxes payable ($38 million), Current tax assets ($22 million), Noncurrent deferred tax assets and other noncurrent tax assets ($135 million), Noncurrent deferred tax liabilities ($2.7 billion) and Other taxes payable ($3.0 billion).
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.
[6]	Includes cash and cash equivalents, short-term investments, accounts receivable, other current assets, assets held for sale, accounts payable and other current liabilities.
[7]	Final amounts recognized as of the acquisition date (as adjusted), included in Current tax assets ($57 million), Noncurrent deferred tax assets and other noncurrent tax assets ($58 million), Income taxes payable ($5 million), Noncurrent deferred tax liabilities ($3.4 billion) and Other taxes payable ($101 million, including accrued interest of $5 million). Preliminary amounts recognized as of the acquisition date (as previously reported), included in Current tax assets ($79 million), Noncurrent deferred tax assets and other noncurrent tax assets ($25 million), Income taxes payable ($5 million), Noncurrent deferred tax liabilities ($3.4 billion) and Other taxes payable ($114 million, including accrued interest of $5 million)
[8]	The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
[9]	Includes purchase accounting charges related to the provisional estimated fair values recognized as of the acquisition date for (i) the fair value adjustment for acquisition-date inventory that has been sold ($378 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Hospira ($161 million pre-tax); (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Hospira ($34 million pre-tax ); and (iv) amortization expense related to the fair value adjustment of long-term debt acquired from Hospira ($13 million income pre-tax), as well as restructuring and integration costs ($556 million pre-tax).
[10]	Comprised of finite-lived developed technology rights with a weighted-average life of approximately 17 years ($7.7 billion) and other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ($570 million).

Acquisitions, Assets and Liab50

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Additional Acquisitions (Details) - USD ($) $ in Millions	Dec. 01, 2014	Sep. 24, 2014	Dec. 31, 2016	[1]	Dec. 31, 2015	[1]	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill			$ 54,449		$ 48,242		$ 42,069
Baxter International Inc. [Member]
Business Acquisition [Line Items]
Total consideration transferred	$ 648
Identifiable intangible assets	376
Inventories	194
Goodwill	12
InnoPharma [Member]
Business Acquisition [Line Items]
Goodwill		$ 125
Payments to acquire businesses		225
Assumed contingent consideration		67
Contingent consideration milestone payments, maximum possible amount		135
Intangible assets		247
Deferred tax liabilities		81
Developed Technology Rights [Member] | Baxter International Inc. [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 371
Developed Technology Rights [Member] | InnoPharma [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		35
In Process Research and Development [Member] | InnoPharma [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets		$ 212
[1]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab51

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Assets and Liabilities Held for Sale (Details) - USD ($) shares in Millions, $ in Millions		Feb. 03, 2017	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014	Oct. 06, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Write-down of HIS net assets to fair value less estimated costs to sell	[1]		$ 1,712	[2]	$ 0	[2]	$ 0
Assets held for sale	[3]		801		9
HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Write-down of HIS net assets to fair value less estimated costs to sell			1,700
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other assets	[4]		58		9
Assets held for sale			801		9
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Write-down of HIS net assets to fair value less estimated costs to sell			1,712
Inventories			377		0
PP&E			457		0
Identifiable intangible assets			1,319		0
Goodwill			119		0
Other assets			152		0
Less: adjustment to HIS assets for net realizable value	[5]		(1,681)		0
Assets held for sale			743		0
Accrued compensation and related items			54		0
Other liabilities			103		0
Total HIS liabilities held for sale			157		$ 0
Selling costs			$ 31
ICU Medical [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and common stock to be received for disposition								$ 1,000
Subsequent Event [Member] | ICU Medical [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and common stock to be received for disposition		$ 900
Shares of common stock received for disposal		3.2
Value of common stock received for disposal		$ 430
Consideration receivable		75
Cash proceeds from disposal		200
Maximum contingent consideration		$ 225
Noncontrolling interest, ownership percentage by parent		16.40%
Share transfer restriction term for disposition		18 months
Consideration receivable, term		3 years
Administrative service period		24 months
Manufacturing service period		5 years
London Interbank Offered Rate (LIBOR) [Member] | Subsequent Event [Member] | ICU Medical [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration receivable interest rate during year 1		2.25%
Consideration receivable interest rate during year 2		2.50%
London Interbank Offered Rate (LIBOR) [Member] | Subsequent Event [Member] | ICU Medical [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration receivable interest rate during year 3		2.50%
[1]	Amounts may not add due to rounding.
[2]	In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[3]	Amounts may not add due to rounding.
[4]	Other assets held for sale consist primarily of PP&E and other assets.
[5]	For 2016, we recorded an adjustment to HIS assets for net realizable value of $1,681 million plus estimated costs to sell of $31 million for a total impairment on HIS net assets of $1,712 million.

Acquisitions, Assets and Liab52

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Licensing Agreements (Details)		Sep. 15, 2014USD ($)	Jul. 11, 2014USD ($)	Nov. 30, 2016	Nov. 30, 2015	Aug. 31, 2014USD ($)target	Aug. 31, 2012USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Long-term investments	[1]							$ 7,116,000,000	$ 15,999,000,000
Acquisitions of intangible assets	[2]							176,000,000	99,000,000	$ 384,000,000
Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to licensing partners						$ 80,000,000
Number of selected targets | target						15
Number of collaboration selected targets | target						4
Collaborative arrangement, milestone, maximum, value						$ 185,000,000
Long-term investments						$ 35,000,000
Licensing Agreements [Member] | AstraZeneca, Nexium, Global, Over-the-counter Rights [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to licensing partners							$ 250,000,000	$ 200,000,000
Acquisitions of intangible assets		$ 50,000,000	$ 200,000,000
Licensing Agreements [Member] | Common Stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment, ownership percentage				8.00%	8.00%	10.00%
Other Current Liabilities [Member] | Licensing Agreements [Member] | AstraZeneca, Nexium, Global, Over-the-counter Rights [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued milestone payments									$ 93,000,000
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab53

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Research and Development and Collaborative Arrangements (Detail) - USD ($)

Oct. 31, 2013

Dec. 31, 2016

May 31, 2016

Apr. 30, 2016

Jan. 31, 2016

Mar. 31, 2015

Feb. 28, 2015

Dec. 31, 2014

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues from collaborative arrangements

[1]

$ 52,824,000,000

$ 48,851,000,000

$ 49,605,000,000

Cost of sales

[1],[2]

(12,329,000,000)

(9,648,000,000)

(9,577,000,000)

Selling, informational and administrative expenses

[1],[2]

(14,837,000,000)

(14,809,000,000)

(14,097,000,000)

Research and development expenses

[1],[2]

(7,872,000,000)

(7,690,000,000)

(8,393,000,000)

Other income/(deductions)—net

[1]

(3,655,000,000)

(2,860,000,000)

(1,009,000,000)

NovaQuest Co-Investment Fund II, L.P. [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Amount refunded to NovaQuest

$ 31,300,000

Maximum funding amount

$ 250,000,000

Percentage of costs to be reimbursed

40.00%

Reduction to research and development expense

180,300,000

NovaQuest Co-Investment Fund V, L.P. [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Maximum funding amount

$ 200,000,000

Percentage of costs to be reimbursed

100.00%

Reduction to research and development expense

46,600,000

Research and development, contingent payments, maximum exposure

$ 267,000,000

Period to pay royalties

8 years

RPI Finance Trust [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Maximum funding amount

$ 300,000,000

Percentage of costs to be reimbursed

100.00%

Reduction to research and development expense

44,900,000

Research and development, contingent payments, maximum exposure

$ 250,000,000

Period to pay royalties

7 years

Collaborative Arrangement [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues from collaborative arrangements

2,405,000,000

1,956,000,000

1,743,000,000

Cost of sales

[3]

(315,000,000)

(282,000,000)

(280,000,000)

Selling, informational and administrative expenses

[4]

(5,000,000)

(287,000,000)

(268,000,000)

Research and development expenses

[5]

64,000,000

(330,000,000)

(1,210,000,000)

Other income/(deductions)—net

[6]

542,000,000

482,000,000

518,000,000

Upfront payments and milestone payments

15,000,000

310,000,000

1,200,000,000

Collaborative arrangement sales based milestones payments

20,000,000

80,000,000

Collaborative Arrangement [Member] | Eli Lilly & Company [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds received from upfront payments and milestone payments

120,000,000

Collaborative Arrangement [Member] | OPKO Health, Inc. [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront payments and milestone payments

$ 295,000,000

Potential milestone payments

$ 275,000,000

Collaborative Arrangement [Member] | Merck KGaA [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential milestone payments

2,000,000,000

Collaborative Arrangement [Member] | Merck KGaA [Member] | Research and Development Expense [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront payments and milestone payments

1,200,000,000

Collaborative Arrangement [Member] | Deferred Revenue [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds received from upfront payments and milestone payments

$ 200,000,000

Collaborative Arrangement [Member] | Deferred Revenue [Member] | Eli Lilly & Company [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds received from upfront payments and milestone payments

$ 200,000,000

Collaborative Arrangement, Product [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues—Revenues

[7]

659,000,000

644,000,000

786,000,000

Collaborative Arrangement, Co-promotion [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues—Alliance revenues

[8]

$ 1,746,000,000

$ 1,312,000,000

957,000,000

Royalty revenue, term

36 months

Collaborative Arrangement, Co-promotion [Member] | Merck KGaA [Member] | Research and Development Expense [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront payments and milestone payments

$ 309,000,000

Collaborative Arrangement, Upfront Cash Payment [Member] | Merck KGaA [Member] | Research and Development Expense [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront payments and milestone payments

$ 850,000,000

[1]

Amounts may not add due to rounding.

[2]

Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

[3]

Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners.

[4]

Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.

[5]

Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $15 million in 2016, $310 million in 2015 (primarily related to our collaboration with OPKO, see below) and $1.2 billion in 2014 (related to our collaboration with Merck KGaA, see below). 2016 also includes a $120 million reimbursement related to our collaboration with Lilly (see below).

[6]

In 2016, 2015 and 2014, includes royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and we became entitled to royalties for a 36-month period thereafter until October 31, 2016.

[7]

Represents sales to our partners of products manufactured by us.

[8]

Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2016 reflects an increase in alliance revenues from Eliquis and the inclusion of Xtandi revenues resulting from the acquisition of Medivation in September 2016, partially offset by the expiration of the Rebif co-promotion collaboration at the end of 2015. The increase in 2015 reflects an increase in alliance revenues from Eliquis, partially offset by Spiriva (as a result of the expiration of the co-promotion collaboration in the U.S. and certain European countries during 2014).

Acquisitions, Assets and Liab54

Acquisitions, Assets and Liabilities Held for Sale, Licensing Agreements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Equity and Cost-Method Investments (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended				12 Months Ended
	Apr. 30, 2015	Dec. 31, 2016	Jul. 03, 2016	Apr. 03, 2016	Sep. 27, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Apr. 01, 2014	Mar. 31, 2014	Sep. 30, 2012
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, registered capital											$ 250
Equity method investments		$ 270				$ 270	$ 775				$ 122.5
Equity method investment, ownership percentage		49.00%				49.00%	49.00%
Equity method investment, other than temporary impairment		$ 241	$ 130	$ 81		$ 452	$ 463
Hisun Pfizer Pharmaceuticals Co. Ltd [Member] | Other Nonoperating Income (Expense) [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, recognized gain (loss)					$ (463)
ViiV Healthcare Limited [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage									11.70%	12.60%
ViiV Healthcare Limited [Member] | Other Nonoperating Income (Expense) [Member]
Schedule of Equity Method Investments [Line Items]
Gain (loss) in increase (reduction) of interest in subsidiary or equity method investment								$ (30)
Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		40.00%				40.00%
Equity method investment, other than temporary impairment						$ 50		56
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Noncontrolling interest, ownership percentage by parent		60.00%				60.00%
Laboratorio Teuto Brasilero [Member] | Other Nonoperating Income (Expense) [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, recognized gain (loss)								55
Equity method investment, other than temporary impairment						$ 50		$ 56
AM Pharma BV [Member]
Schedule of Equity Method Investments [Line Items]
Cost method investment, contingent payments, maximum exposure	$ 512.5
Long-term Investments [Member] | AM Pharma BV [Member]
Schedule of Equity Method Investments [Line Items]
Cost method investment, upfront and milestone payments	$ 87.5

Restructuring Charges and Oth55

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) - USD ($) $ in Millions		Sep. 03, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 03, 2018
Restructuring Cost and Reserve [Line Items]
Integration costs	[1]		$ 441	$ 219	$ 80
Expected cost			$ 3,100
Percentage of non-cash restructuring charges expected			25.00%
Cost-reduction and acquisition-related costs (excluding transaction costs)			$ 2,100
Global Commercial Structure Reorganization [Member] | Business Restructuring Reserves [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred to date			219
Manufacturing Plant Network Rationalization And Optimization [Member] | Acquisition-related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost			367
Manufacturing Plant Network Rationalization And Optimization [Member] | Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost			1,100
Other Cost Reduction / Productivity Initiatives [Member] | Commercial Real Estate [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost			$ 1,400
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Expected integration costs, period		3 years
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Charges for return of acquired rights				$ 215
Forecast [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Integration costs						$ 1,000
[1]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira.

Restructuring Charges and Oth56

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restructuring charges:
Employee terminations	[1]	$ 940	$ 489	$ 68
Asset impairments	[1]	142	254	45
Exit costs	[1]	74	68	58
Total restructuring charges	[1]	1,156	811	170
Transaction costs	[2]	127	123	0
Integration costs	[3]	441	219	80
Restructuring charges and certain acquisition-related costs	[4]	1,724	1,152	250
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	[5]	207	122	261
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	[6]	340	203	270
Total costs associated with acquisitions and cost-reduction/productivity initiatives		2,271	1,478	781
Cost of Sales [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	[5]	201	117	228
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	[6]	230	102	78
Selling, Informational and Administrative Expenses [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	[5]	0	0	1
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	[6]	81	82	140
Research and Development Expense [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows(d):
Additional depreciation	[5]	7	5	31
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	[6]	25	14	52
Other (income)/deductions - net [Member]
Implementation costs recorded in our consolidated statements of income as follows(e):
Implementation costs	[6]	$ 3	$ 5	$ 1
[1]	In 2016, Employee terminations represent the expected reduction of the workforce by approximately 4,900 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges in 2016, are associated with the following:•IH ($272 million); EH ($158 million); WRD, GPD and Medical (M) (WRD/GPD/M) ($169 million); manufacturing operations ($368 million); and Corporate ($189 million).The restructuring charges in 2015, which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following:•IH ($85 million); EH ($402 million); WRD/GPD/M ($80 million); manufacturing operations ($80 million); and Corporate ($164 million), The restructuring charges in 2014 are associated with the following:•IH ($63 million); EH ($57 million); WRD/GPD/M ($37 million); manufacturing operations ($97 million); and Corporate ($65 million). as well as $149 million of income related to the partial reversal of prior-period restructuring charges not directly associated with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.
[2]	Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which in 2016 are directly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and the terminated transaction with Allergan and primarily include expenditures for banking, legal, accounting and other similar services.
[3]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira.
[4]	Amounts may not add due to rounding.
[5]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[6]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth57

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) $ in Millions		12 Months Ended
		Dec. 31, 2016USD ($)Employee	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated | Employee		4,900
Restructuring charges (income)	[1]	$ 1,156	$ 811	$ 170
Intangible asset impairments		869	323	396
Sales Force Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)				(149)
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		189	164	65
Worldwide Research and Development, Global Product Development and Medical [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		169	80	37
Manufacturing Operations [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		368	80	97
Innovative Health Segment [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		272	85	63
Intangible asset impairments		29		12
Essential Health Segment [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		158	402	57
Intangible asset impairments		$ 840	294	$ 166
Venezuela [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)			$ 39
Reduction in labor force, percentage			36.00%
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Write off of prepaid amounts			$ 25
Payments for the return of acquired rights			20
Hospira [Member] | In Process Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Intangible asset impairments			170
Return of Acquired Rights [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Charges for return of acquired rights			$ 215
[1]	In 2016, Employee terminations represent the expected reduction of the workforce by approximately 4,900 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges in 2016, are associated with the following:•IH ($272 million); EH ($158 million); WRD, GPD and Medical (M) (WRD/GPD/M) ($169 million); manufacturing operations ($368 million); and Corporate ($189 million).The restructuring charges in 2015, which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following:•IH ($85 million); EH ($402 million); WRD/GPD/M ($80 million); manufacturing operations ($80 million); and Corporate ($164 million), The restructuring charges in 2014 are associated with the following:•IH ($63 million); EH ($57 million); WRD/GPD/M ($37 million); manufacturing operations ($97 million); and Corporate ($65 million). as well as $149 million of income related to the partial reversal of prior-period restructuring charges not directly associated with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.

Restructuring Charges and Oth58

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Restructuring Reserve [Roll Forward]
Beginning balance		$ 1,157	[1]	$ 1,166
Provision	[2]	1,156		811		$ 170
Utilization and other	[3]	(730)		(820)
Ending balance		1,583	[4]	1,157	[1]	1,166
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		1,109	[1]	1,114
Provision		940		489
Utilization and other	[3]	(502)		(495)
Ending balance		1,547	[4]	1,109	[1]	1,114
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		0	[1]	0
Provision		142		254
Utilization and other	[3]	(142)		(254)
Ending balance		0	[4]	0	[1]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		48	[1]	52
Provision		74		68
Utilization and other	[3]	(86)		(71)
Ending balance		$ 36	[4]	$ 48	[1]	$ 52
[1]	Included in Other current liabilities ($776 million) and Other noncurrent liabilities ($381 million).
[2]	In 2016, Employee terminations represent the expected reduction of the workforce by approximately 4,900 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges in 2016, are associated with the following:•IH ($272 million); EH ($158 million); WRD, GPD and Medical (M) (WRD/GPD/M) ($169 million); manufacturing operations ($368 million); and Corporate ($189 million).The restructuring charges in 2015, which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following:•IH ($85 million); EH ($402 million); WRD/GPD/M ($80 million); manufacturing operations ($80 million); and Corporate ($164 million), The restructuring charges in 2014 are associated with the following:•IH ($63 million); EH ($57 million); WRD/GPD/M ($37 million); manufacturing operations ($97 million); and Corporate ($65 million). as well as $149 million of income related to the partial reversal of prior-period restructuring charges not directly associated with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ($863 million) and Other noncurrent liabilities ($720 million).

Restructuring Charges and Oth59

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 1,583	[1]	$ 1,157	[2]	$ 1,166
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	863		776
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 720		$ 381
[1]	Included in Other current liabilities ($863 million) and Other noncurrent liabilities ($720 million).
[2]	Included in Other current liabilities ($776 million) and Other noncurrent liabilities ($381 million).

Other (Income)_Deductions - N60

Other (Income)/Deductions - Net (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Other Income and Expenses [Abstract]
Interest income	[1]	$ (470)		$ (471)		$ (425)
Interest expense	[1]	1,186		1,199		1,360
Net interest expense		716		728		935
Foreign currency loss related to Venezuela	[2]	0	[3]	806	[3]	0	[4],[5]
Royalty-related income	[6]	(905)		(922)		(1,002)
Certain legal matters, net	[4]	510		975		993
Net gains on asset disposals	[7]	(171)		(232)		(288)
Impairment on remeasurement of HIS net assets	[2]	1,712	[5]	0	[5]	0
Certain asset impairments	[8]	1,447		818		469
Business and legal entity alignment costs	[9]	261		282		168
Other, net	[10]	85		403		(265)
Other (income)/deductions––net	[11]	$ 3,655		$ 2,860		$ 1,009
[1]	2015 v. 2014––Interest income increased primarily due to higher investment returns. Interest expense decreased, primarily due to the repayment of a portion of long-term debt in the first quarter of 2015 and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. Capitalized interest expense totaled $61 million in 2016, $32 million in 2015 and $41 million in 2014.
[2]	Amounts may not add due to rounding.
[3]	In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.30, but rather at the then SIMADI rate of 200, the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy.
[4]	In 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million, partially offset by the reversal of a legal accrual where a loss is no longer deemed probable. For additional information, see Note 17A5. In addition, 2016 includes a settlement related to a patent matter. In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. For additional information, see Note 17A5. In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million to resolve a securities class action against Pfizer in New York federal court, and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable.
[5]	In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[6]	Royalty-related income decreased in 2016, reflecting lower royalty income for Enbrel of $54 million, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), and the expiration of other royalty agreements, partially offset by Xtandi royalty-related income of $63 million.
[7]	In 2016, primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $666 million; (ii) gross realized losses on sales of available-for-sale debt securities of $548 million; (iii) loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of approximately $84 million; and (v) gains on sales of investments in private equity securities of approximately $2 million. Proceeds from the sale of available-for-sale securities were $10.2 billion in 2016. In 2015, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $164 million; (ii) gross realized losses on sales of available-for-sale debt securities of $960 million; (iii) net gain of $937 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of approximately $90 million; and (v) gains on sales of investments in private equity securities of approximately $3 million. Proceeds from the sale of available-for-sale securities were $4.3 billion in 2015.In 2014, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $76 million; (ii) gross realized gains on sales of available-for-sale debt securities of $138 million; (iii) gross realized losses on sales of available-for-sale debt securities of $436 million; (iv) net gain of $323 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of approximately $135 million; and (vi) gains on sales of investments in private equity securities of approximately $39 million. Proceeds from the sale of available-for-sale securities were $10.2 billion in 2014.
[8]	In 2016, primarily includes intangible asset impairment charges of $869 million, reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ($840 million) and IH ($29 million). In addition, 2016 includes an impairment loss of $452 million related to Pfizer’s 49%-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40%-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2E. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.In 2015, primarily includes an impairment loss of $463 million related to Pfizer’s 49%-owned equity-method investment in Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2E) and intangible asset impairment charges of $323 million, reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: EH ($294 million), WRD ($13 million); and Consumer Healthcare ($17 million).The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment.In 2014 includes intangible asset impairment charges of $396 million, reflecting (i) $190 million for an IPR&D compound for the treatment of skin fibrosis (full write-off); (ii) $159 million for developed technology rights, primarily related to Quillivant XR; and (iii) $47 million for indefinite-lived brands. The intangible asset impairment charges for 2014 are associated with the following: IH ($12 million); EH ($166 million); WRD ($190 million); and Consumer Healthcare ($28 million). In addition, 2014 includes an impairment charge of approximately $56 million related to our investment in Teuto. The intangible asset impairment charges for 2014 reflect, among other things, updated commercial forecasts and, with regard to IPR&D, the impact of changes to the development program and new scientific findings
[9]	Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[10]	In 2016, includes among other things, (i) $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A); (ii) income of $116 million from resolution of a contract disagreement; and (iii) a net loss of approximately $312 million upon the early redemption of debt, which includes the related termination of interest rate swaps. In 2015, includes, among other things, (i) charges of $194 million related to the write-down of assets to net realizable value; (ii) charges of $159 million, reflecting the change in the fair value of contingent consideration liabilities; and (iii) income of $45 million associated with equity-method investees. In 2014, includes, among other things, (i) gains of approximately $40 million, reflecting the change in the fair value of contingent consideration liabilities associated with prior acquisitions; (ii) income associated with equity-method investees of $86 million; (iii) income of $55 million resulting from a decline in the estimated loss on an option to acquire the remaining interest in Teuto; and (iv) a loss of $30 million due to a change in our ownership interest in ViiV. For additional information concerning Teuto and ViiV, see Note 2E.
[11]	Amounts may not add due to rounding.

Other (Income)_Deductions - N61

Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Income and Expenses [Abstract]
Interest costs capitalized	$ 61	$ 32	$ 41

Other (Income)_Deductions - N62

Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details) - USD ($) $ in Millions		Oct. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty income	[1]		$ 905	$ 922	$ 1,002
Xtandi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty income	[1]		63
Collaborative Arrangement, Co-promotion [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty revenue, term		36 months
Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Decrease in royalty revenue	[1]		$ (54)
Royalty revenue, term	[1]		36 months
Venezuela [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reduction in labor force, percentage				36.00%
[1]	Royalty-related income decreased in 2016, reflecting lower royalty income for Enbrel of $54 million, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), and the expiration of other royalty agreements, partially offset by Xtandi royalty-related income of $63 million.

Other (Income)_Deductions - N63

Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details) $ in Millions	1 Months Ended	12 Months Ended
	Jul. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)legal_accrual
Violation Of Securities Law, Failure to Disclose Material Information [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)				$ (400)
Accrual No Longer Deemed Probable [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)				$ 130
Number of reversed legal accruals | legal_accrual				2
Protonix / Pantoprazole [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)			$ (784.6)
Neurontin [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)				$ (610)
Effexor [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)				$ (56)
Pending Litigation [Member] | Celebrex and Bextra [Member] | Product Safety Misrepresentation [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 486	$ 486

Other (Income)_Deductions - N64

Other (Income)/Deductions - Net - Footnotes - Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains (losses), sale proceeds	$ 10,200	$ 4,300	$ 10,200
Debt Securities [Member]
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains	666		138
Available-for-sale securities, gross realized losses	548	960	436
Private Equity Funds [Member]
Investment Holdings [Line Items]
Gain on sale of investments	2	3	39
Equity Securities [Member]
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains		164	76
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Debt Securities [Member]
Investment Holdings [Line Items]
Gain (loss) on derivative instruments, net, pretax	(64)	937	323
Distribution Rights [Member]
Investment Holdings [Line Items]
Gain on disposition of intangible assets	$ 84	$ 90	$ 135

Other (Income)_Deductions - N65

Other (Income)/Deductions - Net - Footnotes - Indefinite-Lived Intangibles (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Dec. 31, 2016	Jul. 03, 2016	Apr. 03, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				$ 869	$ 323	$ 396
Operating Segments [Member] | Essential Health Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				840	294	166
Operating Segments [Member] | Innovative Health Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				29		12
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					71	190
In Process Research and Development [Member] | Hospira [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				265
In Process Research and Development [Member] | InnoPharma [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				128
Other In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				110
Other In Process Research and Development [Member] | Hospira [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				81
Other In Process Research and Development [Member] | King [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				29
Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					132
Trade Names [Member] | Xanax/Xanax XR [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments						47
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Indefinite-lived Intangible Assets [Line Items]
Equity method investment, other than temporary impairment	$ 241	$ 130	$ 81	$ 452	$ 463
Equity method investment, ownership percentage	49.00%			49.00%	49.00%
Laboratorio Teuto Brasilero [Member]
Indefinite-lived Intangible Assets [Line Items]
Equity method investment, other than temporary impairment				$ 50		56
Equity method investment, ownership percentage	40.00%			40.00%
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments						159
Developed Technology Rights [Member] | Hospira [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				$ 366
Pfizer's Worldwide Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					$ 13	190
Consumer Healthcare [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					$ 17	$ 28

Other (Income)_Deductions - N66

Other (Income)/Deductions - Net - Footnotes - Finite-Lived Intangibles (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived	$ 366	[1]	$ 120
[1]	Reflects intangible assets written down to fair value in 2016. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Other (Income)_Deductions - N67

Other (Income)/Deductions - Net - Footnotes - Additional Information (Details) - USD ($) $ in Millions	Nov. 21, 2016	Apr. 08, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Payments for merger termination costs		$ 150	$ 150
Income from resolution of contract disagreement			116
Loss on early redemption of debt	$ 312		$ 312
Writedown of assets to net realizable value				$ 194
Income (Loss) from equity method investments				45	$ 86
ViiV Healthcare Limited [Member]
Business Acquisition [Line Items]
Change in fair value of fair value contingent consideration liabilities				$ 159	(40)
ViiV Healthcare Limited [Member] | Other Nonoperating Income (Expense) [Member]
Business Acquisition [Line Items]
Loss on change of interest in investment					30
Laboratorio Teuto Brasilero [Member] | Other Nonoperating Income (Expense) [Member]
Business Acquisition [Line Items]
Equity method investment, recognized gain (loss)					$ 55

Other (Income)_Deductions - N68

Other (Income)/Deductions - Net - Additional Information about Intangible Assets (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	[1]	$ 125
Intangible asset impairments		869		$ 323	$ 396
Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	30
Impairment of intangible assets, finite-lived		366	[2]	120
Intangible asset impairments					159
In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	[1],[2]	95
Impairment of intangible assets, indefinite-lived	[2]	503
Intangible asset impairments				$ 71	$ 190
Fair value inputs Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	[1]	0
Fair value inputs Level 1 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	0
Fair value inputs Level 1 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	[1],[2]	0
Fair value inputs Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	[1]	0
Fair value inputs Level 2 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	0
Fair value inputs Level 2 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	[1],[2]	0
Fair value inputs Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Total intangible assets, fair value disclosure	[1]	125
Fair value inputs Level 3 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	30
Fair value inputs Level 3 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Indefinite-lived intangible assets, fair value disclosure	[1],[2]	$ 95
[1]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
[2]	Reflects intangible assets written down to fair value in 2016. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters - Income from Conti

Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
United States		$ (8,534)	$ (6,809)	$ (4,744)
International		16,886	15,773	16,984
Income from continuing operations before provision for taxes on income	[1],[2]	$ 8,351	$ 8,965	$ 12,240
[1]	2015 v. 2014––The increase in the domestic loss was primarily due to the loss of exclusivity for Celebrex and Zyvox, higher restructuring charges and higher selling, informational and administrative expenses, partially offset by the performance of certain products including Prevnar 13 and Ibrance, and the impact of Hospira operations. The decrease in international income was primarily due to a foreign currency loss related to Venezuela, higher asset impairments, and the loss of exclusivity for Lyrica in certain developed markets, partially offset by lower R&D costs.The following table provides the components of Provision for taxes on income based on the location of the taxing authorities: Year Ended December 31, (MILLIONS OF DOLLARS) 2016 2015 2014United States Current income taxes: Federal $342 $67 $393State and local (52) (8) 85Deferred income taxes: Federal (419) 300 725State and local (106) (36) (256)Total U.S. tax provision (235) 323 948International Current income taxes 1,532 1,951 2,321Deferred income taxes (175) (284) (149)Total international tax provision 1,358 1,667 2,172Provision for taxes on income $1,123 $1,990 $3,120
[2]	2016 v. 2015––The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs.

Tax Matters - Provision for Tax

Tax Matters - Provision for Taxes on Income (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current income taxes:
Federal		$ 342	$ 67	$ 393
State and local		(52)	(8)	85
Deferred income taxes:
Federal		(419)	300	725
State and local		(106)	(36)	(256)
Total U.S. tax provision		(235)	323	948
International
Current income taxes		1,532	1,951	2,321
Deferred income taxes		(175)	(284)	(149)
Total international tax provision		1,358	1,667	2,172
Provision for taxes on income	[1]	$ 1,123	$ 1,990	$ 3,120
[1]	Amounts may not add due to rounding.

Tax Matters - Provision for T71

Tax Matters - Provision for Taxes on Income (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Deferred income taxes on certain current-year funds earned outside of the U.S.	$ 1,100	$ 2,100	$ 2,200
Tax benefits from resolution of certain tax positions	460	360	350
Tax benefit due to adoption of accounting standard	89
Selling, informational and administrative expenses	$ 312	$ 251	$ 362

Tax Matters - Tax Rate Reconcil

Tax Matters - Tax Rate Reconciliation (Details)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate		35.00%	35.00%	35.00%
Taxation of non-U.S. operations	[1],[2],[3]	(13.80%)	(9.60%)	(7.40%)
Tax settlements and resolution of certain tax positions	[4]	(5.50%)	(4.00%)	(2.90%)
U.S. Healthcare Legislation	[4]	1.30%	0.90%	1.00%
U.S. R&D tax credit and manufacturing deduction	[4]	(1.00%)	(1.00%)	(0.90%)
Certain legal settlements and charges	[4]	(2.90%)	3.10%	0.00%
All other, net	[5]	0.30%	(2.10%)	0.50%
Effective tax rate for income from continuing operations		13.40%	22.20%	25.50%
[1]	For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision for taxes on income.
[2]	In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico, Singapore, Costa Rica, and the Dominican Republic. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations. Hospira’s infusion technologies business benefits from income tax exemptions in Costa Rica and the Dominican Republic through 2028 and 2019, respectively.
[3]	The favorable rate impact in 2016 also includes the non-recurrence of the non-deductibility of a foreign currency loss related to Venezuela. The rate impact in 2015 also includes the non-deductibility of a foreign currency loss related to Venezuela. The favorable rate impact in 2014 also includes the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expected to retain the investment indefinitely. For additional information, see Note 2E.
[4]	For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and the impact of certain legal settlements and charges, see Note 5A.
[5]	All other, net in 2015 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business.

Tax Matters - Deferred Taxes (D

Tax Matters - Deferred Taxes (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Deferred Tax Assets
Prepaid/deferred items - Deferred tax assets		$ 2,180	$ 2,247
Inventories - Deferred tax assets		366	381
Intangible assets - Deferred tax assets		1,139	1,063
Property, plant and equipment - Deferred tax assets		92	65
Employee benefits - Deferred tax assets		3,356	3,302
Restructurings and other charges - Deferred tax assets		458	318
Legal and product liability reserves - Deferred tax assets		650	730
Net operating loss/credit carryforwards - Deferred tax assets	[1]	2,957	3,808
State and local tax adjustments - Deferred tax assets		301	328
All other - Deferred tax assets		306	310
Subtotal - Deferred tax assets		11,806	12,552
Valuation allowance		(1,949)	(2,029)
Total deferred taxes - Deferred tax assets		9,857	10,523
Deferred Tax Liabilities
Prepaid/deferred items - Deferred tax liabilities		(68)	(38)
Inventories - Deferred tax liabilities		(47)	(190)
Intangible assets - Deferred tax liabilities		(15,172)	(10,885)
Property, plant and equipment - Deferred tax liabilities		(982)	(1,096)
Employee benefits - Deferred tax liabilities		(74)	(167)
Restructurings and other charges - Deferred tax liabilities		(2)	(20)
Unremitted earnings - Deferred tax liabilities	[2]	(23,108)	(23,626)
All other - Deferred tax liabilities		(503)	(646)
Deferred tax liabilities, gross		(39,956)	(36,668)
Net deferred tax liability	[3]	$ (30,099)	$ (26,145)
[1]	The amounts in 2016 and 2015 are reduced for unrecognized tax benefits of $3.0 billion and $2.9 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
[2]	The decrease in 2016 reflects the reversal of certain prior year accruals for earnings outside the U.S. that were not indefinitely reinvested overseas, partially offset by additional accruals for certain funds earned outside the U.S. in the current year that will not be indefinitely reinvested overseas. For additional information, see Note 5A.
[3]	In 2016, Noncurrent deferred tax assets and other noncurrent tax assets ($654 million), and Noncurrent deferred tax liabilities ($30.8 billion). In 2015, Noncurrent deferred tax assets and other noncurrent tax assets ($732 million), and Noncurrent deferred tax liabilities ($26.8 billion).

Tax Matters - Deferred Taxes -

Tax Matters - Deferred Taxes - Footnotes (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Income Tax Examination [Line Items]
Reduction for unrecognized tax benefit		$ 3,000	$ 2,900
Net deferred tax liability	[1]	30,099	26,145
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Examination [Line Items]
Net deferred tax liability		654	732
Noncurrent Deferred Tax Liabilities [Member]
Income Tax Examination [Line Items]
Net deferred tax liability		$ 30,800	$ 26,800
[1]	In 2016, Noncurrent deferred tax assets and other noncurrent tax assets ($654 million), and Noncurrent deferred tax liabilities ($30.8 billion). In 2015, Noncurrent deferred tax assets and other noncurrent tax assets ($732 million), and Noncurrent deferred tax liabilities ($26.8 billion).

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)jurisdiction	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Income Tax Contingency [Line Items]
Undistributed earnings of foreign subsidiaries	$ 86,000
Unrecognized tax benefits excluding associated interest	$ 4,600	$ 4,800
Number of tax jurisdiction associated with uncertain tax positions | jurisdiction	1
Deferred tax assets associated with unrecognized tax benefits	$ 1,200	1,100
Unrecognized tax benefits, interest on income taxes expense	72	71	$ 40
Unrecognized tax benefits, interest on income taxes accrued	771	714
Unrecognized accrued interest decrease as a result of cash payments	18	5
Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit	(100)
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Contingency [Line Items]
Deferred tax assets associated with unrecognized tax benefits	1,000	963
Deferred Tax Liabilities, Net, Noncurrent [Member]
Income Tax Contingency [Line Items]
Deferred tax assets associated with unrecognized tax benefits	201	179
Income Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued	4
Current Tax Assets [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued	13	12
Other Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued	$ 754	$ 702

Tax Matters - Reconciliation of

Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning		$ (5,919)	[1]	$ (6,182)	[1]	$ (6,087)
Acquisitions	[2]	(83)		(110)		0
Increases based on tax positions taken during a prior period	[3]	(11)		(31)		(110)
Decreases based on tax positions taken during a prior period	[3],[4]	409		496		473
Decreases based on settlements for a prior period	[5]	126		64		70
Increases based on tax positions taken during the current period	[3]	(489)		(675)		(795)
Impact of foreign exchange		(5)		319		161
Other, net	[3],[6]	146		199		106
Balance, ending	[1]	$ (5,826)		$ (5,919)		$ (6,182)
[1]	In 2016, included in Income taxes payable ($14 million), Current tax assets ($17 million), Noncurrent deferred tax assets and other noncurrent tax assets ($184 million), Noncurrent deferred tax liabilities ($2.8 billion) and Other taxes payable ($2.8 billion). In 2015, included in Income taxes payable ($38 million), Current tax assets ($22 million), Noncurrent deferred tax assets and other noncurrent tax assets ($135 million), Noncurrent deferred tax liabilities ($2.7 billion) and Other taxes payable ($3.0 billion).
[2]	For 2016, primarily related to the acquisitions of Medivation and Anacor. For 2015, primarily related to the acquisition of Hospira. See also Note 2A.
[3]	Primarily included in Provision for taxes on income.
[4]	Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A.
[5]	Primarily related to cash payments and reductions of tax attributes.
[6]	Primarily related to decreases as a result of a lapse of applicable statutes of limitations.

Tax Matters - Reconciliation 77

Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) - USD ($) $ in Millions	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014	[1]	Dec. 31, 2013
Income Tax Contingency [Line Items]
Unrecognized tax benefits	$ 5,826	[1]	$ 5,919	[1]	$ 6,182		$ 6,087
Income Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	14		38
Current Tax Assets [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	17		22
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	184		135
Noncurrent Deferred Tax Liabilities [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	2,800		2,700
Other Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	$ 2,800		$ 3,000
[1]	In 2016, included in Income taxes payable ($14 million), Current tax assets ($17 million), Noncurrent deferred tax assets and other noncurrent tax assets ($184 million), Noncurrent deferred tax liabilities ($2.8 billion) and Other taxes payable ($2.8 billion). In 2015, included in Income taxes payable ($38 million), Current tax assets ($22 million), Noncurrent deferred tax assets and other noncurrent tax assets ($135 million), Noncurrent deferred tax liabilities ($2.7 billion) and Other taxes payable ($3.0 billion).

Tax Matters - Taxes on Items of

Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)
Foreign currency translation adjustments, net	[1]	$ (15)	$ 90	$ 42
Unrealized holding gains/(losses) on derivative financial instruments, net		(75)	(173)	(199)
Reclassification adjustments for realized (gains)/losses		158	104	262
Other comprehensive income (loss), derivatives qualifying as hedges, tax, total		83	(69)	63
Unrealized holding gains/(losses) on available-for-sale securities, net		49	(104)	(56)
Reclassification adjustments for realized (gains)/losses		(15)	59	10
Other comprehensive income (loss), available-for-sale securities, tax, total		34	(45)	(46)
Benefit plans: actuarial losses, net		(535)	(23)	(1,416)
Reclassification adjustments related to amortization		186	183	61
Reclassification adjustments related to settlements, net		45	237	35
Other		36	66	61
Defined benefit plan, amounts recognized in other comprehensive income (loss), net actuarial gain (loss), tax		(269)	462	(1,258)
Benefit plans: prior service credits and other, net		67	160	281
Reclassification adjustments related to amortization		(64)	(59)	(28)
Reclassification adjustments related to curtailments, net		(10)	(12)	0
Other		(1)	0	(1)
Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax		(7)	89	253
Tax provision/(benefit) on other comprehensive loss	[2],[3]	$ (174)	$ 528	$ (946)
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.
[3]	See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Loss.

Accumulated Other Comprehensi79

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	[1]	$ 64,720
Ending balance	[1]	59,544	$ 64,720
Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(9,522)	(7,316)	$ (3,271)
Other comprehensive income/(loss)	[2]	(1,514)	(2,206)	(4,045)
Ending balance		(11,036)	(9,522)	(7,316)
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(5,863)	(2,689)	(590)
Other comprehensive income/(loss)	[2]	(797)	(3,174)	(2,099)
Ending balance		(6,659)	(5,863)	(2,689)
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		421	517	79
Other comprehensive income/(loss)	[2]	(73)	(96)	438
Ending balance		348	421	517
Available-For-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(227)	(222)	150
Other comprehensive income/(loss)	[2]	96	(5)	(372)
Ending balance		(131)	(227)	(222)
Actuarial Gains/(Losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(4,733)	(5,654)	(3,223)
Other comprehensive income/(loss)	[2]	(740)	921	(2,432)
Ending balance		(5,473)	(4,733)	(5,654)
Prior Service (Costs)/Credits and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		880	733	313
Other comprehensive income/(loss)	[2]	(1)	148	419
Ending balance		$ 879	$ 880	$ 733
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $3 million loss in 2016, $26 million loss in 2015 and $3 million gain in 2014.

Accumulated Other Comprehensi80

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Foreign currency translation gain (loss) attributable to noncontrolling interests	$ (3)	$ (26)	$ 3

Accumulated Other Comprehensi81

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Available-For-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) to be reclassified in next twelve months	$ 328
Actuarial Gains/(Losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) to be reclassified in next twelve months	(608)
Prior Service (Costs)/Credits and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) to be reclassified in next twelve months	$ 184

Financial Instruments - Assets

Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Other selected financial assets
Total selected financial assets		$ 24,175	$ 38,157
Short-term borrowings:
Short-term borrowings, carried at historical proceeds, as adjusted	[1],[2]	10,688	10,159
Long-term debt:
Long-term debt, carried at historical proceeds, as adjusted	[1],[3]	31,398	28,740
Total	[4]	42,085	38,899
Total selected financial liabilities	[4]	43,750	40,608
Reported Value Measurement [Member]
Other selected financial assets
Held-to-maturity debt securities, carried at amortized cost	[2],[5]	1,242	1,388
Private equity securities, carried at equity-method or at cost	[2],[6]	735	1,336
Total		1,977	2,724
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading funds and securities	[4],[7]	325	287
Selected financial assets measured at fair value on a recurring basis	[4]	22,198	35,433
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[4]	1,665	1,709
Fair Value, Measurements, Recurring [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in a receivable position	[4],[8]	625	837
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[4],[9]	148	139
Fair Value, Measurements, Recurring [Member] | Currency swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in a receivable position	[4],[8]	79	135
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[4],[9]	1,374	1,489
Fair Value, Measurements, Recurring [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in a receivable position	[4],[8]	551	559
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[4],[9]	143	81
Fair Value, Measurements, Recurring [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	[4],[5]	18,632	32,078
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	[4]	1,445	934
Fair Value, Measurements, Recurring [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	[4],[5]	540	603
Short-term Debt [Member]
Short-term borrowings:
Principal amount		10,674	10,160
Net fair value adjustments related to hedging and purchase accounting		24	2
Long-term debt:
Net unamortized discounts, premiums and debt issuance costs	[10]	$ (11)	$ (3)
[1]	Amounts may not add due to rounding.
[2]	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost-method and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2016 or December 31, 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments.
[3]	The fair value of our long-term debt (not including the current portion of long-term debt) was $34.9 billion as of December 31, 2016 and $32.7 billion as of December 31, 2015. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach.
[4]	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value.
[5]	Gross unrealized gains and losses related to 2016 are not significant. Unrealized losses related to 2015 available-for-sale debt securities are $593 million and unrealized gains are $44 million. The vast majority of investments related to 2015, in an unrealized loss position, relate to the foreign exchange impact on foreign currency denominated securities, which are hedged with foreign currency forward-exchange contracts and cross-currency swaps. We have the intent and ability to hold such investments to maturity.
[6]	Our private equity securities represent investments in the life sciences sector.
[7]	As of December 31, 2016, trading funds and securities are composed of $236 million of trading equity funds and $89 million of trading debt funds. As of December 31, 2015, trading funds and securities are composed of $185 million of trading equity funds and $102 million of trading debt funds. As of December 31, 2016 and December 31, 2015, trading equity funds of $71 million and $85 million, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
[8]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $162 million as of December 31, 2016; and foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015.
[9]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $269 million and foreign currency forward-exchange contracts with fair values of $113 million as of December 31, 2016; and foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $59 million as of December 31, 2015.
[10]	We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information.

Financial Instruments - Asset83

Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities, unrealized loss	$ 593
Available-for-sale debt securities, unrealized gain	44
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of financial assets and liabilities measured at fair value inputs Level 1 and Level 3 inputs		2.00%
Trading equity funds	185	$ 236
Trading debt funds	102	89
Trading equity securities	85	71
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Instruments used as offsets (assets)	136	162
Instruments used as offsets (liabilities)	59	113
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument [Member] | Currency swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Instruments used as offsets (liabilities)	234	269
Fair value inputs Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	32,700	$ 34,900
Foreign Currency Short Term Borrowings [Member] | Designated as Hedging Instrument [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term borrowings	$ 547

Financial Instruments - Balance

Financial Instruments - Balance Sheet Grouping (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		$ 24,175	$ 38,157
Selected financial liabilities	[1]	43,750	40,608
Cash and Cash Equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		547	978
Short-term Investments [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		15,255	19,649
Other Current Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[2]	567	587
Long-term Investments [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		7,116	15,999
Other Noncurrent Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[3]	689	944
Short-Term Borrowings, including Current Portion of Long-term Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[4]	10,688	10,159
Other Current Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[5]	443	645
Long-term Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[4]	31,398	28,740
Other Noncurrent Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[6]	$ 1,222	$ 1,064
[1]	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value.
[2]	As of December 31, 2016, derivative instruments at fair value include interest rate swaps ($26 million), foreign currency swaps ($43 million) and foreign currency forward-exchange contracts ($497 million) and, as of December 31, 2015, include interest rate swaps ($2 million), foreign currency swaps ($46 million) and foreign currency forward-exchange contracts ($538 million).
[3]	As of December 31, 2016, derivative instruments at fair value include interest rate swaps ($599 million), foreign currency swaps ($36 million) and foreign currency forward-exchange contracts ($54 million) and, as of December 31, 2015, include interest rate swaps ($835 million), foreign currency swaps ($89 million) and foreign currency forward-exchange contracts ($20 million).
[4]	We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information.
[5]	At December 31, 2016, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($300 million) and foreign currency forward-exchange contracts ($143 million) and, as of December 31, 2015, include interest rate swaps ($5 million), foreign currency swaps ($560 million) and foreign currency forward-exchange contracts ($80 million).
[6]	At December 31, 2016, derivative instruments at fair value include interest rate swaps ($147 million) and foreign currency swaps ($1.1 billion) and, as of December 31, 2015, include interest rate swaps ($134 million), foreign currency swaps ($928 million) and foreign currency forward-exchange contracts ($1 million).

Financial Instruments - Balan85

Financial Instruments - Balance Sheet Grouping - Footnotes (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		$ 24,175	$ 38,157
Selected financial liabilities	[1]	43,750	40,608
Other Current Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[2]	567	587
Other Current Assets [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		26	2
Other Current Assets [Member] | Currency swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		43	46
Other Current Assets [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		497	538
Other Noncurrent Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[3]	689	944
Other Noncurrent Assets [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		599	835
Other Noncurrent Assets [Member] | Currency swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		36	89
Other Noncurrent Assets [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		54	20
Other Current Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[4]	443	645
Other Current Liabilities [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		1	5
Other Current Liabilities [Member] | Currency swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		300	560
Other Current Liabilities [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		143	80
Other Noncurrent Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[5]	1,222	1,064
Other Noncurrent Liabilities [Member] | Interest Rate Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		147	134
Other Noncurrent Liabilities [Member] | Currency swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		$ 1,100	928
Other Noncurrent Liabilities [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities			$ 1
[1]	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value.
[2]	As of December 31, 2016, derivative instruments at fair value include interest rate swaps ($26 million), foreign currency swaps ($43 million) and foreign currency forward-exchange contracts ($497 million) and, as of December 31, 2015, include interest rate swaps ($2 million), foreign currency swaps ($46 million) and foreign currency forward-exchange contracts ($538 million).
[3]	As of December 31, 2016, derivative instruments at fair value include interest rate swaps ($599 million), foreign currency swaps ($36 million) and foreign currency forward-exchange contracts ($54 million) and, as of December 31, 2015, include interest rate swaps ($835 million), foreign currency swaps ($89 million) and foreign currency forward-exchange contracts ($20 million).
[4]	At December 31, 2016, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($300 million) and foreign currency forward-exchange contracts ($143 million) and, as of December 31, 2015, include interest rate swaps ($5 million), foreign currency swaps ($560 million) and foreign currency forward-exchange contracts ($80 million).
[5]	At December 31, 2016, derivative instruments at fair value include interest rate swaps ($147 million) and foreign currency swaps ($1.1 billion) and, as of December 31, 2015, include interest rate swaps ($134 million), foreign currency swaps ($928 million) and foreign currency forward-exchange contracts ($1 million).

Financial Instruments - Investm

Financial Instruments - Investments in Debt Securities (Details) $ in Millions	Dec. 31, 2016USD ($)
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Debt securities maturities within 1 year	$ 14,371
Debt securities maturities over 1 to 5 years	3,898
Debt securities maturities over 5 to 10 years	1,579
Debt securities maturities after 10 Years	26
Total debt securities	19,873
Corporate debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	2,783	[1]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	2,727	[1]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	1,557	[1]
Available-for-sale securities, debt maturities, over 10 years, fair value	23	[1]
Available-for-sale securities, debt maturities, total	7,089	[1]
Western European, Asian, Scandinavian and Other Government Debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	4,661	[2]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	432	[2]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0	[2]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[2]
Available-for-sale securities, debt maturities, total	5,093	[2]
U.S. government debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	2,134
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	88
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0
Available-for-sale securities, debt maturities, over 10 years, fair value	0
Available-for-sale securities, debt maturities, total	2,222
Western European, Scandinavian, Australian and other government agency debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	1,746	[2]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	137	[2]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0	[2]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[2]
Available-for-sale securities, debt maturities, total	1,883	[2]
Supranational debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	910	[2]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	294	[2]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0	[2]
Available-for-sale securities, debt maturities, over 10 years, fair value	0	[2]
Available-for-sale securities, debt maturities, total	1,204	[2]
Other Asset-backed Debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	367	[3]
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	217	[3]
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	18	[3]
Available-for-sale securities, debt maturities, over 10 years, fair value	3	[3]
Available-for-sale securities, debt maturities, total	605	[3]
Government National Mortgage Association Certificates and other U.S. Government guaranteed asset-backed securities [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Available-for-sale securities, debt maturities, within 1 year, fair value	535
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	0
Available-for-sale securities, debt maturities, over 5 to 10 years, fair value	0
Available-for-sale securities, debt maturities, over 10 years, fair value	0
Available-for-sale securities, debt maturities, total	535
Time deposits and other [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Held-to-maturity securities, debt maturities, within 1 year, fair value	1,000
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value	1
Held-to-maturity securities, debt maturities, over 5 to 10 years, fair value	3
Held-to-maturity securities, debt maturities, over 10 years, fair value	0
Held-to-maturity securities, debt maturities, total	1,004
Western European and government debt [Member]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Held-to-maturity securities, debt maturities, within 1 year, fair value	236	[2]
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value	2	[2]
Held-to-maturity securities, debt maturities, over 5 to 10 years, fair value	0	[2]
Held-to-maturity securities, debt maturities, over 10 years, fair value	0	[2]
Held-to-maturity securities, debt maturities, total	$ 238	[2]
[1]	Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade.
[2]	Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade.
[3]	Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Jun. 24, 2016	Dec. 31, 2015
Credit Risk Derivatives, at Fair Value, Net [Abstract]
Concentration risk, credit risk, financial instrument, maximum exposure	$ 1,200
Line of Credit [Member]
Short-term Debt [Abstract]
Line of credit facility, current borrowing capacity	7,900
Line of credit facility, current borrowing capacity, expiring within one year	$ 790
Debt instrument, expiration period	1 year
Line of credit facility, remaining borrowing capacity	$ 7,800
Line of credit facility, committed amount	7,100
Cash and Cash Equivalents [Member]
Credit Risk Derivatives, at Fair Value, Net [Abstract]
Securities received as collateral	613
Commercial Paper [Member]
Short-term Debt [Abstract]
Commercial paper	$ 5,800		$ 4,900
Commercial paper, weighted average interest rate	1.30%		1.90%
Commercial Paper [Member] | Line of Credit [Member]
Short-term Debt [Abstract]
Line of credit facility, remaining borrowing capacity	$ 7,000
Anacor [Member]
Short-term Debt [Abstract]
Debt assumed		$ 698

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt Narrative (Details) - USD ($)	Nov. 21, 2016	Jun. 03, 2016	Dec. 31, 2016	Oct. 31, 2015	Oct. 05, 2015	Sep. 03, 2015
Debt Instrument [Line Items]
Repurchased debt	$ 3,400,000,000
Redemption value	3,700,000,000
Loss on early redemption of debt	312,000,000		$ 312,000,000
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 6,000,000,000	$ 5,000,000,000
Weighted average interest rate	3.10%	2.09%
Redemption price, percentage	100.00%	100.00%	100.00%
Unsecured Debt [Member] | US Treasury Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.10%	0.05%	0.05%
Unsecured Debt [Member] | US Treasury Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.20%	0.15%	0.50%
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	1,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2026 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	1,750,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2036 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	1,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2046 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	1,250,000,000
Unsecured Debt [Member] | Senior Unsecured Debt, 6.20%, Due 2019 [Member]
Debt Instrument [Line Items]
Repurchased debt	$ 3,270,000,000
Interest rate, percentage			6.20%
Hospira [Member]
Debt Instrument [Line Items]
Fair value of debt acquired						$ 1,928,000,000
Hospira [Member] | Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 1,700,000,000	$ 1,700,000,000	$ 1,750,000,000

Financial Instruments - Long-89

Financial Instruments - Long-Term Debt (Details) $ in Millions, £ in Billions		Dec. 31, 2016USD ($)	Dec. 31, 2016GBP (£)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Long-term debt		$ 31,398
Long-term debt	[1],[2]	31,398		$ 28,740
Current portion of long-term debt	[1]	4,225		3,719
Unsecured Debt [Member]
Debt Instrument [Line Items]
Long-term debt | £			£ 1.9
Total principal amount of long-term debt		30,529		27,573
Net fair value adjustments related to hedging and purchase accounting		998		1,294
Net unamortized discounts, premiums and debt issuance costs	[3]	(130)		(127)
Current portion of long-term debt	[4]	$ 4,225		3,719
Unsecured Debt [Member] | Senior Unsecured Euro Debt, 4.55%, Due 2017 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		4.55%	4.55%
Long-term debt	[4],[5]	$ 0		980
Unsecured Debt [Member] | Senior Unsecured Debt, 1.10%, Due 2017 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		1.10%	1.10%
Long-term debt	[4],[5]	$ 0		1,000
Unsecured Debt [Member] | Senior Unsecured Debt, 1.20%, Due 2039 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		1.20%	1.20%
Long-term debt	[4]	$ 1,250		0
Unsecured Debt [Member] | Senior Unsecured Debt, 1.50%, Due 2018 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		1.50%	1.50%
Long-term debt	[4]	$ 1,000		1,000
Unsecured Debt [Member] | Senior Unsecured Debt, 6.20%, Due 2019 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		6.20%	6.20%
Long-term debt	[4]	$ 0		3,250
Unsecured Debt [Member] | Senior Unsecured Debt, 2.10%, Due 2019 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		2.10%	2.10%
Long-term debt	[4]	$ 1,500		1,500
Unsecured Debt [Member] | Senior Unsecured Debt, 1.70%, Due 2019 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		1.70%	1.70%
Long-term debt	[4]	$ 1,000		0
Unsecured Debt [Member] | Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		5.75%	5.75%
Long-term debt	[4]	$ 2,108		2,178
Unsecured Debt [Member] | Senior Unsecured Debt, 1.95%, Due 2021 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		1.95%	1.95%
Long-term debt	[4]	$ 1,150		0
Unsecured Debt [Member] | Senior Unsecured Debt, 2.20%, Due 2021 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		2.20%	2.20%
Long-term debt	[4]	$ 1,000		0
Unsecured Debt [Member] | Senior Unsecured Debt, 3.00%, Due 2023 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		3.00%	3.00%
Long-term debt	[4]	$ 1,000		1,000
Unsecured Debt [Member] | Senior Unsecured Debt, 3.40%, Due 2024 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		3.40%	3.40%
Long-term debt	[4]	$ 1,000		1,000
Unsecured Debt [Member] | Senior Unsecured Debt, 2.75%, Due 2026 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		2.75%	2.75%
Long-term debt	[4]	$ 1,250		0
Unsecured Debt [Member] | Senior Unsecured Debt, 3.00%, Due 2026 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		3.00%	3.00%
Long-term debt	[4]	$ 1,750		0
Unsecured Debt [Member] | Senior Unsecured Debt, 4.00%, Due 2036 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		4.00%	4.00%
Long-term debt	[4]	$ 1,000		0
Unsecured Debt [Member] | Senior Unsecured Debt, 5.95%, Due 2037 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		5.95%	5.95%
Long-term debt	[4]	$ 2,000		2,000
Unsecured Debt [Member] | U.K. Pound Debt, 6.50%, Due 2038 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		6.50%	6.50%
Long-term debt	[4]	$ 1,852		2,223
Unsecured Debt [Member] | Senior Unsecured Debt, 7.20%, Due 2039 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		7.20%	7.20%
Long-term debt	[4]	$ 2,500		2,500
Unsecured Debt [Member] | Senior Unsecured Debt, 4.40%, Due 2044 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		4.40%	4.40%
Long-term debt	[4]	$ 1,000		500
Unsecured Debt [Member] | Senior Unsecured Debt, 4.125%, Due 2046 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		4.125%	4.125%
Long-term debt	[4]	$ 1,250		0
Unsecured Debt [Member] | Notes Payable And Other Debt, Weighted Average Interest Rate 3.30%, Due 2018-2021 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		3.30%	3.30%
Long-term debt	[4],[6]	$ 2,464		3,974
Unsecured Debt [Member] | Notes Payable And Other Debt, Weighted Average Interest Rate 5.99%, Due 2023-2043 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		5.99%	5.99%
Long-term debt	[4],[7]	$ 4,455		$ 4,468
[1]	Amounts may not add due to rounding.
[2]	The fair value of our long-term debt (not including the current portion of long-term debt) was $34.9 billion as of December 31, 2016 and $32.7 billion as of December 31, 2015. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach.
[3]	We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information.
[4]	Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus an incremental spread ranging from 0.05% to 0.50%, plus, in each case, accrued and unpaid interest.
[5]	At December 31, 2016, the debt issuances have been reclassified to the current portion of long-term debt.
[6]	Contains debt issuances with a weighted-average maturity of approximately two years for balances that exist as of December 31, 2016.
[7]	Contains debt issuances with a weighted-average maturity of approximately 16 years for balances that exist as of December 31, 2016.The following table provides the maturity schedule of our Long-term debt outstanding as of December 31, 2016:(MILLIONS OF DOLLARS) 2018 2019 2020 2021 After 2021 TotalMaturities $3,567 $3,350 $360 $4,241 $19,879 $31,398

Financial Instruments - Long-90

Financial Instruments - Long-Term Debt - Footnotes (Details) - Unsecured Debt [Member]	Nov. 21, 2016	Jun. 03, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Redemption price, percentage	100.00%	100.00%	100.00%
Minimum [Member] | US Treasury Rate [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.10%	0.05%	0.05%
Maximum [Member] | US Treasury Rate [Member]
Debt Instrument [Line Items]
Debt redemption price, basis spread percentage	0.20%	0.15%	0.50%
Notes Payable And Other Debt, Weighted Average Interest Rate 3.30%, Due 2018-2021 [Member] | Weighted Average [Member]
Debt Instrument [Line Items]
Debt instrument, term			2 years
Notes Payable And Other Debt, Weighted Average Interest Rate 5.99%, Due 2023-2043 [Member]
Debt Instrument [Line Items]
Debt instrument, term			16 years

Financial Instruments - Long-91

Financial Instruments - Long-Term Debt Outstanding Maturities (Details) $ in Millions	Dec. 31, 2016USD ($)
Disclosure - Financial Instruments - Long-Term Debt Outstanding Maturities [Abstract]
2,018	$ 3,567
2,019	3,350
2,020	360
2,021	4,241
After 2,021	19,879
Total	$ 31,398

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) $ in Millions, £ in Billions		12 Months Ended
		Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016GBP (£)
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt		$ 31,398
Unrealized gain on foreign currency derivatives, before tax		222
Pre-tax gain expected to be reclassified to AOCI		164
Derivative, net liability position, aggregate fair value		936
Collateral already posted, aggregate fair value		958
Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(483)	$ 461
Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	(107)	(64)
Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	(452)	367
Foreign currency forward-exchange contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount		27,500
Derivative, notional amount		3,100
Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount		16,000
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign Currency Short Term Borrowings [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(26)	3
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign Currency Short Term Borrowings [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign Currency Short Term Borrowings [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
All other, net [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	1	0
All other, net [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	(16)
All other, net [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	(1)	0
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency swap [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(280)	(826)
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	0
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency swap [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	(387)	(613)
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(164)	1,028
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	(4)	0
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	(65)	980
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(15)	256
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	1	(1)
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
Not Designated as Hedging Instrument [Member] | Foreign currency swap [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0
Not Designated as Hedging Instrument [Member] | Foreign currency swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	(13)	(4)
Not Designated as Hedging Instrument [Member] | Foreign currency swap [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0
Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	(92)	(42)
Not Designated as Hedging Instrument [Member] | Foreign currency forward-exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	$ 0	$ 0
Unsecured Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt | £				£ 1.9
[1]	For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive loss––Foreign currency translation adjustments, net.
[2]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income.
[3]	Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.
[4]	There was no significant ineffectiveness for any period presented.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished goods		$ 2,293	$ 2,714
Work in process		3,696	3,932
Raw materials and supplies		793	867
Inventories	[1],[2]	6,783	7,513
Noncurrent inventories not included above	[3]	683	594
HIS [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories		$ 377	$ 0
[1]	Amounts may not add due to rounding.
[2]	The change from December 31, 2015 reflects, among other things, the reclassification of $377 million to Assets held for sale (see Note 2B).
[3]	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Property, Plant and Equipment94

Property, Plant and Equipment (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation		$ 28,125		$ 27,268
Less: Accumulated depreciation		14,807		13,502
Property, plant and equipment	[2]	13,318	[1],[3]	13,766	[1],[3]	$ 11,762
Land [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation		530		588
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation		9,810		9,604
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation		11,248		10,933
Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation		4,410		4,351
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation		$ 2,127		1,791
Minimum [Member] | Buildings [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)		33 years
Minimum [Member] | Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)		8 years
Minimum [Member] | Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)		3 years
Maximum [Member] | Buildings [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)		50 years
Maximum [Member] | Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)		20 years
Maximum [Member] | Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)		12 years 6 months
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Property, Plant and Equipment [Line Items]
PP&E		$ 457		$ 0
[1]	Amounts may not add due to rounding.
[2]	Reflects legacy Medivation and legacy Anacor amounts in 2016, commencing on the Medivation acquisition date, September 28, 2016, and Anacor acquisition date, June 24, 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date, September 3, 2015.
[3]	The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $457 million to Assets held for sale (see Note 2B) and, to a lesser extent, impairments and the impact of foreign exchange, partially offset by capital additions.

Identifiable Intangible Asset95

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		$ 87,351	$ 81,205
Finite-lived intangible assets, accumulated amortization		(51,687)	(49,040)
Finite-lived intangible assets, less accumulated amortization		35,664	32,165
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		16,984	8,192
Intangible assets, gross carrying amount		104,335	89,396
Identifiable Intangible Assets, less Accumulated Amortization	[1]	52,648	40,356
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		6,883	7,021
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	[2]	10,101	1,171
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		83,390	77,613
Finite-lived intangible assets, accumulated amortization		(49,650)	(47,193)
Finite-lived intangible assets, less accumulated amortization		33,740	30,419
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		2,092	1,973
Finite-lived intangible assets, accumulated amortization		(1,032)	(928)
Finite-lived intangible assets, less accumulated amortization		1,060	1,044
Licensing Agreements And Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		1,869	1,619
Finite-lived intangible assets, accumulated amortization		(1,005)	(918)
Finite-lived intangible assets, less accumulated amortization		864	701
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Indefinite-lived Intangible Assets [Line Items]
Identifiable intangible assets		$ 1,319	$ 0
[1]	Amounts may not add due to rounding.
[2]	The increase in Identifiable intangible assets, less accumulated amortization, is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A), and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale (see Note 2B). For information about impairments, see Note 4. The increase in IPR&D, is primarily related to assets acquired as part of the acquisitions of Anacor and Medivation, largely crisaborole and Xtandi. The intellectual property for crisaborole is owned by an international entity.

Identifiable Intangible Asset96

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Dec. 31, 2016
Operating Segments [Member] | Innovative Health Segment [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	64.00%
Operating Segments [Member] | Innovative Health Segment [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	73.00%
Operating Segments [Member] | Essential Health Segment [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	35.00%
Operating Segments [Member] | Essential Health Segment [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	27.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	0.00%

Identifiable Intangible Asset97

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Dec. 31, 2016
Operating Segments [Member] | Innovative Health Segment [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	71.00%
Operating Segments [Member] | Innovative Health Segment [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	92.00%
Operating Segments [Member] | Essential Health Segment [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	29.00%
Operating Segments [Member] | Essential Health Segment [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	5.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	4.00%

Identifiable Intangible Asset98

Identifiable Intangible Assets and Goodwill - Narrative (Details) $ in Billions	12 Months Ended
	Dec. 31, 2016USD ($)Operating_Segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of operating segments | Operating_Segment	2
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets | $	$ 4.1	$ 3.8	$ 4.1
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	11 years

Identifiable Intangible Asset99

Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details) $ in Millions	Dec. 31, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 4,827
2,018	4,706
2,019	4,481
2,020	3,442
2,021	$ 3,348

Identifiable Intangible Asse100

Identifiable Intangible Assets and Goodwill - Goodwill (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015
Goodwill [Roll Forward]
Beginning balance		$ 48,242	[1]	$ 42,069
Additions		6,369	[2]	7,323	[3]
Other		(162)	[4]	(1,149)	[5]
Ending balance	[1]	54,449		48,242
Innovative Health Segment [Member]
Goodwill [Roll Forward]
Beginning balance		23,809		24,430
Additions		6,357	[2]	39	[3]
Other		(32)	[4]	(660)	[5]
Ending balance		30,134		23,809
Essential Health Segment [Member]
Goodwill [Roll Forward]
Beginning balance		24,433		17,639
Additions		12	[2]	7,284	[3]
Other		(130)	[4]	(489)	[5]
Ending balance		24,315		24,433
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Goodwill [Roll Forward]
Goodwill		$ 119		$ 0
[1]	Amounts may not add due to rounding.
[2]	IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo and are subject to change until we complete the valuations of assets acquired and liabilities assumed from Medivation, Anacor and Bamboo (see Note 2A).
[3]	EH additions relate to our acquisition of Hospira. For additional information, see Note 2A.
[4]	Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $119 million to Assets held for sale during 2016 (see Note 2B).
[5]	Primarily reflects the impact of foreign exchange.

Pension and Postretirement B101

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) - USD ($) $ in Millions		Sep. 03, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, cost recognized			$ 317	$ 287	$ 278
Hospira [Member]
Defined Benefit Plan Disclosure [Line Items]
Benefit obligation		$ 115
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Benefit obligation	[1],[2]		$ 15,547	$ 14,926	$ 16,575
U.S. Qualified Pension Plans [Member] | Hospira [Member]
Defined Benefit Plan Disclosure [Line Items]
Increase in benefit obligation from plan termination		$ 122
[1]	For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $15.4 billion in 2016 and $14.8 billion in 2015. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2016 and $1.3 billion in 2015. The ABO for our international pension plans was $9.3 billion in 2016 and $8.8 billion in 2015.
[2]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016.

Pension and Postretirement B102

Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details) - USD ($) $ in Millions		Jan. 15, 2015	Jan. 31, 2017	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[1]			$ 257	[2],[3]	$ 287	[2],[3]	$ 253
Interest cost	[1]			646	[2],[3]	676	[2],[3]	697
Expected return on plan assets	[1]			(958)		(1,089)		(1,043)
Amortization of actuarial losses	[1]			395		346		63
Amortization of prior service credits	[1]			5		(5)		(7)
Curtailments	[1]			10		3		2
Settlements	[1]			90		556		52
Special termination benefits	[1]			0	[2],[3]	0	[2],[3]	0
Net periodic benefit costs/(income) reported in Income	[1]			444		773		16
(Income)/cost reported in Other comprehensive loss	[1],[4]			253		(396)		2,768
(Income)/cost recognized in Comprehensive income	[1]			697		378		$ 2,784
Decrease in plan assets						1,100
Settlements						419
Voluntary contribution		$ 1,000		$ 1,000	[3]	$ 1,000	[3]
Expected return on plan assets, percentage				8.00%		8.30%		8.50%
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[5]			$ 18	[2],[6]	$ 22	[2],[6]	$ 20
Interest cost	[5]			53	[2],[6]	54	[2],[6]	57
Expected return on plan assets	[5]			0		0		0
Amortization of actuarial losses	[5]			37		44		29
Amortization of prior service credits	[5]			(1)		(2)		(2)
Curtailments	[5]			1		0		0
Settlements	[5]			28		34		28
Special termination benefits	[5]			0	[2],[6]	0	[2],[6]	0
Net periodic benefit costs/(income) reported in Income	[5]			137		153		132
(Income)/cost reported in Other comprehensive loss	[4],[5]			121		(143)		163
(Income)/cost recognized in Comprehensive income	[5]			258		10		294
Voluntary contribution	[6]			151		158
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[7]			165	[2],[8]	186	[2],[8]	199
Interest cost	[7]			233	[2],[8]	307	[2],[8]	394
Expected return on plan assets	[7]			(381)		(418)		(459)
Amortization of actuarial losses	[7]			93		122		97
Amortization of prior service credits	[7]			(3)		(7)		(7)
Curtailments	[7]			(2)		5		0
Settlements	[7]			9		81		22
Special termination benefits	[7]			1	[2],[8]	1	[2],[8]	8
Net periodic benefit costs/(income) reported in Income	[7]			115		277		254
(Income)/cost reported in Other comprehensive loss	[4],[7]			640		(542)		260
(Income)/cost recognized in Comprehensive income	[7]			755		(265)		$ 514
Voluntary contribution	[8]			$ 209		$ 558
Expected return on plan assets, percentage				5.20%		5.50%		5.80%
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[9]			$ 41	[2],[10]	$ 55	[2],[10]	$ 55
Interest cost	[9]			101	[2],[10]	117	[2],[10]	169
Expected return on plan assets	[9]			(34)		(53)		(63)
Amortization of actuarial losses	[9]			32		38		6
Amortization of prior service credits	[9]			(174)		(146)		(57)
Curtailments	[9]			(26)		(31)		(7)
Settlements	[9]			0		0		0
Special termination benefits	[9]			0	[2],[10]	0	[2],[10]	0
Net periodic benefit costs/(income) reported in Income	[9]			(59)		(21)		102
(Income)/cost reported in Other comprehensive loss	[4],[9]			3		(540)		(174)
(Income)/cost recognized in Comprehensive income	[9]			(56)		(560)		$ (72)
Voluntary contribution	[10]			$ (12)		$ 84
Expected return on plan assets, percentage				8.00%		8.30%		8.50%
Subsequent Event [Member] | U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Voluntary contribution			$ 1,000
Change in Accounting Method Accounted for as Change in Estimate [Member] | International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected reduction in net periodic benefit costs				$ 42
[1]	2016 v. 2015––The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a year-over-year decrease in settlement activity compared to that of 2015 related to the non-recurring lump-sum settlement option to certain plan participants discussed in the 2015 v. 2014 analysis, below, (ii) lower service costs resulting from a higher discount rate, and (iii) lower interest costs resulting from a lower beginning benefit obligation. The aforementioned decreases were partially offset by (i) a lower expected return on plan assets resulting from both a lower expected rate of return, and a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, and (ii) an increase in the amounts amortized for actuarial losses, primarily resulting from the remeasurement in 2015 of Hospira’s U.S. qualified pension plan due to its plan termination. 2015 v. 2014––The increase in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a non-recurring charge of $419 million related to the settlement of pension obligations in accordance with an offer to certain terminated employees who are vested in their pension benefits to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or an annuity of their deferred vested pension benefits, and (ii) the increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation (which increased the amount of deferred actuarial losses), and, to a lesser extent, a 2014 change in mortality assumptions (reflecting a longer life expectancy for plan participants). The aforementioned increases were partially offset by (i) a greater expected return on plan assets resulting from an increased plan asset base due to a voluntary contribution of $1.0 billion made at the beginning of January 2015, which in turn was partially offset by a decrease in the expected rate of return on plan assets from 8.5% to 8.3% and (ii) lower interest costs resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.
[2]	For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $15.4 billion in 2016 and $14.8 billion in 2015. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2016 and $1.3 billion in 2015. The ABO for our international pension plans was $9.3 billion in 2016 and $8.8 billion in 2015.
[3]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016.
[4]	For details of the changes in Other comprehensive loss, see the benefit plan activity in the consolidated statements of comprehensive income.
[5]	2016 v. 2015––The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation, (ii) lower settlement activity, and (iii) lower service costs resulting from a higher discount rate. 2015 v. 2014––The increase in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (ii) higher settlement activity.
[6]	Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations. The increase in the benefit obligation is primarily due to a decrease in the discount rate.
[7]	2016 v. 2015––The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) lower service and interest costs, resulting from a change in our approach for measuring service and interest costs (see (f) below), (ii) lower settlement activity, and (iii) a decrease in the amounts amortized for actuarial losses resulting from large gains in 2015, which decreased the plan net loss position. The aforementioned decreases to our net periodic benefit costs were partially offset by a decrease in the expected return on plan assets due to a lower asset base and a lower expected rate of return on plan assets.2015 v. 2014––The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets, (ii) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (iii) higher settlement charges due to the settlement of a pension plan in Sweden. The aforementioned increase in net periodic benefit costs was partially offset by the decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.
[8]	The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets.
[9]	2016 v. 2015––The increase in net periodic benefit income for our postretirement plans was primarily driven by (i) an increase in prior service credits due to the postretirement medical plan cap changes during 2016 and 2015, (ii) lower interest costs resulting from a lower benefit obligation, (iii) lower service costs resulting from a higher discount rate, and (iv) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. The aforementioned changes were partially offset by (i) a decrease in expected return on plan assets, primarily resulting from a decrease in plan assets, reflecting payments by the plan for IRC Section 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees, and (ii) lower curtailment gains.2015 v. 2014––The decrease in net periodic benefit costs for our postretirement plans was primarily driven by (i) the increase in the amounts amortized for prior service credits and (ii) an increase in curtailment gains resulting from the implementation of changes to certain retiree medical benefits to adopt programs eligible for the Medicare Part D plan subsidy, as allowed under the EGWP, and another plan change to establish benefit caps for certain plan participants, as well as (iii) a decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. The aforementioned decreases were partially offset by an increase in actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.
[10]	The favorable change in the funded status of our postretirement plans was primarily due to plan amendments for certain U.S. and Puerto Rico postretirement plans. The U.S. plan change applied a fixed cap on costs for certain groups within the plan. The Puerto Rico plan change includes: (i) a cap on costs for certain groups within the plan, and (ii) the adoption of the EGWP. The changes resulted in reductions to the plan liabilities of $82 million for the U.S. postretirement plan and $95 million for the Puerto Rico postretirement plan.

Pension and Postretirement B103

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ (414)
Prior service credits and other	(5)
Total	(419)
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	(50)
Prior service credits and other	1
Total	(49)
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	(113)
Prior service credits and other	4
Total	(109)
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	(31)
Prior service credits and other	184
Total	$ 153

Pension and Postretirement B104

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
U.S. Qualified Pension Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		4.30%	4.50%	4.20%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase		2.80%	2.80%	2.80%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate		4.50%	4.20%	5.20%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets		8.00%	8.30%	8.50%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase		2.80%	2.80%	2.80%
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		4.20%	4.50%	4.00%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase		2.80%	2.80%	2.80%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate		4.50%	4.00%	4.80%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase		2.80%	2.80%	2.80%
International Pension Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		2.40%	3.10%	3.00%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase		2.60%	2.60%	2.70%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine interest cost, Discount rate	[1]	2.70%	3.00%	3.90%
Weighted-average assumptions used to determine service cost, Discount rate	[1]	3.00%	3.00%	3.90%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets		5.20%	5.50%	5.80%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase		2.60%	2.70%	2.90%
Postretirement Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		4.20%	4.50%	4.20%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate		4.50%	4.20%	5.10%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets		8.00%	8.30%	8.50%
[1]	effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with this change, the effective rate for interest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans.

Pension and Postretirement B105

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) - Postretirement Plans [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Healthcare cost trend rate assumed for next year (up to age 65)	6.30%	6.50%
Healthcare cost trend rate assumed for next year (age 65 and older)	7.40%	7.90%
Rate to which the cost trend rate is assumed to decline	4.50%	4.50%
Year that the rate reaches the ultimate trend rate	2,037	2,037

Pension and Postretirement B106

Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details) - Postretirement Plans [Member] $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Defined Benefit Plan Disclosure [Line Items]
Effect on total service and interest cost components, increase	$ 5
Effect on total service and interest cost components, decrease	(5)
Effect on postretirement benefit obligation, increase	37
Effect on postretirement benefit obligation, decrease	$ (50)

Pension and Postretirement B107

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) - USD ($) $ in Millions		Jan. 15, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
U.S. Qualified Pension Plans [Member]
Change in benefit obligation
Benefit obligation, beginning	[1],[2]	$ 16,575	$ 14,926		$ 16,575
Service cost	[3]		257	[1],[2]	287	[1],[2]	$ 253
Interest cost	[3]		646	[1],[2]	676	[1],[2]	697
Employee contributions	[1],[2]		0		0
Plan amendments	[1],[2]		0		62
Changes in actuarial assumptions and other	[1],[2]		725		(774)
Foreign exchange impact	[1],[2]		0		0
Acquisitions/divestitures/other, net	[1],[2]		0		542
Curtailments	[1],[2]		9		3
Settlements	[1],[2]		(449)		(2,034)
Special termination benefits	[3]		0	[1],[2]	0	[1],[2]	0
Benefits paid	[1],[2]		(568)		(412)
Benefit obligation, ending	[1],[2]		15,547		14,926		16,575
Change in plan assets
Fair value of plan assets, beginning	[2]	12,706	11,633		12,706
Actual gain/(loss) on plan assets	[2]		(939)		124
Company contributions		1,000	1,000	[2]	1,000	[2]
Employee contributions	[1],[2]		0		0
Foreign exchange impact	[2]		0		0
Acquisitions/divestitures, net	[2]		0		496
Settlements	[2]		(449)		(2,034)
Benefits paid	[1],[2]		(568)		(412)
Fair value of plan assets, ending	[2]		12,556		11,633		12,706
Funded status—Plan assets less than benefit obligation	[2]		(2,990)		(3,292)
Defined benefit plan, accumulated benefit obligation			15,400		14,800
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Change in benefit obligation
Benefit obligation, beginning	[1],[4]	1,481	1,343		1,481
Service cost	[5]		18	[1],[4]	22	[1],[4]	20
Interest cost	[5]		53	[1],[4]	54	[1],[4]	57
Employee contributions	[1],[4]		0		0
Plan amendments	[1],[4]		0		4
Changes in actuarial assumptions and other	[1],[4]		185		(70)
Foreign exchange impact	[1],[4]		0		0
Acquisitions/divestitures/other, net	[1],[4]		0		9
Curtailments	[1],[4]		1		0
Settlements	[1],[4]		(78)		(93)
Special termination benefits	[5]		0	[1],[4]	0	[1],[4]	0
Benefits paid	[1],[4]		(72)		(65)
Benefit obligation, ending	[1],[4]		1,450		1,343		1,481
Change in plan assets
Fair value of plan assets, beginning	[4]	0	0		0
Company contributions	[4]		151		158
Employee contributions	[1],[4]		0		0
Foreign exchange impact	[4]		0		0
Settlements	[4]		(78)		(93)
Benefits paid	[1],[4]		(72)		(65)
Fair value of plan assets, ending	[4]		0		0		0
Funded status—Plan assets less than benefit obligation	[4]		(1,450)		(1,343)
Defined benefit plan, accumulated benefit obligation			1,400		1,300
International Pension Plans [Member]
Change in benefit obligation
Benefit obligation, beginning	[1],[6]	10,796	9,214		10,796
Service cost	[7]		165	[1],[6]	186	[1],[6]	199
Interest cost	[7]		233	[1],[6]	307	[1],[6]	394
Employee contributions	[1],[6]		7		7
Plan amendments	[1],[6]		(6)		(1)
Changes in actuarial assumptions and other	[1],[6]		1,273		(273)
Foreign exchange impact	[1],[6]		(781)		(938)
Acquisitions/divestitures/other, net	[1],[6]		1		19
Curtailments	[1],[6]		(14)		(2)
Settlements	[1],[6]		(45)		(499)
Special termination benefits	[7]		1	[1],[6]	1	[1],[6]	8
Benefits paid	[1],[6]		(358)		(389)
Benefit obligation, ending	[1],[6]		9,691		9,214		10,796
Change in plan assets
Fair value of plan assets, beginning	[6]	8,588	7,959		8,588
Actual gain/(loss) on plan assets	[6]		(693)		(290)
Company contributions	[6]		209		558
Employee contributions	[1],[6]		7		7
Foreign exchange impact	[6]		(782)		(602)
Acquisitions/divestitures, net	[6]		(1)		6
Settlements	[6]		(45)		(499)
Benefits paid	[1],[6]		(358)		(389)
Fair value of plan assets, ending	[6]		7,683		7,959		8,588
Funded status—Plan assets less than benefit obligation	[6]		(2,008)		(1,255)
Defined benefit plan, accumulated benefit obligation			9,300		8,800
Postretirement Plans [Member]
Change in benefit obligation
Benefit obligation, beginning	[1],[8]	3,168	2,463		3,168
Service cost	[9]		41	[1],[8]	55	[1],[8]	55
Interest cost	[9]		101	[1],[8]	117	[1],[8]	169
Employee contributions	[1],[8]		85		79
Plan amendments	[1],[8]		(177)		(497)
Changes in actuarial assumptions and other	[1],[8]		22		(185)
Foreign exchange impact	[1],[8]		0		(20)
Acquisitions/divestitures/other, net	[1],[8]		0		49
Curtailments	[1],[8]		0		(3)
Settlements	[1],[8]		0		0
Special termination benefits	[9]		0	[1],[8]	0	[1],[8]	0
Benefits paid	[1],[8]		(282)		(300)
Benefit obligation, ending	[1],[8]		2,254		2,463		3,168
Change in plan assets
Fair value of plan assets, beginning	[8]	$ 762	622	[10]	762
Actual gain/(loss) on plan assets	[8]		(44)		3
Company contributions	[8]		(12)		84
Employee contributions	[1],[8]		85		79
Foreign exchange impact	[8]		0		0
Acquisitions/divestitures, net	[8]		0		0
Settlements	[8]		0		0
Benefits paid	[1],[8]		(282)		(300)
Fair value of plan assets, ending	[8]		458	[10]	622	[10]	$ 762
Funded status—Plan assets less than benefit obligation	[8]		(1,796)		$ (1,841)
United States Postretirement Benefit Plan of US Entity [Member]
Change in plan assets
Reduction in posteretirement plan liabilities			82
Foreign Postretirement Benefit Plan [Member]
Change in plan assets
Reduction in posteretirement plan liabilities			$ 95
[1]	For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $15.4 billion in 2016 and $14.8 billion in 2015. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.4 billion in 2016 and $1.3 billion in 2015. The ABO for our international pension plans was $9.3 billion in 2016 and $8.8 billion in 2015.
[2]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016.
[3]	2016 v. 2015––The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a year-over-year decrease in settlement activity compared to that of 2015 related to the non-recurring lump-sum settlement option to certain plan participants discussed in the 2015 v. 2014 analysis, below, (ii) lower service costs resulting from a higher discount rate, and (iii) lower interest costs resulting from a lower beginning benefit obligation. The aforementioned decreases were partially offset by (i) a lower expected return on plan assets resulting from both a lower expected rate of return, and a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, and (ii) an increase in the amounts amortized for actuarial losses, primarily resulting from the remeasurement in 2015 of Hospira’s U.S. qualified pension plan due to its plan termination. 2015 v. 2014––The increase in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) a non-recurring charge of $419 million related to the settlement of pension obligations in accordance with an offer to certain terminated employees who are vested in their pension benefits to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or an annuity of their deferred vested pension benefits, and (ii) the increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation (which increased the amount of deferred actuarial losses), and, to a lesser extent, a 2014 change in mortality assumptions (reflecting a longer life expectancy for plan participants). The aforementioned increases were partially offset by (i) a greater expected return on plan assets resulting from an increased plan asset base due to a voluntary contribution of $1.0 billion made at the beginning of January 2015, which in turn was partially offset by a decrease in the expected rate of return on plan assets from 8.5% to 8.3% and (ii) lower interest costs resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.
[4]	Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations. The increase in the benefit obligation is primarily due to a decrease in the discount rate.
[5]	2016 v. 2015––The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation, (ii) lower settlement activity, and (iii) lower service costs resulting from a higher discount rate. 2015 v. 2014––The increase in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (ii) higher settlement activity.
[6]	The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets.
[7]	2016 v. 2015––The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) lower service and interest costs, resulting from a change in our approach for measuring service and interest costs (see (f) below), (ii) lower settlement activity, and (iii) a decrease in the amounts amortized for actuarial losses resulting from large gains in 2015, which decreased the plan net loss position. The aforementioned decreases to our net periodic benefit costs were partially offset by a decrease in the expected return on plan assets due to a lower asset base and a lower expected rate of return on plan assets.2015 v. 2014––The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets, (ii) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (iii) higher settlement charges due to the settlement of a pension plan in Sweden. The aforementioned increase in net periodic benefit costs was partially offset by the decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.
[8]	The favorable change in the funded status of our postretirement plans was primarily due to plan amendments for certain U.S. and Puerto Rico postretirement plans. The U.S. plan change applied a fixed cap on costs for certain groups within the plan. The Puerto Rico plan change includes: (i) a cap on costs for certain groups within the plan, and (ii) the adoption of the EGWP. The changes resulted in reductions to the plan liabilities of $82 million for the U.S. postretirement plan and $95 million for the Puerto Rico postretirement plan.
[9]	2016 v. 2015––The increase in net periodic benefit income for our postretirement plans was primarily driven by (i) an increase in prior service credits due to the postretirement medical plan cap changes during 2016 and 2015, (ii) lower interest costs resulting from a lower benefit obligation, (iii) lower service costs resulting from a higher discount rate, and (iv) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. The aforementioned changes were partially offset by (i) a decrease in expected return on plan assets, primarily resulting from a decrease in plan assets, reflecting payments by the plan for IRC Section 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees, and (ii) lower curtailment gains.2015 v. 2014––The decrease in net periodic benefit costs for our postretirement plans was primarily driven by (i) the increase in the amounts amortized for prior service credits and (ii) an increase in curtailment gains resulting from the implementation of changes to certain retiree medical benefits to adopt programs eligible for the Medicare Part D plan subsidy, as allowed under the EGWP, and another plan change to establish benefit caps for certain plan participants, as well as (iii) a decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. The aforementioned decreases were partially offset by an increase in actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.
[10]	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.

Pension and Postretirement B108

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	$ 0	$ 0
Current liabilities	[2]	(160)	0
Noncurrent liabilities	[3]	(2,830)	(3,292)
Funded status		(2,990)	(3,292)
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	0	0
Current liabilities	[2]	(152)	(126)
Noncurrent liabilities	[3]	(1,297)	(1,216)
Funded status		(1,450)	(1,343)
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	300	572
Current liabilities	[2]	(28)	(25)
Noncurrent liabilities	[3]	(2,279)	(1,801)
Funded status		(2,008)	(1,255)
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	0	0
Current liabilities	[2]	(30)	(31)
Noncurrent liabilities	[3]	(1,766)	(1,809)
Funded status		$ (1,796)	$ (1,841)
[1]	Included primarily in Other noncurrent assets.
[2]	Included in Accrued compensation and related items.
[3]	Included in Pension benefit obligations, net and Postretirement benefit obligations, net, as appropriate.

Pension and Postretirement B109

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($) $ in Millions		Dec. 31, 2016	Dec. 31, 2015
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	$ (4,530)	$ (4,272)
Prior service (costs)/credits		(27)	(33)
Total		(4,558)	(4,305)
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	(538)	(419)
Prior service (costs)/credits		2	4
Total		(536)	(415)
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	(2,629)	(1,979)
Prior service (costs)/credits		40	29
Total		(2,589)	(1,949)
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	(502)	(523)
Prior service (costs)/credits		1,392	1,415
Total		$ 889	$ 892
[1]	The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants, using the corridor approach. The average amortization periods to be utilized for 2017 are 8.2 years for our U.S. qualified plans, 8.1 years for our U.S. supplemental (non-qualified) plans, 19.3 years for our international plans, and 9.1 years for our postretirement plans.

Pension and Postretirement B110

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income - Footnotes (Details)	12 Months Ended
	Dec. 31, 2016
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	8 years 2 months 12 days
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	8 years 1 month 6 days
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	19 years 3 months 18 days
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Average period actuarial losses are amortized into net periodic pension costs	9 years 1 month 6 days

Pension and Postretirement B111

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
U.S. Qualified Pension Plans [Member]
Pension plans with an ABO in excess of plan assets:
Fair value of plan assets	$ 12,556	$ 11,633
ABO	15,422	14,755
Pension plans with a PBO in excess of plan assets:
Fair value of plan assets	12,556	11,633
PBO	15,547	14,926
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Pension plans with an ABO in excess of plan assets:
ABO	1,410	1,324
Pension plans with a PBO in excess of plan assets:
PBO	1,450	1,343
International Pension Plans [Member]
Pension plans with an ABO in excess of plan assets:
Fair value of plan assets	4,625	976
ABO	6,558	2,495
Pension plans with a PBO in excess of plan assets:
Fair value of plan assets	4,936	1,546
PBO	$ 7,244	$ 3,373

Pension and Postretirement B112

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) - USD ($) $ in Millions		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	$ 12,556		$ 11,633		$ 12,706
Assets Measured at NAV	[2]	2,615		2,636
U.S. Qualified Pension Plans [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	4,049		3,801
U.S. Qualified Pension Plans [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	5,891		5,193
U.S. Qualified Pension Plans [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	1		3
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		672		417
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	92		81
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	580		336
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		3,970		3,720
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1,062		951
Assets Measured at NAV	[2]	290		262
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	3,943		3,717
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	27		2
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	772		689
U.S. Qualified Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 3 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	0		1
U.S. Qualified Pension Plans [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		3,232		2,866
U.S. Qualified Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	14		3
U.S. Qualified Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	3,217		2,861
U.S. Qualified Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	1		2
U.S. Qualified Pension Plans [Member] | Government and Agency Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1,060		989
U.S. Qualified Pension Plans [Member] | Government and Agency Obligations [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	1,060		989
U.S. Qualified Pension Plans [Member] | Government and Agency Obligations [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	0
U.S. Qualified Pension Plans [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		92		222
Assets Measured at NAV	[2]	92		165
U.S. Qualified Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	0		57
U.S. Qualified Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	0		0
U.S. Qualified Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	1,093		1,120
Assets Measured at NAV	[2],[4]	1,093		1,120
U.S. Qualified Pension Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[4]	0		0
U.S. Qualified Pension Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		235		259
U.S. Qualified Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	0
U.S. Qualified Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	235		259
U.S. Qualified Pension Plans [Member] | Other Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[5]	1,140		1,089
Assets Measured at NAV	[2],[5]	1,140		1,089
U.S. Qualified Pension Plans [Member] | Other Commingled Funds [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[5]	0		0
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[6]	7,683		7,959		8,588
Assets Measured at NAV	[2]	2,346		2,155
International Pension Plans [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	201		1,222
International Pension Plans [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	4,558		3,965
International Pension Plans [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	578		618
International Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		439		207
International Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	38		14
International Pension Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	401		193
International Pension Plans [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		174		901
International Pension Plans [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,490		2,218
Assets Measured at NAV	[2]	1,224		1,348
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	163		816
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]			16
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	11		85
International Pension Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	1,265		854
International Pension Plans [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		489		653
Assets Measured at NAV	[2]	15		12
International Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]			171
International Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	474		469
International Pension Plans [Member] | Corporate debt [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	0		0
International Pension Plans [Member] | Government and Agency Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		853		1,224
Assets Measured at NAV	[2]	67		67
International Pension Plans [Member] | Government and Agency Obligations [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]			109
International Pension Plans [Member] | Government and Agency Obligations [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	786		1,048
International Pension Plans [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1,750		1,216
Assets Measured at NAV	[2]	576		260
International Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]			37
International Pension Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	1,174		919
International Pension Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	32		40
Assets Measured at NAV	[2],[4]	32		33
International Pension Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[4]			0
International Pension Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[4]	0		6
International Pension Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[4]	0		0
International Pension Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		272		257
Assets Measured at NAV	[2]	1		17
International Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3]	17		21
International Pension Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		254	[3]	219	[3],[7]	254	[7]
International Pension Plans [Member] | Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[5]	1,185		1,245
Assets Measured at NAV	[2],[5]	431		418
International Pension Plans [Member] | Other [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[5]			59
International Pension Plans [Member] | Other [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[5]	430		370
International Pension Plans [Member] | Other [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		324	[3],[5]	398	[3],[5],[7]	395	[7]
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[9]	458	[8]	622	[8]	$ 762
Assets Measured at NAV	[2],[8]			45
Postretirement Plans [Member] | Fair value inputs Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		64
Postretirement Plans [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	458		514
Postretirement Plans [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		0
Postretirement Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	0		6
Postretirement Plans [Member] | Cash and Cash Equivalents [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		6
Postretirement Plans [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	0		64
Postretirement Plans [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	0		16
Assets Measured at NAV	[2],[8]			4
Postretirement Plans [Member] | Equity Securities [Member] | Fair value inputs Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		64
Postretirement Plans [Member] | Equity Securities [Member] | Fair value inputs Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		12
Postretirement Plans [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	0		49
Postretirement Plans [Member] | Corporate debt [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		49
Postretirement Plans [Member] | Government and Agency Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	0		17
Postretirement Plans [Member] | Government and Agency Obligations [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		17
Postretirement Plans [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	0		4
Assets Measured at NAV	[2],[8]			3
Postretirement Plans [Member] | Fixed Income Commingled Funds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	0		1
Postretirement Plans [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[8]	0		19
Assets Measured at NAV	[2],[4],[8]			19
Postretirement Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[4],[8]	0		0
Postretirement Plans [Member] | Partnership Interest [Member] | Fair value inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[4],[8]	0		0
Postretirement Plans [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	458		429
Postretirement Plans [Member] | Insurance Contracts [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[8]	458		429
Postretirement Plans [Member] | Other Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[5],[8]	0		19
Assets Measured at NAV	[2],[5],[8]			19
Postretirement Plans [Member] | Other Commingled Funds [Member] | Fair value inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[3],[5],[8]	$ 0		$ 0
[1]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016.
[2]	In accordance with the provisions of a new accounting standard we adopted on January 1, 2016, described below, certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets. As a result, a reclassification has been made to the prior year’s plan asset classification table to conform to the current year’s presentation.
[3]	Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E).
[4]	Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.
[5]	Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
[6]	The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets.
[7]	We adopted a new accounting standard as of January 1, 2016 whereby certain investments in 2016 and 2015 that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been classified as Level 1, 2 or 3 in the above fair value hierarchy table, but are included in the total. As a result, a reclassification has been made to the prior year's plan asset classification table to conform to the current year's presentation.
[8]	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
[9]	The favorable change in the funded status of our postretirement plans was primarily due to plan amendments for certain U.S. and Puerto Rico postretirement plans. The U.S. plan change applied a fixed cap on costs for certain groups within the plan. The Puerto Rico plan change includes: (i) a cap on costs for certain groups within the plan, and (ii) the adoption of the EGWP. The changes resulted in reductions to the plan liabilities of $82 million for the U.S. postretirement plan and $95 million for the Puerto Rico postretirement plan.

Pension and Postretirement B113

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) - International Pension Plans [Member] - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[1]	$ 7,959		$ 8,588
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Exchange rate changes	[1]	(782)		(602)
Fair value of plan assets, ending	[1]	7,683		7,959
Insurance Contracts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning		257
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending		272		257
Other Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[2]	1,245
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	[2]	1,185		1,245
Fair value inputs Level 3 [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[3]	618
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Fair value of plan assets, ending	[3]	578		618
Fair value inputs Level 3 [Member] | Insurance Contracts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[4]	219	[3]	254
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Assets held, ending		11		16
Purchases, sales and settlements, net		20		(19)
Exchange rate changes		4		(33)
Fair value of plan assets, ending	[3]	254		219	[4]
Fair value inputs Level 3 [Member] | Other Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[4]	398	[2],[3]	395
Defined Benefit Plan, Actual Return on Plan Assets [Abstract]
Assets held, ending		(1)		30
Assets sold during the period		6		13
Purchases, sales and settlements, net		(18)		(21)
Exchange rate changes		(61)		(19)
Fair value of plan assets, ending	[2],[3]	$ 324		$ 398	[4]
[1]	The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets.
[2]	Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
[3]	Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E).
[4]	We adopted a new accounting standard as of January 1, 2016 whereby certain investments in 2016 and 2015 that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been classified as Level 1, 2 or 3 in the above fair value hierarchy table, but are included in the total. As a result, a reclassification has been made to the prior year's plan asset classification table to conform to the current year's presentation.

Pension and Postretirement B114

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		100.00%
Equity and debt securities, percentage of plan assets		99.90%		100.00%
Plan assets	[1]	$ 12,556		$ 11,633		$ 12,706
U.S. Qualified Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		0.00%
Equity and debt securities, target allocation percentage, maximum		10.00%
Equity and debt securities, percentage of plan assets		5.30%		3.60%
U.S. Qualified Pension Plans [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		35.00%
Equity and debt securities, target allocation percentage, maximum		55.00%
Equity and debt securities, percentage of plan assets		40.10%		40.20%
U.S. Qualified Pension Plans [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		30.00%
Equity and debt securities, target allocation percentage, maximum		55.00%
Equity and debt securities, percentage of plan assets		34.90%		35.00%
U.S. Qualified Pension Plans [Member] | Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	[2]	5.00%
Equity and debt securities, target allocation percentage, maximum	[2]	17.50%
Equity and debt securities, percentage of plan assets	[2]	19.70%		21.20%
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		100.00%
Equity and debt securities, percentage of plan assets		100.00%		100.00%
Plan assets	[3]	$ 7,683		$ 7,959		8,588
International Pension Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		0.00%
Equity and debt securities, target allocation percentage, maximum		10.00%
Equity and debt securities, percentage of plan assets		5.70%		2.60%
International Pension Plans [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		25.00%
Equity and debt securities, target allocation percentage, maximum		50.00%
Equity and debt securities, percentage of plan assets		34.70%		39.20%
International Pension Plans [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		30.00%
Equity and debt securities, target allocation percentage, maximum		55.00%
Equity and debt securities, percentage of plan assets		40.20%		38.80%
International Pension Plans [Member] | Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum	[2]	10.00%
Equity and debt securities, target allocation percentage, maximum	[2]	30.00%
Equity and debt securities, percentage of plan assets		19.40%		19.40%
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		100.00%
Equity and debt securities, percentage of plan assets		100.00%		100.00%
Plan assets	[5]	$ 458	[4]	$ 622	[4]	$ 762
Postretirement Plans [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		0.00%
Equity and debt securities, target allocation percentage, maximum		5.00%
Equity and debt securities, percentage of plan assets		0.00%		1.00%
Postretirement Plans [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		0.00%
Equity and debt securities, percentage of plan assets		0.00%		12.80%
Postretirement Plans [Member] | Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		0.00%
Equity and debt securities, percentage of plan assets		0.00%		11.20%
Postretirement Plans [Member] | Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage, minimum		95.00%
Equity and debt securities, target allocation percentage, maximum		100.00%
Equity and debt securities, percentage of plan assets		100.00%		75.00%
Insurance Contracts [Member] | U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets		$ 235		$ 259
Insurance Contracts [Member] | U.S. Qualified Pension Plans [Member] | Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets		235		259
Insurance Contracts [Member] | International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets		272		257
Insurance Contracts [Member] | Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets	[4]	458		429
Equity Securities [Member] | U.S. Qualified Pension Plans [Member] | Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets		$ 144		$ 129
[1]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016.
[2]	Actual percentage of plan assets in Other investments for 2016 includes $235 million (this amount was $259 million in 2015) related to a group fixed annuity insurance contract that was executed by legacy Wyeth for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $144 million (this amount was $129 million in 2015) related to an investment in a partnership whose primary holdings are public equity securities.
[3]	The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets.
[4]	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
[5]	The favorable change in the funded status of our postretirement plans was primarily due to plan amendments for certain U.S. and Puerto Rico postretirement plans. The U.S. plan change applied a fixed cap on costs for certain groups within the plan. The Puerto Rico plan change includes: (i) a cap on costs for certain groups within the plan, and (ii) the adoption of the EGWP. The changes resulted in reductions to the plan liabilities of $82 million for the U.S. postretirement plan and $95 million for the Puerto Rico postretirement plan.

Pension and Postretirement B115

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details) - USD ($) $ in Millions		Jan. 15, 2015	Jan. 31, 2017	Dec. 31, 2016		Dec. 31, 2015
U.S. Qualified Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2017	[1]			$ 1,160
Expected benefit payments:
2,017				1,519
2,018				1,058
2,019				947
2,020				952
2,021				930
2022-2026				4,391
Company contributions		$ 1,000		1,000	[2]	$ 1,000	[2]
U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2017	[1]			152
Expected benefit payments:
2,017				152
2,018				128
2,019				118
2,020				119
2,021				112
2022-2026				503
Company contributions	[3]			151		158
International Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2017	[1]			175
Expected benefit payments:
2,017				331
2,018				333
2,019				335
2,020				350
2,021				356
2022-2026				1,867
Company contributions	[4]			209		558
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2017	[1]			179
Expected benefit payments:
2,017				186
2,018				196
2,019				198
2,020				197
2,021				196
2022-2026				919
Company contributions	[5]			$ (12)		$ 84
Subsequent Event [Member] | U.S. Qualified Pension Plans [Member]
Expected benefit payments:
Company contributions			$ 1,000
[1]	For the U.S. qualified plans, the $1.0 billion voluntary contribution, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums, was paid in January 2017.
[2]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2016.
[3]	Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations. The increase in the benefit obligation is primarily due to a decrease in the discount rate.
[4]	The unfavorable change in the international plans’ funded status was primarily due to plan losses related to a decrease in the discount rate (reflecting lower interest rates), partially offset by an increase in the actual return on plan assets.
[5]	The favorable change in the funded status of our postretirement plans was primarily due to plan amendments for certain U.S. and Puerto Rico postretirement plans. The U.S. plan change applied a fixed cap on costs for certain groups within the plan. The Puerto Rico plan change includes: (i) a cap on costs for certain groups within the plan, and (ii) the adoption of the EGWP. The changes resulted in reductions to the plan liabilities of $82 million for the U.S. postretirement plan and $95 million for the Puerto Rico postretirement plan.

Equity - Summary of Common Stoc

Equity - Summary of Common Stock Purchases (Details) - USD ($) shares in Millions, $ in Millions		Jun. 20, 2016	Mar. 10, 2016	Jul. 13, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Equity [Abstract]
Shares of common stock purchased		18	136	151	154	[1]	182	[2]	165
Cost of purchase	[3]				$ 5,000	[1]	$ 6,160	[2]	$ 5,000
Payments for repurchase of common stock				$ 5,200	$ 5,000	[4]	$ 6,160	[4]	$ 5,000	[4]
[1]	Represents shares purchased pursuant to and received upon settlement of the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.
[2]	Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.

Equity - Narrative (Details)

Equity - Narrative (Details)	Jun. 20, 2016$ / sharesshares	Mar. 10, 2016USD ($)$ / sharesshares	Mar. 08, 2016USD ($)	Jul. 13, 2015USD ($)$ / sharesshares	Dec. 31, 2016USD ($)employee_stock_ownership_plan$ / sharesshares		Dec. 31, 2015USD ($)shares		Dec. 31, 2014USD ($)shares		Feb. 11, 2015USD ($)	Oct. 23, 2014USD ($)	Jun. 27, 2013USD ($)
Equity, Class of Treasury Stock [Line Items]
Amount of shares authorized in stock purchase plan, value			$ 5,000,000,000				$ 11,000,000,000					$ 11,000,000,000	$ 10,000,000,000
Accelerated share repurchases, cash paid		$ 5,000,000,000		$ 160,000,000							$ 5,000,000,000
Shares repurchased | shares	18,000,000	136,000,000		151,000,000	154,000,000	[1]	182,000,000	[2]	165,000,000
Shares repurchased, initial price per share (in dollars per share) | $ / shares		$ 29.36
Accelerated share repurchase, percentage of agreement			80.00%
Accelerated share repurchase, final average price paid (in dollars per share) | $ / shares	$ 32.38			$ 34.13
Payments for repurchase of common stock				$ 5,200,000,000	$ 5,000,000,000	[3]	$ 6,160,000,000	[3]	$ 5,000,000,000	[3]
Amount of remaining shares authorized in stock purchase plan, value					$ 11,400,000,000
Number of employee stock ownership plans | employee_stock_ownership_plan					2
Common ESOP Plan [Member]
Equity, Class of Treasury Stock [Line Items]
ESOP compensation expense					$ 9,000,000		$ 8,000,000		$ 133,000,000
Preferred Stock [Member] | Series A, Convertible Preferred Stock [Member] | Preferred Employee Stock Ownership Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Series A convertible perpetual preferred stock, dividends rate					6.25%
Series A convertible perpetual preferred stock, per share stated value (in dollars per share) | $ / shares					$ 40,300
Preferred stock, redemption price per share (in dollars per share) | $ / shares					$ 40,300
Common Stock [Member] | Preferred Employee Stock Ownership Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Series A convertible perpetual preferred stock, common stock shares when converted | shares					2,574.87
Convertible preferred stock, number of shares convertible | shares					1,000,000
Common Stock [Member] | Common ESOP Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Number of shares in ESOP | shares					55,000,000
[1]	Represents shares purchased pursuant to and received upon settlement of the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.
[2]	Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.
[3]	Amounts may not add due to rounding.

Share-Based Payments - Narrativ

Share-Based Payments - Narrative (Detail)	12 Months Ended
	Dec. 31, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for award	391,000,000
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized	520,000,000
Number of equity awards period	36 months
Maximum shares available per individual during the plan period	20,000,000
2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares available per individual during the plan period	8,000,000
Restricted Stock Units (RSUs) [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Restricted Stock Units (RSUs) [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	2
Employee Stock Option [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1
Portfolio Performance Shares [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Portfolio Performance Shares [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	2,000,000
Performance Shares [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Performance Shares [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	2,000,000
Total Shareholder Return Units (TSRU) [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1
Total Shareholder Return Units (TSRU) [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1,000,000

Share-Based Payments - Impact o

Share-Based Payments - Impact on Net Income (Detail) - 2004 Stock Plan, Amended and Restated [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	$ 691	$ 669	$ 586
Tax benefit for share-based compensation expense	(205)	(198)	(179)
Share-based payment expense, net of tax	486	471	407
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	299	306	270
Portfolio Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	135	147	96
Total Shareholder Return Units (TSRU) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	134	36	37
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	106	165	150
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	13	11	30
Directors' compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense	$ 4	$ 4	$ 3

Share-Based Payments - Restrict

Share-Based Payments - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares | shares	29,135
Granted, shares | shares	10,581
Vested, shares | shares	(9,630)
Reinvested dividend equivalents, shares | shares	1,093
Forfeited, shares | shares	(1,574)
Nonvested, end of period, shares | shares	29,605
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 31.53
Granted, weighted-average grant-date fair value per share (in dollars per share) | $ / shares	30.74
Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares	27.41
Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share) | $ / shares	32.56
Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares	32.18
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.59

Share-Based Payments - Data Rel

Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 293	$ 371	$ 401
Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax	$ 262	$ 279	$ 255
Weighted-average period over which RSU cost is expected to be recognized (years)	1 year 8 months 12 days	1 year 9 months 18 days	1 year 9 months 18 days

Share-Based Payments - Stock Op

Share-Based Payments - Stock Option Narrative (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Contractual term (years)	10 years
Holding period	1 year
Exercise period in the event of a divestiture or restructuring	3 months

Share-Based Payments - Valuatio

Share-Based Payments - Valuation Assumptions of Stock Options (Detail) - Employee Stock Option [Member]		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	[1]	3.85%	3.19%	3.18%
Risk-free interest rate	[2]	1.55%	1.89%	1.94%
Expected stock price volatility	[3]	21.64%	18.34%	19.76%
Expected term (years)	[4]	6 years 9 months	6 years 9 months	6 years 6 months
[1]	Determined using a constant dividend yield during the expected term of the option.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility, after consideration of historical volatility.
[4]	Determined using historical exercise and post-vesting termination patterns.The following table summarizes all stock option activity during 2016: Shares(Thousands) Weighted-AverageExercise PricePer Share Weighted-AverageRemaining Contractual Term(Years) AggregateIntrinsic Value(a)(Millions)Outstanding, December 31, 2015 232,554 $26.41 Granted 1,371 30.59 Exercised (42,550) 24.03 Forfeited (2,949) 33.18 Expired (1,750) 28.55 Outstanding, December 31, 2016 186,676 26.86 5.7 $1,138Vested and expected to vest, December 31, 2016(b) 184,537 26.77 5.6 1,138Exercisable, December 31, 2016 105,862 $21.85 4.1 $1,126

Share-Based Payments - Stock124

Share-Based Payments - Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning of period, shares | shares	232,554
Granted, shares | shares	1,371
Exercised, shares | shares	(42,550)
Forfeited, shares | shares	(2,949)
Expired, shares | shares	(1,750)
Outstanding, end of period, shares | shares	186,676
Vested and expected to vest, end of period, shares | shares	184,537	[1]
Exercisable, end of period, shares | shares	105,862
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share) | $ / shares	$ 26.41
Granted, weighted-average exercise price per share (in dollars per share) | $ / shares	30.59
Exercised, weighted-average exercise price per share (in dollars per share) | $ / shares	24.03
Forfeited, weighted-average exercise price per share (in dollars per share) | $ / shares	33.18
Expired, weighted-average exercise price per share (in dollars per share) | $ / shares	28.55
Outstanding, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares	26.86
Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares	26.77	[1]
Exercisable, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares	$ 21.85
Outstanding, end of period, weighted-average remaining contractual term	5 years 8 months 12 days
Vested and expected to vest, end of period, weighted-average remaining contractual term	5 years 7 months 6 days	[1]
Exercisable, end of period, weighted-average remaining contractual term	4 years 1 month 6 days
Outstanding, end of period, aggregate intrinsic value | $	$ 1,138	[2]
Vested and expected to vest, end of period, aggregate intrinsic value | $	1,138	[1],[2]
Exercisable, end of period, aggregate intrinsic value | $	$ 1,126	[2]
[1]	The number of options expected to vest takes into account an estimate of expected forfeitures.
[2]	Market price of underlying Pfizer common stock less exercise price.

Share-Based Payments - Data 125

Share-Based Payments - Data Related to All Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per stock option (in dollars per share)	$ 3.89	$ 4.30	$ 4.40
Aggregate intrinsic value on exercise	$ 389	$ 666	$ 458
Cash received upon exercise	1,019	1,263	1,002
Tax benefits realized related to exercise	112	187	131
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost related to nonvested stock options not yet recognized, pre-tax	$ 58	$ 159	$ 147
Weighted-average period over which stock option compensation cost is expected to be recognized (years)	1 year 1 month 6 days	1 year 9 months 18 days	1 year 9 months 18 days

Share-Based Payments - Portfoli

Share-Based Payments - Portfolio Performance Shares Narrative (Details) - Portfolio Performance Shares [Member]	12 Months Ended
	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period	3 years
Award vesting period	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	200.00%

Share-Based Payments - Portf127

Share-Based Payments - Portfolio Performance Shares Activity (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Vested and expected to vest, end of period, shares	184,537,000	[1]
Portfolio Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	22,503,000
Granted, shares	8,059,000
Vested, shares	(6,900,000)	[2]
Forfeited, shares	(1,396,000)
Nonvested, end of period, shares	22,266,000	[2]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.28
Granted, weighted-average grant date fair value per share (in dollars per share) | $ / shares	30.59
Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares	30.23	[2]
Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares	33.29
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.48	[2]
Vested and expected to vest, end of period, shares	32,521
[1]	The number of options expected to vest takes into account an estimate of expected forfeitures.
[2]	Vested and non-vested shares outstanding, but not paid as of December 31, 2016 were 32,521.

Share-Based Payments - Data 128

Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details) - Portfolio Performance Shares [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 118	$ 60	$ 0
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$ 93	$ 102	$ 139
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 9 months 18 days	1 year 8 months 12 days	1 year 9 months 18 days

Share-Based Payments - Total Sh

Share-Based Payments - Total Shareholder Return Units Narrative (Details) - Total Shareholder Return Units (TSRU) [Member]	Oct. 26, 2016USD ($)Employeetrading_day	Dec. 31, 2016trading_day
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Trading day average used to calculate the conversion | trading_day	20	20
Age of eligible unit holder which can elect to exercise and convert TSRUs when vested into PTUs	55 years
Award requisite service period	10 years
Number of employees affected by plan modification | Employee	2,900
Incremental compensation cost resulting from plan modification | $	$ 0
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term (years)		5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term (years)		7 years

Share-Based Payments - Valua130

Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail) - Total Shareholder Return Units (TSRU) [Member]		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	[1]	3.85%	3.19%	3.18%
Risk-free interest rate	[2]	1.31%	1.76%	1.78%
Expected stock price volatility	[3]	21.64%	18.41%	19.76%
Contractual term (years)		5 years 1 month 13 days	5 years 10 months 28 days	5 years 11 months 19 days
[1]	Determined using a constant dividend yield during the expected term of the TSRU.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility, after consideration of historical volatility.

Share-Based Payments - Total131

Share-Based Payments - Total Shareholder Return Units Activity (Details) - Total Shareholder Return Units (TSRU) [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	18,067
Granted, shares	53,467
Vested, shares	(6,440)
Forfeited, shares	(3,087)
Nonvested, end of period, shares	62,007	18,067
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)	$ 6.07
Granted, weighted-average grant-date fair value per share (in dollars per share)	5.83	$ 6.66	$ 6.51
Vested, weighted-average grant date fair value per share (in dollars per share)	5.14
Forfeited, weighted-average grant date fair value per share (in dollars per share)	5.91
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)	5.97	6.07
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]
Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)	31.27
Granted, weighted-average exercise price per share (in dollars per share)	30.59
Forfeited, weighted-average exercise price per share (in dollars per share)	27.41
Expired, weighted-average exercise price per share (in dollars per share)	30.90
Outstanding, end of period, weighted-average exercise price per share (in dollars per share)	$ 31.10	$ 31.27

Share-Based Payments - Outstand

Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Total Shareholder Return Units (TSRU) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Share Units	81,413,000	[1],[2]
Outstanding, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares	$ 29.15	[1],[2]
Outstanding, Weighted-Average Remaining Contractual Term (Years)	3 years 6 months	[1],[2]
Outstanding, Aggregate Intrinsic Value | $	$ 439	[1],[2]
Vested, Share Units	19,406,000	[1],[2]
Vested, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares	$ 22.93	[1],[2]
Vested, Weighted-Average Remaining Contractual Term (Years)	1 year 6 months	[1],[2]
Vested, Aggregate Intrinsic Value | $	$ 279	[1],[2]
Expected to vest, Share Units	58,362,000	[1],[2]
Expected to vest, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares	$ 31.13	[1],[2]
Expected to vest, Weighted-Average Remaining Contractual Term (Years)	4 years 2 months 12 days	[1],[2]
Expected to vest, Aggregate Intrinsic Value | $	$ 150	[1],[2]
Settled, Share Units	4,442,865
Settled, Weighted-Average Grant Price Per Share Per Unit (in dollars per share) | $ / shares	$ 18.95
Exercised during period, Share Units	237,246
Exercised during period, Weighted-Average Grant Price (in dollars per share) | $ / shares	$ 20.86
Profit Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Share Units	120,000	[1],[2]
Outstanding, Weighted-Average Remaining Contractual Term (Years)	2 months 12 days	[1],[2]
Outstanding, Aggregate Intrinsic Value | $	$ 4	[1],[2]
Vested, Share Units	0	[1],[2]
Expected to vest, Share Units	0	[1],[2]
Converted awards	120,273
[1]	In 2016, 237,246 TSRUs with a weighted-average grant price of $20.86 per unit were converted into 120,273 PTUs.
[2]	In 2016, we settled 4,442,865 TSRUs with a weighted-average grant price of $18.95 per unit.

Share-Based Payments - Data 133

Share-Based Payments - Data Related to All Total Shareholder Return Units (Details) - Total Shareholder Return Units (TSRU) [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per stock option (in dollars per share)	$ 5.83	$ 6.66	$ 6.51
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$ 164	$ 29	$ 30
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 10 months 24 days	1 year 9 months 18 days	1 year 9 months 18 days

Share-Based Payments - Performa

Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details) - Performance Shares [Member]	12 Months Ended
	Dec. 31, 2016measureperiod
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Number of measures used to determine share payout | measure	2
Share payout measures, operating income, number of periods | period	3
Share payout measures, operating income, duration of period	1 year
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	200.00%

Share-Based Payments - Perfo135

Share-Based Payments - Performance Share Awards (PSAs) Activity (Details) - Performance Shares [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares | shares	3,871
Granted, shares | shares	1,900
Vested, shares | shares	(289)
Forfeited, shares | shares	(936)
Nonvested, end of period, shares | shares	4,546
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.28
Granted, weighted-average grant date fair value per share (in dollars per share) | $ / shares	30.59
Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares	30.23
Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares	30.61
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.48

Share-Based Payments - Data 136

Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details) - Performance Shares [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 9	$ 14	$ 39
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$ 30	$ 24	$ 21
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 9 months 18 days	1 year 10 months 24 days	1 year 8 months 12 days

Earnings Per Common Share At137

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted Numerator and Denominator (Details) - USD ($) shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
EPS Numerator-Basic
Income from continuing operations	[1]	$ 7,229	$ 6,975	$ 9,119
Less: Net income attributable to noncontrolling interests		31	26	32
Income from continuing operations attributable to Pfizer Inc.		7,198	6,949	9,087
Less: Preferred stock dividends––net of tax		1	1	1
Income from continuing operations attributable to Pfizer Inc. common shareholders		7,197	6,948	9,086
Discontinued operations––net of tax	[1]	17	11	48
Less: Discontinued operations––net of tax, attributable to noncontrolling interests		0	0	0
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders		17	11	48
Net income attributable to Pfizer Inc. common shareholders		7,214	6,959	9,134
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		7,197	6,948	9,087
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 7,214	$ 6,960	$ 9,135
EPS Denominator
Weighted-average number of common shares outstanding––Basic	[1]	6,089	6,176	6,346
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements(a)	[2]	70	81	78
Weighted-average number of common shares outstanding––Diluted(a)	[1],[2],[3]	6,159	6,257	6,424
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans	[4]	63	50	44
[1]	Amounts may not add due to rounding.
[2]	Amount for 2016 reflects the adoption of a new accounting standard, as of January 1, 2016, that requires when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B).
[3]	Amount for 2016 reflects the adoption of a new accounting standard, as of January 1, 2016, that requires when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B).
[4]	These common stock equivalents were outstanding for the years ended December 31, 2016, 2015 and 2014, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease Commitments (Detail)

Lease Commitments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Leases [Abstract]
Operating leases, rent expense, net	$ 292	$ 243	$ 216
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,017	220
2,018	188
2,019	163
2,020	138
2,021	125
After 2,021	$ 967

Commitments and Contingencies (

Commitments and Contingencies (Action In Which We Are the Plaintiff) (Details)

1 Months Ended

2 Months Ended

4 Months Ended

Feb. 23, 2017Patents

Jan. 31, 2017Patents

Aug. 31, 2016Patents

Jul. 31, 2016Patents

Jan. 31, 2016Patents

Dec. 31, 2015Patents

Jul. 31, 2015Defendant

Jun. 30, 2015Patents

Jan. 31, 2015Patents

Jun. 30, 2013Patents

Jul. 31, 2015Defendant

Dec. 31, 2015Patents

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

4

Precedex Premix [Member] | Hospira Versus Fresenius [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

4

Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

4

Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

5

5

5

5

Number of defendants | Defendant

4

Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of defendants | Defendant

4

Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

3

3

3

Tygacil [Member] | Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Subsequent Event [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

5

Subsequent Event [Member] | Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Commitments and Contingencie140

Commitments and Contingencies (Action In Which We Are The Defendant) (Details) £ in Millions	1 Months Ended
	Mar. 31, 2015Patents	Apr. 30, 2014	Mar. 31, 2013lagoon	Dec. 31, 2016GBP (£)Claim
Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed	6
Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed	2
Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Number of claims dismissed	4
Regents Versus Medivation [Member] | Xtandi [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Percentage of payments sought by plaintiff		10.00%
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of claims seeking damages | Claim				56,200
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of claims seeking damages | Claim				1
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Feasibility study, number of lagoons | lagoon			2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £				£ 84

Commitments and Contingencie141

Commitments and Contingencies (Certain Matters Resolved And Purchase Commitments) (Details) CAD in Millions, $ in Millions	Feb. 12, 2016USD ($)	Jun. 30, 2014CAD	Jul. 31, 2016USD ($)	Oct. 31, 2014Patents	Jun. 30, 2010Patents	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2006Patents	Dec. 31, 2012CAD	Dec. 31, 2009Actions
Loss Contingencies [Line Items]
Long-term purchase commitment, amount						$ 4,700
Sutent [Member] | Pfizer Versus Mylan Pharmaceuticals Inc. [Member] | Patent Infringement [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon | Patents					3
Number of patents infringed upon | Patents				2
Protonix / Pantoprazole [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)							$ (784.6)
Protonix / Pantoprazole [Member] | U.S. Department of Justice Versus Pfizer [Member] | Product Pricing [Member]
Loss Contingencies [Line Items]
Number of actions | Actions											2
Litigation settlement income (loss)	$ (784.6)
Effexor [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)								$ (56)
Effexor [Member] | Teva Canada Limited Versus Pfizer Canada Inc. [Member] | Pending Litigation [Member] | Patent Infringement [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss) | CAD										CAD (52.5)
Number of patents allegedly infringed | Patents									1
Damages awarded | CAD		CAD 125
Celebrex and Bextra [Member] | Pending Litigation [Member] | Product Safety Misrepresentation [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 486			$ 486

Segment, Geographic and Othe142

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		3 Months Ended	12 Months Ended
		Apr. 03, 2016USD ($)	Dec. 31, 2016USD ($)Operating_SegmentCountry	Dec. 31, 2015USD ($)Country	Dec. 31, 2014USD ($)Country
Segment Reporting Information [Line Items]
Number of operating segments | Operating_Segment			2
Total assets	[1]		$ 171,615	$ 167,381
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Outside United States [Member]
Segment Reporting Information [Line Items]
Number of countries outside the U.S | Country			11	12	12
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | United States [Member}
Segment Reporting Information [Line Items]
Percentage of total revenues			10.00%	10.00%	10.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler One [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues			16.00%	14.00%	13.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler Two [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues			12.00%	11.00%	10.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler Three [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues			10.00%	10.00%	9.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest U.S. Wholesaler Customers [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues			29.00%	23.00%	25.00%
Innovative Health Business [Member] | Scenario, Adjustment [Member] | Operating Segments [Member] | Innovative Health Segment [Member]
Segment Reporting Information [Line Items]
Costs		$ (76)		$ (318)	$ (271)
Pfizer's Worldwide Research and Development [Member] | Scenario, Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs				(274)	(281)
Pfizer's Global Product Development [Member] | Scenario, Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs		76		318	271
Transfer of Certain Development-Related Functions [Member] | Pfizer's Worldwide Research and Development [Member] | Scenario, Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs		(78)		(341)	(343)
Transfer of Certain Development-Related Functions [Member] | Pfizer's Global Product Development [Member] | Scenario, Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs		$ 78		$ 341	$ 343
[1]	Amounts may not add due to rounding.

Segment, Geographic and Othe143

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues	[1]	$ 52,824	$ 48,851	$ 49,605
Earnings	[1],[2]	8,351	8,965	12,240
Depreciation and Amortization	[3]	5,757	5,157	5,537
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		52,824	48,851	49,406
Earnings	[2]	28,752	27,295	28,763
Depreciation and Amortization	[3]	1,183	998	1,012
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[4]	0	0	0
Earnings	[2],[4]	(3,184)	(3,091)	(3,151)
Depreciation and Amortization	[3],[4]	86	77	74
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	0	0	0
Earnings	[2],[5]	(5,326)	(5,430)	(5,200)
Depreciation and Amortization	[3],[5]	356	354	384
Innovative Health Segment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	29,197	26,758	24,005
Earnings	[2],[6]	15,854	14,581	12,743
Depreciation and Amortization	[3],[6]	583	552	522
Essential Health Segment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[7]	23,627	22,094	25,401
Earnings	[2],[7]	12,898	12,714	16,020
Depreciation and Amortization	[3],[7]	600	446	490
Purchase Accounting Adjustments [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	0	0	0
Earnings	[2],[5]	(4,185)	(3,953)	(3,641)
Depreciation and Amortization	[3],[5]	3,890	3,573	3,782
Acquisition-Related Costs [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	0	0	0
Earnings	[2],[5]	(785)	(894)	(183)
Depreciation and Amortization	[3],[5]	7	75	53
Certain Significant Items [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[8]	0	0	198
Earnings	[2],[8]	(5,888)	(4,321)	(3,749)
Depreciation and Amortization	[3],[8]	200	48	207
Other Unallocated [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	0	0	0
Earnings	[2],[5]	(1,032)	(642)	(601)
Depreciation and Amortization	[3],[5]	$ 35	$ 33	$ 24
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income.
[3]	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
[4]	Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations.
[5]	For a description, see the “Other Costs and Business Activities” section above.
[6]	On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations and IH’s operating results for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. Additionally, in connection with the formation in early 2016 of the GPD organization, effective in the second quarter of 2016, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, $318 million of costs in 2015 and $271 million of costs in 2014 from IH to GPD to conform to the presentation as part of GPD in 2016.
[7]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations and EH’s operating results include legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira International operations. See Note 2A for additional information. Beginning in 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including the revenues and expenses related to our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. We have reclassified prior period PCS operating results ($506 million of PCS revenues and $96 million of PCS earnings in 2015, which in 2015 includes revenues and expenses related to our manufacturing and supply agreements with Zoetis, and $253 million of PCS revenues and $69 million of PCS earnings in 2014) to conform to the current period presentation as part of EH. As noted above, in connection with the formation in 2016 of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $274 million of costs in 2015 and $281 million of costs in 2014 from WRD to EH to conform to the current period presentation as part of EH.
[8]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in 2014, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis.For Earnings in 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion, (ii) charges for certain legal matters of $494 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion, (iv) certain asset impairment charges of $1.4 billion, (v) charges for business and legal entity alignment of $261 million and (vi) other charges of $509 million. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million, (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million, (iii) certain asset impairment charges of $787 million, (iv) a charge related to pension settlements of $491 million, (v) charges for business and legal entity alignment of $282 million, (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million. For additional information, see Note 3 and Note 4.For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million, (ii) certain asset impairments of $440 million, (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million. For additional information, see Note 2D, Note 3 and Note 4.

Segment, Geographic and Othe144

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Apr. 03, 2016	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues	[1]		$ 52,824		$ 48,851		$ 49,605
Net income (loss)	[1]		7,215	[2]	6,960		9,135
Write-down of HIS net assets to fair value less estimated costs to sell	[3]		1,712	[4]	0	[4]	0
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[5]		0		0		0
Restructuring charges and implementation costs			1,500		584		598
Certain asset impairments			1,400		787		440
Other legal matters, net			494		968		999
Alignment costs			261		282		168
Other charges			509		332		165
Settlements of pension obligations related to terminated employees					491
Branded prescription drug fee							215
Segment Reconciling Items [Member] | Merck KGaA [Member]
Segment Reporting Information [Line Items]
Upfront payments and milestone payments							1,200
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues			52,824		48,851		49,406
Venezuela [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Foreign currency loss and inventory impairment					878
HIS [Member]
Segment Reporting Information [Line Items]
Write-down of HIS net assets to fair value less estimated costs to sell			1,700
Scenario, Adjustment [Member] | Pfizer's Global Product Development [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs		$ 76			318		271
Essential Health Segment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[6]		23,627		22,094		25,401
Essential Health Business [Member] | Essential Health Segment [Member]
Segment Reporting Information [Line Items]
Revenues	[7]		$ 23,627		22,094		25,600
Essential Health Business [Member] | Essential Health Segment [Member] | Scenario, Adjustment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Costs					274		281
Revenues					506		253
Net income (loss)					$ 96		$ 69
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[5]	Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations.
[6]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations and EH’s operating results include legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira International operations. See Note 2A for additional information. Beginning in 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including the revenues and expenses related to our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. We have reclassified prior period PCS operating results ($506 million of PCS revenues and $96 million of PCS earnings in 2015, which in 2015 includes revenues and expenses related to our manufacturing and supply agreements with Zoetis, and $253 million of PCS revenues and $69 million of PCS earnings in 2014) to conform to the current period presentation as part of EH. As noted above, in connection with the formation in 2016 of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $274 million of costs in 2015 and $281 million of costs in 2014 from WRD to EH to conform to the current period presentation as part of EH.
[7]	The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems (through February 2, 2017), Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. Also, effective as of the beginning of 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. We have reclassified prior period PCS revenues ($506 million in 2015 and $253 million in 2014) to conform to the current period presentation as part of EH.

Segment, Geographic and Othe145

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 52,824	$ 48,851	$ 49,605
United States [Member}
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	26,369	21,704	19,073
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2],[3]	9,306	9,714	11,719
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2],[4]	6,729	6,298	7,314
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2],[5]	$ 10,420	$ 11,136	$ 11,499
[1]	Amounts may not add due to rounding.
[2]	On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations include the operating results of Anacor and Medivation. In accordance with our domestic reporting period, our results of operations for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations include the operating results of Hospira. In accordance with our domestic and international reporting periods, our results of operations for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.
[3]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.2 billion in 2016, $7.4 billion in 2015 and $9.0 billion in 2014.
[4]	Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.
[5]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.

Segment, Geographic and Othe146

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 52,824	$ 48,851	$ 49,605
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2],[3]	9,306	9,714	11,719
Euro Member Countries, Euro | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 7,200	$ 7,400	$ 9,000
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.2 billion in 2016, $7.4 billion in 2015 and $9.0 billion in 2014.
[3]	On June 24, 2016, we acquired Anacor and on September 28, 2016, we acquired Medivation. Commencing from their respective acquisition dates, our results of operations include the operating results of Anacor and Medivation. In accordance with our domestic reporting period, our results of operations for 2016 include approximately six months of legacy Anacor operations, which were immaterial, and approximately three months of legacy Medivation operations. On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our results of operations include the operating results of Hospira. In accordance with our domestic and international reporting periods, our results of operations for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.

Segment, Geographic and Othe147

Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail) - USD ($) $ in Millions		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[2]	$ 13,318	[1],[3]	$ 13,766	[1],[3]	$ 11,762
United States [Member}
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[2]	6,649		7,072		5,575
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[2],[4]	4,228		4,376		4,606
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[2],[5]	643		660		617
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[2]	$ 1,797		$ 1,658		$ 963
[1]	Amounts may not add due to rounding.
[2]	Reflects legacy Medivation and legacy Anacor amounts in 2016, commencing on the Medivation acquisition date, September 28, 2016, and Anacor acquisition date, June 24, 2016. Reflects legacy Hospira amounts in 2016 and 2015 commencing on the Hospira acquisition date, September 3, 2015.
[3]	The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $457 million to Assets held for sale (see Note 2B) and, to a lesser extent, impairments and the impact of foreign exchange, partially offset by capital additions.
[4]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.
[5]	Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.

Segment, Geographic and Othe148

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue from External Customer [Line Items]
Revenues	[1]	$ 52,824	$ 48,851	$ 49,605
Innovative Health and Essential Health [Member]
Revenue from External Customer [Line Items]
Revenues		52,824	48,851	49,605
Innovative Health and Essential Health [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	4,966	4,839	5,168
Innovative Health and Essential Health [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,564	1,708	1,685
Innovative Health and Essential Health [Member] | Alliance Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		1,746	1,312	957
Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	29,197	26,758	24,005
Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	23,627	22,094	25,600
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		8,858	7,611	6,727
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	4,165	3,655	3,350
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,181	1,297	1,181
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Chantix Champix [Member]
Revenue from External Customer [Line Items]
Revenues		842	671	647
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		258	267	288
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues		251	232	228
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Alliance Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	1,588	1,256	759
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	573	233	276
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		6,071	6,454	4,480
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Prevenar Family [Member]
Revenue from External Customer [Line Items]
Revenues		5,718	6,245	4,464
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | FSME-IMMUN/TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		114	104	0
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Other Vaccines Products [Member]
Revenue from External Customer [Line Items]
Revenues		239	104	16
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		4,563	2,955	2,218
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		2,135	723	0
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		1,095	1,120	1,174
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		561	488	438
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		401	430	410
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xtandi Alliance [Member]
Revenue from External Customer [Line Items]
Revenues		140	0	0
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Other Oncology Products [Member]
Revenue from External Customer [Line Items]
Revenues		231	194	195
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		3,928	3,918	4,241
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Enbrel [Member]
Revenue from External Customer [Line Items]
Revenues		2,909	3,333	3,850
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		927	523	308
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		93	61	82
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		2,369	2,425	2,893
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		712	752	856
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		579	617	723
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | ReFacto AF Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		554	533	631
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		232	218	229
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Rapamune [Member]
Revenue from External Customer [Line Items]
Revenues		170	197	339
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Rare Disease Products [Member]
Revenue from External Customer [Line Items]
Revenues		122	108	114
Consumer Healthcare [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		3,407	3,395	3,446
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	11,194	11,745	13,016
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		1,758	1,860	2,061
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Premarin Family [Member]
Revenue from External Customer [Line Items]
Revenues		1,017	1,018	1,076
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		962	991	1,112
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Epi Pen [Member]
Revenue from External Customer [Line Items]
Revenues		386	339	294
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Xalatan Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		363	399	495
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues		323	352	382
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		304	374	423
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		278	288	344
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zithromax Zmax [Member]
Revenue from External Customer [Line Items]
Revenues		272	275	311
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Xanax/Xanax XR [Member]
Revenue from External Customer [Line Items]
Revenues		222	224	253
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Cardura [Member]
Revenue from External Customer [Line Items]
Revenues		192	210	263
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Neurontin [Member]
Revenue from External Customer [Line Items]
Revenues		182	196	210
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Tikosyn [Member]
Revenue from External Customer [Line Items]
Revenues		153	179	141
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Depo-Provera [Member]
Revenue from External Customer [Line Items]
Revenues		126	170	201
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Diflucan [Member]
Revenue from External Customer [Line Items]
Revenues		119	181	208
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		4,538	4,689	5,242
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	6,018	3,944	3,277
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		450	402	381
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		396	339	354
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		318	335	364
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		274	304	323
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		4,579	2,563	1,855
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	4,220	5,326	8,855
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	801	1,183	1,818
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	383	411	504
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		733	830	2,699
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		732	715	737
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		590	682	756
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		421	883	1,352
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		285	260	276
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		276	362	714
Infusion Systems [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	1,158	403	0
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	319	63	0
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues		192	30	0
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues		127	33	0
CentreOne [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[12]	718	612	451
Segment Reconciling Items [Member]
Revenue from External Customer [Line Items]
Revenues	[13]	$ 0	0	0
Scenario, Adjustment [Member] | Segment Reconciling Items [Member] | CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues			$ (506)	$ (253)
[1]	Amounts may not add due to rounding.
[2]	Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3]	Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[4]	The IH business, previously known as the Innovative Products business, encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Anacor and Medivation commercial operations. Anacor's and Medivation's commercial operations are included in IH's operating results in our consolidated statements of income, commencing from the acquisition date of June 24, 2016 for Anacor and from the acquisition date of September 28, 2016 for Medivation. As a result, IH's revenues for 2016 reflect approximately six months of legacy Anacor operations, which were immaterial, and three months of legacy Medivation operations.
[5]	The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems (through February 2, 2017), Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. Also, effective as of the beginning of 2016, our contract manufacturing business, Pfizer CentreOne, is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including our manufacturing and supply agreements with Zoetis, which prior to 2016 was managed outside EH as part of PGS and previously reported in “Other Unallocated” costs; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. We have reclassified prior period PCS revenues ($506 million in 2015 and $253 million in 2014) to conform to the current period presentation as part of EH.
[6]	Includes Eliquis for all years presented and Rebif for 2015 and 2014.
[7]	Includes Eliquis direct sales markets.
[8]	Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products).
[9]	Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Lyrica in certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and Revatio in most developed markets, Vfend and Viagra in certain developed Europe markets and Japan, and Inspra in the EU.
[10]	Infusion Systems (through February 2, 2017) include Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.
[11]	Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle East markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle East markets.
[12]	Pfizer CentreOne includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation (previously known as Pfizer CentreSource or PCS), including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation.
[13]	Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations.

Subsequent Event (Details)

Subsequent Event (Details) - USD ($) $ / shares in Units, shares in Millions

Feb. 06, 2017

Feb. 02, 2017

Jun. 20, 2016

Mar. 10, 2016

Mar. 08, 2016

Jul. 13, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Feb. 11, 2015

Oct. 23, 2014

Jun. 27, 2013

Subsequent Event [Line Items]

Accelerated share repurchases, authorized amount

$ 5,000,000,000

$ 11,000,000,000

$ 11,000,000,000

$ 10,000,000,000

Accelerated share repurchases, cash paid

$ 5,000,000,000

$ 160,000,000

$ 5,000,000,000

Shares repurchased

18

136

151

154

[1]

182

[2]

165

Shares repurchased, initial price per share (in dollars per share)

$ 29.36

Accelerated share repurchase, percentage of agreement

80.00%

Amount of remaining shares authorized in stock purchase plan, value

$ 11,400,000,000

Share Repurchase Agreement with Citibank [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Accelerated share repurchases, authorized amount

$ 5,000,000,000

Accelerated share repurchases, cash paid

$ 5,000,000,000

Shares repurchased

126

Shares repurchased, initial price per share (in dollars per share)

$ 31.73

Accelerated share repurchase, percentage of agreement

80.00%

Amount of remaining shares authorized in stock purchase plan, value

$ 6,400,000,000

[1]

Represents shares purchased pursuant to and received upon settlement of the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.

[2]

Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.